

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 02 February 1998 (02.02.98)	
International application No. PCT/US97/09099	Applicant's or agent's file reference 481.2PC
International filing date (day/month/year) 30 May 1997 (30.05.97)	Priority date (day/month/year) 31 May 1996 (31.05.96)
Applicant BROOKS, Peter et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
16 December 1997 (16.12.97)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p>The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland</p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer Nicola Wolff</p> <p>Telephone No.: (41-22) 338.83.38</p>
--	--

PATENT COOPERATION TREATY

PCT

**NOTIFICATION CONCERNING
AMENDMENTS OF THE CLAIMS**

(PCT Rule 62 and
Administrative Instructions, Section 417)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

in its capacity as International Preliminary Examining Authority

Date of mailing:

02 February 1998 (02.02.98)

International application No.:

PCT/US97/09099

International filing date:

30 May 1997 (30.05.97)

Applicant:

THE SCRIPPS RESEARCH INSTITUTE et al

The International Bureau hereby informs the International Preliminary Examining Authority that no amendments under Article 19 have been received by the International Bureau (Administrative Instructions, Section 417)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorised officer:

Nicola Wolff

Telephone No.: (41-22) 338.83.38

07/194530
US/1

PATENT COOPERATION TREATY

PCT

COMMUNICATION OF
INTERNATIONAL APPLICATIONS

(PCT Article 20)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark
Office
(Box PCT)
Crystal Plaza 2
Washington, DC 20231
ETATS-UNIS D'AMERIQUE

Date of mailing:

12 March 1998 (12.03.98)

in its capacity as designated Office

The International Bureau transmits herewith copies of the international applications having the following international application numbers and international publication numbers:

International application no.:

PCT/US97/09099

International publication no.:

WO97/45447

**CORRECTED VERSION
VERSION CORRIGEE**

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer:

J. Zahra

09/194552
123

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

PCT 09 OCT 1998

Applicant's or agent's file reference 481.2PC	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US97/09099	International filing date (day/month/year) 30 MAY 1997	Priority date (day/month/year) 31 MAY 1996
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant THE SCRIPPS RESEARCH INSTITUTE		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 5 sheets.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 16 DECEMBER 1997	Date of completion of this report 27 AUGUST 1998
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer NANCY A. JOHNSON 
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US97/09099

I. Basis of the report

1. This report has been drawn on the basis of *(Substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments):*

- ☒ the international application as originally filed.
- ☒ the description, pages 1-87 , as originally filed.
pages NONE , filed with the demand.
pages NONE , filed with the letter of _____.
pages _____ , filed with the letter of _____.
- ☒ the claims, Nos. 1-48 , as originally filed.
Nos. NONE , as amended under Article 19.
Nos. NONE , filed with the demand.
Nos. NONE , filed with the letter of _____.
Nos. _____ , filed with the letter of _____.
- ☒ the drawings, sheets/fig 1-26 , as originally filed.
sheets/fig NONE , filed with the demand.
sheets/fig NONE , filed with the letter of _____.
sheets/fig _____ , filed with the letter of _____.

2. The amendments have resulted in the cancellation of:

- ☒ the description, pages NONE .
- ☒ the claims, Nos. NONE .
- ☒ the drawings, sheets/fig NONE .

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the ~~Supplemental Box~~ Additional observations below (Rule 70.2(c)).

4. Additional observations, if necessary:

NONE

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US97/09099

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The question whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 2, 7, 9, 15 and 17

because:

- ☐ the said international application, or the said claim Nos. _ relate to the following subject matter which does not require international preliminary examination (*specify*).

- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _ are so unclear that no meaningful opinion could be formed (*specify*).

- ☐ the claims, or said claims Nos. _ are so inadequately supported by the description that no meaningful opinion could be formed.

- ☒ an international search report has been established for said claims Nos. 2, 7, 9, 15 and 17.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US97/09099

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. STATEMENT**

Novelty (N)	Claims	<u>(Please See supplemental sheet)</u>	YES
	Claims	<u>(Please See supplemental sheet)</u>	NO
Inventive Step (IS)	Claims	<u>(Please See supplemental sheet)</u>	YES
	Claims	<u>(Please See supplemental sheet)</u>	NO
Industrial Applicability (IA)	Claims	<u>(Please See supplemental sheet)</u>	YES
	Claims	<u>(Please See supplemental sheet)</u>	NO

2. CITATIONS AND EXPLANATIONS

Claims 11-13, 18, 21-22, 24, 26-27, 29-30 32-33, 35-36, 41-42, 44, 46-48 lack novelty under PCT Article 33(2) as being anticipated by Friedlander. Friedlander discloses methods of inhibiting angiogenesis comprising the administration of a the P1F6 monoclonal antibody or a cyclic peptide that are the same as those claimed. The disclosed method is used to inhibit angiogenesis in inflammation, cancer (tumor growth), retinal angiogenesis and diabetic retinopathy. In the disclosed method, angiogenesis is induced by the cytokine VEGF. The administration of a cytokine is interpreted to meet the limitation "said administering is conducted in conjunction with chemotherapy" in claim 24.

Claims 1, 3-5, 16, 19-20, 23, 25, 38-39 and 45 lack an inventive step under PCT Article 33(3) as being obvious over Frielander. The teachings of Frielander, of a method of inhibiting angiogenesis comprising the administration of a monoclonal antibody or a cyclic peptide, have been discussed in the paragraph above. Frielander does not teach an article of manufacture comprising said monoclonal antibody or cyclic peptide with packaging material, wherein said packaging material "comprises a label which indicates that said pharmaceutical agent can be used for treating conditions by inhibition of angiogenesis" (claims 1, 3-5). However, such instructions would be obvious, in view of the demonstrated effectiveness of the pharmaceuticals in the inhibition of angiogenesis in Frielander. The intended uses of the claimed article of manufacture (claims 1, 3-5) are given no structural weight in the application of the art. Frielander does not a fusion protein of the angiogenesis inhibitory antibody (claim 16). However, the further engineering of an antibody as a fusion protein, once therapeutic effectiveness has been demonstrated is well known in the art. Frielander does not teach a method of treating arthritis (claims 19-20). However, the treatment of arthritis is obvious in view of the teachings of the treatment of inflammation, as arthritis is an inflammatory disease. Frielander does not teach the modes of administration set forth in claims 23 and 25. However, such modes of administration are art know modes of administration for (Continued on Supplemental Sheet.)

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

~~Sheet 10~~**CLASSIFICATION:**

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(6): C07K 14/435, 14/705, 14/78, 16/28; A61K 38/16, 38/39, 39/395, and US Cl.: 424/130.1, 143.1, 155.1; 514/12; 530/350, 387.1, 388.22

V. 1. REASONED STATEMENTS:

The report as to Novelty was positive (YES) with respect to claims 1, 3-6, 8, 10, 14, 16, 19-20, 23, 25, 28, 31, 34, 37-40, 43, 45.

The report as to Novelty was negative (NO) with respect to claims 11-13, 18, 21-22, 24, 26-27, 29-30, 32-33, 35-36, 41-42, 44, 46-48.

The report as to Inventive Step was positive (YES) with respect to claims 6, 8, 10, 14, 28, 31, 34, 37, 40, 43.

The report as to Inventive Step was negative (NO) with respect to claims 1, 3-5, 11-13, 16, 18-27, 29-30, 32-33, 35-36, 38-39, 41-42, 44-48.

The report as to Industrial Applicability was positive (YES) with respect to claims 1, 3-6, 8, 10-14, 16, 18-48.

The report as to Industrial Applicability was negative (NO) with respect to claims NONE.

V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):

the in vivo administration of an antibody. Frielanders does not teach a method of treating restenosis (claims 38-39). However, the treatment of restenosis, an angiogenesis based condition, is obvious in view of the general teachings of the inhibition of angiogenesis. Frielanders does not teach the treatment of the specific listing of corneal neovascular disorders listed in claim 45. However, in view of the general treatments of the inhibition of corneal angiogenesis, the treatment of these specific conditions is obvious.

Claims 6, 8, 10, 14, 28, 31, 34, 37, 40 and 43 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest "an alpha₂beta₁ antagonist comprising a polypeptide having an amino acid residue sequence that includes a portion of the carboxy terminal domain of matrix metalloproteinase, said polypeptide capable of binding to integrin alpha₂beta₁," and methods of inhibiting angiogenesis comprising the administration of said polypeptides.

Claims 1, 3-6, 8, 10-14, 16, 18-48 have industrial applicability as defined by PCT Article 33(4).

NEW CITATIONS

NONE

09/194552

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/435, 14/705, 14/78, 16/28, A61K 38/16, 38/39, 39/395		A1	(11) International Publication Number: WO 97/45447
			(43) International Publication Date: 4 December 1997 (04.12.97)
(21) International Application Number: PCT/US97/09099		(74) Agents: FITTING, Thomas et al.; The Scripps Research Institute, 10550 North Torrey Pines Road, TPC-8, La Jolla, CA 92037 (US).	
(22) International Filing Date: 30 May 1997 (30.05.97)			
(30) Priority Data:		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
60/018,733 31 May 1996 (31.05.96) US 60/015,869 31 May 1996 (31.05.96) US			
(60) Parent Applications or Grants			
(63) Related by Continuation			
US 60/018,733 (CIP)			
Filed on 31 May 1996 (31.05.96)			
US 60/015,869 (CIP)			
Filed on 31 May 1996 (31.05.96)			
(71) Applicant (for all designated States except US): THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US).		Published With international search report.	
(72) Inventors; and			
(75) Inventors/Applicants (for US only): BROOKS, Peter [US/US]; Apartment 6113, 3550 Lebon Drive, San Diego, CA 92122 (US). CHERESH, David, A. [US/US]; 2108 Sea Village Circle, Cardiff, CA 92007 (US). FRIEDLANDER, Martin [US/US]; 1720 Zapo Street, Del Mar, CA 92014 (US).			
(54) Title: METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF $\alpha_v\beta_5$ MEDIATED ANGIOGENESIS			
(57) Abstract			
<p>The present invention describes methods for inhibiting angiogenesis in tissues using vitronectin $\alpha_v\beta_5$ antagonists. The $\alpha_v\beta_5$-mediated angiogenesis is correlated with exposure to cytokines including vascular endothelial growth factor, transforming growth factor-α and epidermal growth factor. Inhibition of $\alpha_v\beta_5$-mediated angiogenesis is particularly preferred in vascular endothelial ocular neovascular diseases, in tumor growth and in inflammatory conditions, using therapeutic compositions containing $\alpha_v\beta_5$ antagonists.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF $\alpha_v\beta_3$ MEDIATED ANGIOGENESIS

5 Technical Field

The present invention relates generally to the field of medicine, and relates specifically to methods and compositions for inhibiting $\alpha_v\beta_3$ -mediated angiogenesis of tissues using antagonists of the vitronectin receptor $\alpha_v\beta_3$.

10 Background

Integrins are a class of cellular receptors known to bind extracellular matrix proteins, and therefore mediate cell-cell and cell-extracellular matrix interactions, referred generally to as cell adhesion events. However, although many integrins and their respective ligands are described in the literature, the biological function of many of the integrins remains elusive. The integrin
15 receptors constitute a family of proteins with shared structural characteristics of noncovalent heterodimeric glycoprotein complexes formed of α and β subunits.

The vitronectin receptor, named for its original characteristic of preferential binding to vitronectin, is now known to refer to three different integrins, designated $\alpha_v\beta_1$, $\alpha_v\beta_3$ and $\alpha_v\beta_5$. Horton, Int. J. Exp. Pathol., 71:741-759 (1990). $\alpha_v\beta_1$ binds fibronectin and vitronectin. $\alpha_v\beta_3$
20 binds a large variety of ligands, including fibrin, fibrinogen, laminin, thrombospondin, vitronectin, von Willebrand's factor, osteospondin and bone sialoprotein I. $\alpha_v\beta_5$ binds vitronectin. The specific cell adhesion roles these three integrins play in the many cellular interactions in tissues are still under investigation. However, it is clear that there are different integrins with different biological functions as well as different integrins and subunits having
25 shared biological specificities.

One important recognition site in a ligand for many integrins is the arginine-glycine-aspartic acid (RGD) tripeptide sequence. RGD is found in all of the ligands identified above for the vitronectin receptor integrins. This RGD recognition site can be mimicked by polypeptides ("peptides") that contain the RGD sequence, and such RGD peptides are known inhibitors of
30 integrin function. It is important to note, however, that depending upon the sequence and structure of the RGD peptide, the specificity of the inhibition can be altered to target specific integrins.

For discussions of the RGD recognition site, see Pierschbacher et al., Nature, 309:30-33 (1984), and Pierschbacher et al., Proc. Natl. Acad. Sci. USA, 81:5985-5988 (1984). Various
35 RGD polypeptides of varying integrin specificity have also been described by Grant et al., Cell, 58:933-943 (1989), Cheresh, et al., Cell, 58:945-953 (1989), Aumailley et al., FEBS Letts., 291:50-54 (1991), and Pfaff et al., J. Biol. Chem., 269:20233-20238 (1994), and in United States Patent Nos. 4,517,686, 4,578,079, 4,589,881, 4,614,517, 4,661,111, 4,792,525, 4,683,291,

4,879,237, 4,988,621, 5,041,380 and 5,061,693.

Angiogenesis, also referred to as neovascularization, is a process of tissue vascularization that involves the growth of new developing blood vessels into a tissue. The process is mediated by the infiltration of endothelial cells and smooth muscle cells. The process is believed to proceed in any one of three ways: 1) The vessels can sprout from pre-existing vessels; 2) De novo development of vessels can arise from precursor cells (vasculogenesis); or 3) Existing small vessels can enlarge in diameter. Blood et al., Bioch. Biophys. Acta, 1032:89-118 (1990). Vascular endothelial cells are known to contain at least five RGD-dependent integrins, including the vitronectin receptor ($\alpha_v\beta_3$ or $\alpha_v\beta_5$), the collagen Types I and IV receptor ($\alpha_1\beta_1$), the laminin receptor ($\alpha_2\beta_1$), the fibronectin/laminin/collagen receptor ($\alpha_3\beta_1$) and the fibronectin receptor ($\alpha_5\beta_1$). Davis et al., J. Cell. Biochem., 51:206-218 (1993). The smooth muscle cell is known to contain at least six RGD-dependent integrins, including $\alpha_3\beta_1$, $\alpha_v\beta_3$ and $\alpha_v\beta_5$.

Angiogenesis is an important process in neonatal growth, but is also important in wound healing and in the pathogenesis of a large variety of clinically important diseases including tissue inflammation, arthritis, psoriasis, cancer, diabetic retinopathy, macular degeneration and other neovascular eye diseases. These clinical entities associated with angiogenesis are referred to as angiogenic diseases. Folkman et al., Science, 235:442-447 (1987). Angiogenesis is generally absent in adult or mature tissues, although it does occur in wound healing and in the corpus luteum growth cycle. See, for example, Moses et al., Science, 248:1408-1410 (1990).

Inhibition of cell adhesion in vitro using monoclonal antibodies immunospecific for various integrin α or β subunits have implicated the vitronectin receptor $\alpha_v\beta_3$ in cell adhesion of a variety of cell types including microvascular endothelial cells. Davis et al., J. Cell. Biol., 51:206-218 (1993). In addition, Nicosia et al., Am. J. Pathol., 138:829-833 (1991), described the use of the RGD peptide, GRGDS, to inhibit the in vitro formation of "microvessels" from rat aorta cultured in collagen gel.

However, the inhibition of formation of "microvessels" in vitro in collagen gel cultures is not a model for inhibition of angiogenesis in a tissue because it is not shown that the microvessel structures are the same as capillary sprouts or that the formation of the microvessel in collagen gel culture is the same as neo-vascular growth into an intact tissue, such as arthritic tissue, tumor tissue or disease tissue where inhibition of angiogenesis is desirable.

The role of $\alpha_v\beta_3$ in angiogenesis was recently confirmed. See, Brooks, et al. Science, 264:569-571 (1994). The integrin was shown to be expressed on blood vessels in human wound granulation tissue but not in normal skin. Monoclonal antibodies against the $\alpha_v\beta_3$ receptor inhibited angiogenesis induced by the growth factors (cytokines) basic fibroblast growth factor

(bFGF) and tumor necrosis factor- α (TNF- α), as well as by melanoma fragments. However, the antagonists only inhibited new and not preexisting vessels. In addition, specific linear and cyclic RGD-containing peptides were also shown to inhibit neovascularization.

It has been proposed that inhibition of angiogenesis would be a useful therapy for restricting tumor growth. Inhibition of angiogenesis has been proposed by (1) inhibition of release of "angiogenic molecules" such as bFGF (basic fibroblast growth factor), (2) neutralization of angiogenic molecules, such as by use of anti-bFGF antibodies, and (3) inhibition of endothelial cell response to angiogenic stimuli. This latter strategy has received attention, and Folkman et al., Cancer Biology, 3:89-96 (1992), have described several endothelial cell response inhibitors, including collagenase inhibitor, basement membrane turnover inhibitors, angiostatic steroids, fungal-derived angiogenesis inhibitors, platelet factor 4, thrombospondin, arthritis drugs such as D-penicillamine and gold thiomalate, vitamin D₃ analogs, alpha-interferon, and the like that might be used to inhibit angiogenesis. For additional proposed inhibitors of angiogenesis, see Blood et al., Bioch. Biophys. Acta., 1032:89-118 (1990), Moses et al., Science, 248:1408-1410 (1990), Ingber et al., Lab. Invest., 59:44-51 (1988), and United States Patent Nos. 5,092,885, 5,112,946, 5,192,744, and 5,202,352.

However, the role of the integrin $\alpha_v\beta_3$ in angiogenesis has neither been suggested or identified until the present invention nor have any of the inhibitors of angiogenesis described in the foregoing references been targeted at inhibition of $\alpha_v\beta_3$. Moreover, no references, other than the present invention, have implicated the $\alpha_v\beta_3$ integrin in neovascularization, particularly that induced by the growth factors, vascular endothelial growth factor (VEGF), transforming growth factor- α (TGF- α) and epidermal growth factor (EGF).

Although the numbers of growth factors involved in the control of angiogenesis are limited, different levels of control of the process exist for conversion of a quiescent state to a neovascular state. See, D'Amore, Investigative Ophthal. Visual Sci., 35:3974-3979 (1994). While some growth factors involved in angiogenesis are regulated at the synthesis level, others are regulated by the state of activation. These cellular events occur as a quiescent vessel undergoes neovascularization following injury or ischemia.

VEGF, in particular, is thought to be a major mediator of angiogenesis in a primary tumor and in ischemic ocular diseases. For review, see Folkman, Nature Medicine, 1:27-31 (1995). VEGF is a 46 kilodalton (kDa) homodimer that is an endothelial cell-specific angiogenic (Ferrara et al., Endocrin. Rev., 13:18-32 (1992)) and vasopermeable factor (Senger et al., Cancer Res., 46:5629-5632 (1986)) that binds to high-affinity membrane-bound receptors with tyrosine kinase activity (Jakeman et al., J. Clin. Invest., 89:244-253 (1992)).

Activation of receptor tyrosine kinases has recently been shown to promote integrin-dependent cell migration on extracellular matrix proteins. In particular, Klemke et al., J. Cell Biol., 127:859-866 (1994) have implicated the EGF receptor (EGFR) tyrosine kinase in promoting cell motility but not adhesion of FG human pancreatic carcinoma cells on vitronectin using the $\alpha_v\beta_3$ integrin. The authors provide direct evidence that occupation of EGFR with the EGF ligand activates the tyrosine kinase activation of the EGFR that ultimately stimulates a protein kinase C (PKC)-dependent pathway leading to the induction of $\alpha_v\beta_3$ -dependent cell migration of a vitronectin substrate on which the cells are normally unable to migrate. Thus, the Klemke et al. findings provide evidence for correlating the presence of cytokines, specifically EGF, with integrin activity in cell migration. Activation of PKC has been shown to be involved in the regulation of angiogenesis in the chick chorioallantoic membrane model system. See, Tsopanoglou et al., J. Vasc. Res., 30:202-208 (1993). The authors identified specific activators and inhibitors of PKC that respectively stimulated and inhibited angiogenesis in the model system.

However, neither Klemke et al. nor Tsopanoglou et al. discussed above describe the role of cytokines and expression and/or activation of the $\alpha_v\beta_3$ integrin in promoting angiogenesis in various conditions and disease states and inhibition thereof with $\alpha_v\beta_3$ -specific antagonists.

Recent experimental evidence has shown in a monkey model system of eye disease that retinal ischemia induced by retinal vein occlusion resulted in a rapid rise of VEGF in the aqueous chambers of the eye. This rise coincided with the iris neovascularization that was observed as described by Miller et al., Am. J. Path., 145:574-584 (1994). Additional data in an mouse model system of proliferative retinopathy in which hypoxia is induced, VEGF messenger RNA was shown to increase within 6-12 hours of relative hypoxia that remained elevated until neovascularization developed. As the new blood vessels declined, so did the VEGF expression as described by Pierce et al., Proc. Natl. Acad. Sci., USA, 92:905-909 (1995).

Thus, the recent data as demonstrated in animal models of ischemia have correlated the induction of VEGF with that of ischemia followed by neovascularization. VEGF, as well as other growth factors, have also been implicated in other conditions and disease states involving neovascularization as reviewed by Folkman, Nature Medicine, 1:27-31 (1995).

The Folkman et al. reference also summarizes the current clinical approaches used to control undesirable angiogenesis. Patients in clinical trials have received therapeutic treatments with angiogenic inhibitors including platelet factor 4, a fumagillin-derivative, carboxy-amino-triazole, and the like. However, no references or current therapeutic references correlate the

expression of $\alpha_v\beta_3$ with angiogenesis, particularly that induced by VEGF. Thus, prior to the present invention, no one has described nor utilized a therapeutic regimen with $\alpha_v\beta_3$ antagonists to control angiogenesis in a tissue undergoing angiogenesis correlated with the presence and activation of $\alpha_v\beta_3$.

Therefore, other than the studies reported here on $\alpha_v\beta_3$ and the relationship with growth factors to angiogenesis, Applicants are unaware of any other demonstration that angiogenesis could be inhibited in a tissue using inhibitors of $\alpha_v\beta_3$ -mediated cell adhesion. In particular, it has never been previously demonstrated that $\alpha_v\beta_3$ function is required for angiogenesis in a tissue or that $\alpha_v\beta_3$ antagonists can inhibit angiogenesis in a tissue, particularly in ocular neovascular diseases.

Brief Description of the Invention

The present invention demonstrates that in addition to an $\alpha_v\beta_3$ -requiring angiogenesis pathway in tissues, a separate novel $\alpha_v\beta_3$ -dependent pathway also exists. Thus, the invention describes inhibitors of $\alpha_v\beta_3$ that can inhibit angiogenesis. The invention further describes that $\alpha_v\beta_3$ -mediated activity in promoting angiogenesis is correlated with growth factor (cytokine) activation of growth factor receptor tyrosine kinases and protein kinase C (PKC). The growth factors (cytokines) that function in this manner include vascular endothelial growth factor (VEGF), transforming growth factor- α (TGF- α), epidermal growth factor (EGF), and the like.

The invention therefore describes methods for inhibiting angiogenesis in a tissue comprising administering to the tissue a composition comprising an angiogenesis-inhibiting amount of an $\alpha_v\beta_3$ antagonist.

The tissue to be treated can be any tissue in which inhibition of angiogenesis is desirable, such as diseased tissue where neovascularization is occurring. Exemplary tissues include ocular tissue undergoing neovascularization, inflamed tissue, solid tumors, metastases, tissues undergoing restenosis, and the like tissues. In preferred embodiments, the neovascularization associated with expression of $\alpha_v\beta_3$ is the result of exposure to the growth factors, VEGF, TGF- α and EGF.

Particularly preferred are therapeutic methods directed to inhibiting VEGF-induced vascularization in tissues such as the eye where angiogenesis is pronounced in diseases, including diabetic retinopathy (also called proliferative diabetic retinopathy), age-related macular degeneration, presumed ocular histoplasmosis, retinopathy of prematurity, sickle cell retinopathy and neovascular glaucoma. In further preferred embodiments, the therapeutic methods are directed to inhibiting angiogenesis that occurs in corneal neovascular disorders that

include corneal transplantation, herpetic keratitis, luetic keratitis, pterygium, neovascular pannus associated with contact lens use, and the like.

An $\alpha_v\beta_3$ antagonist for use in the present methods is capable of binding to $\alpha_v\beta_3$ and competitively inhibiting the ability of $\alpha_v\beta_3$ to bind to the natural vitronectin ligand. Preferably, the antagonist exhibits specificity for $\alpha_v\beta_3$ over other integrins. In a particularly preferred embodiment, the $\alpha_v\beta_3$ antagonist inhibits binding of vitronectin or other RGD-containing ligands to $\alpha_v\beta_3$ but does not substantially inhibit binding of vitronectin to $\alpha_v\beta_3$ or $\alpha_{IIb}\beta_3$. A preferred $\alpha_v\beta_3$ antagonist can be a fusion polypeptide, a linear or cyclic polypeptide, a derivatized polypeptide, a monoclonal antibody or a functional fragment thereof, or an organic molecule that is a mimetic of an $\alpha_v\beta_3$ ligand that is also referred to as an organic mimetic, all of which specifically interacts with $\alpha_v\beta_3$.

Administration of the $\alpha_v\beta_3$ antagonists of this invention includes intraocular, intravenous, transdermal, intrasynovial, intramuscular and oral administration. In other preferred embodiments, administration is coordinated with a chemotherapeutic regimen to control tumorigenesis and cancer metastasis.

Brief Description of the Drawings

In the drawings forming a portion of this disclosure:

Figures 1A-1D illustrate inhibition of cytokine-induced rabbit corneal angiogenesis by α_v integrin antibody antagonists. Induction of angiogenesis by treatment with either bFGF or VEGF and effects of treatment thereof with the α_v integrin antibody antagonists, P1F6 ($\alpha_v\beta_3$) and LM609 ($\alpha_v\beta_3$), are described in Example 4. OD and OS are respectively the right and left eyes of an experimental rabbit. Large arrows indicate corneal angiogenesis with edema while small arrows point to normal conjunctival limbal vessels. Figures 1A and 1B show induction of angiogenesis with bFGF while Figures 1C and 1D show that with VEGF. Rabbit corneas in Figures 1A and 1C show treatment with P1F6 while Figures 1B and 1D show treatment with LM609.

Figures 2A and 2B are histograms showing the mean neovascular area in $\text{mm}^2 \pm$ the standard error ($n = 8$ for each of two series) after induction respectively with either bFGF or VEGF followed by mAb treatment with either P1F6 or LM609. The results are discussed in Example 4.

Figures 3A-3F photographically illustrate the effects of anti-integrin antibody treatment on the chick CAM preparation. The results are described in Example 6A. Angiogenesis is either induced with bFGF or VEGF followed by intravenous administration of phosphate

buffered saline (PBS) as a control or with P1F6 or LM609 monoclonal antibodies described in the legend for Figure 1. CAMs treated with bFGF are shown in Figures 3A, 3C and 3E while CAMs treated with VEGF are shown in Figures 3B, 3D and 3F. Control CAMs receiving intravenous injections of PBS are shown in Figures 3A and 3B. The P1F6 antibody was used to treat CAMs shown in Figures 3C and 3D while the LM609 antibody was used to treat CAMs in Figures 3E and 3F.

Figures 4A and 4B provide in histogram format the quantitation of results shown in Figures 3A-3F. The angiogenesis index is plotted on the Y-axis against control or antibody treatment. Figures 4A and 4B respectively show bFGF- and VEGF-induced angiogenesis. The results are discussed in Example 4.

Figures 5A-5F photographically illustrate the effects of synthetic peptide treatment on the chick CAM preparation as described in Example 6. Angiogenesis is either induced with bFGF or VEGF followed by intravenous administration of phosphate buffered saline (PBS) as a control or with the synthetic cyclic peptides RGDfV (SEQ ID NO 4) or RADfV (SEQ ID NO 5). CAMs treated with bFGF are shown in Figures 5A, 5C and 5E while CAMs treated with VEGF are shown in Figures 5B, 5D and 5F. Control CAMs receiving intravenous injections of PBS are shown in Figures 5A and 5B. The RGDfV peptide was used to treat CAMs shown in Figures 5C and 5D while the RADfV peptide was used to treat CAMs in Figures 5E and 5F.

Figures 6A and 6B provide, in histogram format, the quantitation of results shown in Figures 5A-5F. The angiogenesis index is plotted on the Y-axis against control or antibody treatment. Figures 6A and 6B respectively show bFGF- and VEGF-induced angiogenesis. The results are discussed in Example 6.

Figures 7A-7E show the effects of anti-integrin monoclonal antibodies and calphostin C on CAM angiogenesis induced by the separate cytokines, bFGF, TNF- α , VEGF and TGF- α . PMA was also evaluated. The assays and results are described in Example 6. The results are plotted in histogram format where angiogenesis index is graphed on the Y-axis and the various control or inhibitors are shown on the X-axis. Figures 7A-7E respectively show angiogenesis induced with bFGF, TNF- α , VEGF, TGF- α and PMA.

Figure 8 is a histogram showing the effects of antibody treatment on CS1 melanoma tumor growth in the chick embryo CAM assayed performed as described in Examples 5C and 6D. The weight of the tumors in milligrams (mg) is plotted on the Y-axis against the various treatments indicated on X-axis. CSAT is a control antibody specific for the integrin β 1 subunit. LM609 and P1F6 are previously described.

Figure 9 is a histogram of the effects of control versus an $\alpha_v\beta_3$ peptide antagonist, labeled

peptide 189 (SEQ ID NO 9) on melanoma tumor growth as measured by tumor volume in mm³ plotted on the Y-axis. The assay and results are described in Example 8.

Figure 10 illustrates the synthesis of Compound 7 as described in Example 10A-G.

Figure 11 illustrates the synthesis of Compound 9 as described in Example 10A-C; H-I.

Figure 12 illustrates the synthesis of Compound 10 as described in Example 10J.

Figure 13 illustrates the synthesis of Compound 12 and Compound 14 as respectively described in Example 10K-L and 10M-N.

Figure 14 shows the chemical structures of Compound 15, Compound 16, Compound 17 and Compound 18. The detailed synthesis of said compounds are described in Example 10O-R.

Figures 15A and 15B show the consecutive cDNA sequence of chicken MMP-2 along with the deduced amino acid sequence shown on the second line. The third and fourth lines respectively show the deduced amino acid sequence of human and mouse MMP-2 as described in Example 7. The chicken cDNA sequence is listed in SEQ ID NO 23 along with the encoded amino acid sequence that is also presented separately as SEQ ID NO 24. The numbering of the first nucleotide of the 5' untranslated region and region encoding the proenzyme shown in Figure 15A as a negative number is actually presented as number 1 in Sequence Listing making the latter appear longer than the figure; however, the nucleotide sequence in the figure is identical in length and sequence to that as presented in the listing with the exception of the numbering. Accordingly, references to nucleotide position for chicken or human MMP-2 in the specification, such as in primers for use in amplifying MMP-2 fragments, are based on the nucleotide position as indicated in the figure and not as listed in the Sequence Listing.

Figure 16 shows the amino acid residue sequence of mature human MMP-2 protein having 631 residues. Amino acid residue positions of human MMP-2-derived fragments correspond to those in the figure. The amino acid residue sequence is listed in SEQ ID NO 25.

Figure 17 shows the effects of peptides 85189 and inert salt counterpart 121974 on VEGF-induced angiogenesis in the CAM model as further described in Example 6A. The effect is compared to untreated (labeled as NT) and control (labeled as 69601) peptide treated preparations. The effect on angiogenesis is measured by calculation of the number of branch points as further described in Example 6A.

Figures 18, 19 and 20 respectively show the reduction in tumor weight for UCLAP-3, M21-L and FgM tumors following intravenous exposure to control peptide 69601 and antagonist 85189 as further described in Example 6D. The data is plotted with tumor weight on the Y-axis against the peptide treatments on the X-axis.

Figure 21 illustrates the effect of peptides and antibodies on melanoma tumor growth in

the chimeric mouse:human model as further described in Example 8. The peptides assessed included control 69601 (labeled 601) and antagonist 85189 (labeled 189). The antibody tested was LM609. Tumor volume in mm³ is plotted on the Y-axis against the various treatments on the X-axis.

Figures 22A and 22B respectively show the effect of antagonist 85189 (labeled 189) compared to control peptide 69601 (labeled 601) in reducing the volume and wet weight of M21L tumors over a dosage range of 10, 50 and 250 µg/injection as further described in Example 8.

Figures 23A and 23B show the effectiveness of antagonist peptide 85189 (labeled 189 with a solid line and filled circles) against control peptide 69601 (labeled 601 on a dotted line and open squares) at inhibiting M21L tumor volume in the mouse:human model with two different treatment regimens as further described in Example 8. Tumor volumes in mm³ is plotted on the Y-axis against days on the X-axis.

Detailed Description of the Invention

A. Definitions

Amino Acid Residue: An amino acid formed upon chemical digestion (hydrolysis) of a polypeptide at its peptide linkages. The amino acid residues described herein are preferably in the "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide. NH₂ refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. In keeping with standard polypeptide nomenclature (described in J. Biol. Chem., 243:3552-59 (1969) and adopted at 37 CFR §1.822(b)(2)), abbreviations for amino acid residues are shown in the following Table of Correspondence:

TABLE OF CORRESPONDENCE

<u>SYMBOL</u>		<u>AMINO ACID</u>
<u>1-Letter</u>	<u>3-Letter</u>	
Y	Tyr	tyrosine
G	Gly	glycine
F	Phe	phenylalanine
M	Met	methionine
A	Ala	alanine

	S	Ser	serine
	I	Ile	isoleucine
	L	Leu	leucine
	T	Thr	threonine
5	V	Val	valine
	P	Pro	proline
	K	Lys	lysine
	H	His	histidine
	Q	Gln	glutamine
10	E	Glu	glutamic acid
	Z	Glx	Glu and/or Gln
	W	Trp	tryptophan
	R	Arg	arginine
	D	Asp	aspartic acid
15	N	Asn	asparagine
	B	Asx	Asn and/or Asp
	C	Cys	cysteine
	X	Xaa	Unknown or other

20 In addition the following have the meanings below:

	BOC	tert-butyloxycarbonyl
	DCCI	dicyclohexylcarbodiimide
	DMF	dimethylformamide
	OMe	methoxy
25	HOBt	1-hydroxybenzotriazole

It should be noted that all amino acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino acid residues.

Polypeptide: A linear series of amino acid residues connected to one another by peptide bonds between the alpha-amino group and carboxy group of contiguous amino acid residues.

Peptide: A linear series of no more than about 50 amino acid residues connected one to

the other as in a polypeptide.

Cyclic peptide: refers to a compound having a heteroatom ring structure that includes several amide bonds as in a typical peptide. The cyclic peptide can be a "head to tail" cyclized linear polypeptide in which a linear peptide's n-terminus has formed an amide bond with the terminal carboxylate of the linear peptide, or it can contain a ring structure in which the polymer is homodetic ore heterodetic and comprises amide bonds and/or other bonds to close the ring, such as disulfide bridges, thioesters, thioamides, guanidino, and the like linkages.

Protein: A linear series of greater than 50 amino acid residues connected one to the other as in a polypeptide.

Fusion protein: refers to a polypeptide containing at least two different polypeptide domains operatively linked by a typical peptide bond ("fused"), where the two domains correspond to peptides no found fused in nature.

Synthetic peptide: A chemically produced chain of amino acid residues linked together by peptide bonds that is free of naturally occurring proteins and fragments thereof.

B. General Considerations

The present invention relates generally to the discovery that angiogenesis is mediated by the specific vitronectin receptor $\alpha_v\beta_3$, and that inhibition of $\alpha_v\beta_3$ function inhibits angiogenesis. This discovery is important because of the role that angiogenesis plays in a variety of disease processes. By inhibiting angiogenesis, one can intervene in the disease, ameliorate the symptoms, and in some cases cure the disease.

Where the growth of new blood vessels is the cause of, or contributes to, the pathology associated with a disease, inhibition of angiogenesis will reduce the deleterious effects of the disease. Examples include rheumatoid arthritis, diabetic retinopathy, inflammatory diseases, restenosis, and the like. Where the growth of new blood vessels is required to support growth of a deleterious tissue, inhibition of angiogenesis will reduce the blood supply to the tissue and thereby contribute to reduction in tissue mass based on blood supply requirements. Examples include growth of new blood vessels in response to ischemia, resulting in growth factor-induced angiogenesis, growth of tumors where neovascularization is a continual requirement in order that the tumor grow beyond a few millimeters in thickness, and for the establishment of solid tumor metastases.

The methods of the present invention are effective in part because the therapy is highly selective for angiogenesis and not other biological processes. As shown in the Examples, only new vessel growth contains substantial $\alpha_v\beta_3$, and therefore the therapeutic methods do not

adversely effect mature vessels.

The discovery that inhibition of $\alpha_v\beta_3$ alone will effectively inhibit angiogenesis allows for the development of therapeutic compositions with potentially high specificity, and therefore relatively low toxicity. Although the invention discloses the use of peptide-based reagents which have the ability to inhibit one or more integrins, one can design other reagents which more selectively inhibit $\alpha_v\beta_3$. Therefore, certain peptide-based reagents do not have the side effect of inhibiting other biological processes other than those mediated by $\alpha_v\beta_3$.

For example, as shown by the present teachings, it is possible to prepare monoclonal antibodies highly selective for immunoreaction with $\alpha_v\beta_3$, and not $\alpha_v\beta_1$, $\alpha_v\beta_3$, or $\alpha_{IIB}\beta_3$, that are similarly selective for inhibition of $\alpha_v\beta_3$ function. In addition, RGD-containing peptides can be designed to be selective for inhibition of $\alpha_v\beta_3$, as described further herein.

Prior to the discoveries of the present invention, it was not known that angiogenesis, and any of the processes dependent on angiogenesis, could be inhibited *in vivo* by the use of reagents that antagonize the biological function of $\alpha_v\beta_3$.

C. Methods For Inhibition of Angiogenesis

The invention provides for a method of inhibiting angiogenesis in a tissue, and thereby inhibiting events in the tissue which depend upon angiogenesis. Generally, the method comprises administering to the tissue a composition comprising an angiogenesis-inhibiting amount of an $\alpha_v\beta_3$ antagonist.

The target tissue used in practicing the methods of this invention is defined as $\alpha_v\beta_3$ -containing tissue that is characterized by the detectable presence of $\alpha_v\beta_3$ integrin receptor. In other words, an $\alpha_v\beta_3$ -containing tissue is defined by the presence of the $\alpha_v\beta_3$ receptor complex in the cell membranes. Such tissues include epithelially and mesenchymally derived cells. The presence of the receptor can be determined by a number of means including immunoreactivity of the receptor with an anti- $\alpha_v\beta_3$ integrin receptor antibody, wherein the immunoreaction is detected in tissues by microscopy, by immunoprecipitation, by competition in ligand binding assays and the like techniques. Preferred antibodies for use in detecting the presence of $\alpha_v\beta_3$ in a tissue are described below and in Example 1. For example, the distribution of $\alpha_v\beta_3$ in kidney, skin and ocular tissues by immunofluorescence microscopy is described in Example 2.

In the context of the methods of this invention, an $\alpha_v\beta_3$ -containing tissue is also characterized as one that has an indicia of angiogenesis. As described earlier, angiogenesis includes a variety of processes involving neovascularization of a tissue including "sprouting", vasculogenesis, or vessel enlargement, all of which angiogenesis processes are mediated by and

dependent upon the expression of $\alpha_v\beta_5$. With the exception of traumatic wound healing, corpus luteum formation and embryogenesis, it is believed that the majority of angiogenesis processes are associated with disease processes and therefore the use of the present therapeutic methods are selective for the disease and do not have deleterious side effects.

5 There are a variety of diseases in which angiogenesis is believed to be important, referred to as angiogenic diseases, including but not limited to, inflammatory disorders such as immune and non-immune inflammation, chronic articular rheumatism and psoriasis, disorders associated with inappropriate or inopportune invasion of vessels such as restenosis, capillary proliferation in atherosclerotic plaques and osteoporosis, and cancer associated disorders, such as solid
10 tumors, solid tumor metastases, angiofibromas, retrolental fibroplasia, hemangiomas, Kaposi sarcoma and the like cancers which require neovascularization to support tumor growth.

Eye diseases characterized by neovascularization present a particularly preferred target for therapy. Ocular neovascularization is the most common pathological change observed in the vast majority of eye diseases that result in catastrophic loss of vision. The growth of new blood
15 vessels from the preexisting choroidal, retinal or paralimbal vessels can lead to edema, hemorrhage or fibrovascular membrane formation resulting in disruption of the normal anatomic relationships of the eye and concomitant loss of normal visual function.

Eye diseases characterized by angiogenesis include corneal neovascular disorders that include corneal transplantation, herpetic keratitis, luetic keratitis, pterygium, neovascular pannus
20 associated with contact lens use, and the like. Additional eye diseases also include diabetic retinopathy (DR), age-related macular degeneration (ARMD), presumed ocular histoplasmosis (POHS), retinopathy of prematurity (ROP) and neovascular glaucoma and the like. While inhibition of angiogenesis in these diseases would not necessarily cure the underlying disease, it would significantly reduce the visual morbidity associated with them.

25 For example, 90% of the 300,000 persons having diabetes for over 25 years will have some form of DR that is a retinal disease characterized by leaking and/or proliferating blood vessels. Thirty percent of these patients will in fact have the latter condition that can be ameliorated with the therapeutic methods of this invention. For ARDM, 25% of the population over 65, approximately 630,000, will have some form of the disease with the expectation that by
30 the year 2030, over 6.3 million individuals will have ARDM. As a result, having the ability to inhibit $\alpha_v\beta_5$ -associated angiogenesis with the therapeutic compositions and methods of this invention has great medicinal value.

Thus, methods which inhibit angiogenesis in a diseased tissue ameliorate symptoms of the disease and, depending upon the disease, can contribute to cure of the disease. In one

embodiment, the invention contemplates inhibition of angiogenesis, per se, in a tissue. The extent of angiogenesis in a tissue, and therefore the extent of inhibition achieved by the present methods, can be evaluated by a variety of methods, such as are described in the Examples for detecting $\alpha_v\beta_3$ -immunopositive nascent and immature vessel structures by immunohistochemistry.

As described herein, any of a variety of tissues, or organs comprised of organized tissues, can support angiogenesis in disease conditions including skin, muscle, gut, connective tissue, joints, bones and the like tissue in which blood vessels can invade upon angiogenic stimuli.

In particular, the methods and $\alpha_v\beta_3$ antagonist compositions of this invention are therapeutically useful for inhibiting angiogenesis that has been induced by growth factors, also referred to as cytokines. Under physiological conditions, angiogenesis is highly regulated and as previously published by Brooks et al., Science, 264:569-5761 (1994), has been shown to be activated by specific angiogenic molecules such as basic fibroblast growth factor (bFGF). Negative regulators of angiogenesis have also been described. Angiogenesis is thus regulated by an intricate balance between local stimulators and inhibitors. See, D'Amore, Investigative Ophthalmol. Visual Sci., 35:3974-3979 (1994).

When the physiologic balance of angiogenic stimulators and inhibitors that tightly control the normally quiescent capillary vascular is disturbed, as occurs in certain disease states, capillary endothelial cells are induced to proliferate, migrate and ultimately differentiate to form new blood vessels.

Angiogenesis is characterized as an event cascade having a set of early events followed by a set of late events as reviewed by Leibovich, "Role of Cytokines in the Process of Tumor Angiogenesis", in "Human Cytokines: Their Role in Disease and Therapy", eds. Aggarwal and Puri, Chapter 35, Blackwell Science, Inc. (1995). The early events are preceded by the delivery of angiogenic growth factors and cytokines delivered from an extravascular source. The early events then proceed in the target microvasculature with the disruption of intercellular junctions, induction of expression of endothelial cell activation antigens and a proteolytic phenotype, and initiation of endothelial cell migration in a directional manner. The late events are characterized with autocrine and paracrine expression of growth factor and cytokine genes within the cells, endothelial cells, pericytes and smooth muscle cells, of the developing capillary bud. These cells in turn modulate the interactions of the cells with the extracellular matrix resulting in the formation of new functional capillary loops from existing mature vessels.

As discussed herein and in the Background, reports in the literature describe an association between the appearance of growth factors, including those associated with an

increase of $\alpha_v\beta_3$ expression, namely VEGF, TGF- α and EGF, with the expansion of a tumor mass and in the onset of angiogenesis in proliferative neovascular eye diseases, both in humans and experimental animals.

Thus, VEGF, EGF, TGF- α , among many others, are considered growth factors which are characterized by their properties of stimulating cellular growth. Growth factors are proteins that are secreted by one cell that act on the secreting cell or another cell. Their ability to act is dependent on the presence of growth factor receptors that are usually transmembrane proteins. Growth factors such as VEGF are also referred to generally as cytokines that are defined as polypeptide hormones, secreted by a cell, that affect growth and metabolism either of the same (autocrine) or of another (paracrine) cell. The term cytokine is not limited to molecules produced by cells of the immune system and the biological response modifiers of the same system. Thus, the term cytokine is a broad category of which one subcategory based on the type of biological response is stimulatory growth factors or enhancers such as VEGF, bFGF, EGF, TGF- α , and the like. For review see, Aggarwal et al., "Common and Uncommon Features of Cytokines and Cytokine Receptors: An Overview", in "Human Cytokines: Their Role in Disease and Therapy", eds. Aggarwal and Puri, Chapter 1, Blackwell Science, Inc. (1995).

In the present invention, $\alpha_v\beta_3$ -specific antagonists, and not growth factor antagonists such as antibodies against VEGF, are contemplated for use in inhibiting angiogenesis in a tissue. In preferred embodiments, the $\alpha_v\beta_3$ antagonists described herein are useful for inhibiting growth factor-induced angiogenesis in which the expression of the $\alpha_v\beta_3$ integrin receptor is induced. Preferred growth factors in this context include VEGF, EGF, TGF- α and the like.

As discussed in the Background, the growth factors EGF and VEGF are both known to bind to their cellular receptors that act as tyrosine kinases. Activation of the EGF receptor has further been shown to be correlated with activation of protein kinase C that results in activation of $\alpha_v\beta_3$ to allow for migration of specific cells on a vitronectin substrate. Thus, the mechanism of action between exposure to cytokines or growth factors and the coordinate response in integrin expression or activation is a complex biological process. As shown in the present invention (see Example 6A), treatment of tissues in either the rabbit eye model or the chick chorioallantoic model with the cytokine VEGF results in the $\alpha_v\beta_3$ -potentiated angiogenesis that is dependent on activation of protein kinase C.

In a particularly preferred embodiment, the present invention contemplates the use of $\alpha_v\beta_3$ antagonists for inhibiting angiogenesis in any tissue in which angiogenesis has been induced by VEGF. For example, ischemia of the retina in various animal model systems has been shown to result in the upregulation of VEGF that is secreted from Muller cells, the

production of which consequently induces neovascularization of tissues within the eye. See, Miller et al., Am. J. Path., 145:574-584 (1994) and Pierce et al., Proc. Natl. Acad. Sci., USA, 92:905-909 (1995).

Thus, in the present invention, a tissue to be treated is a retinal tissue of a patient with
5 diabetic retinopathy, macular degeneration, neovascular glaucoma or the like diseases as discussed above and the angiogenesis to be inhibited is retinal tissue angiogenesis where there is neovascularization of retinal tissue. Exemplary tissues, including corneal tissues, from patients with ocular neovascularization conditions or diseases are described above and in the Examples. An exemplary model system for assessing the effects of an $\alpha_v\beta_5$ antagonist of this invention for
10 treating retinal angiogenesis is the murine model of retinal neovascularization as described in Example 9.

In another related embodiment, a tissue to be treated is an inflamed tissue and the angiogenesis to be inhibited is inflamed tissue angiogenesis where there is neovascularization of inflamed tissue. In this class, the method contemplates inhibition of angiogenesis in arthritic
15 tissues, such as in a patient with chronic articular rheumatism, in immune or non-immune inflamed tissues, in psoriatic tissue and the like.

The cytokines, interleukin 1 and tumor necrosis factor- α , are thought to be associated with rheumatoid arthritis with their direct role in joint destructions based on the induction of adhesion molecule expression on endothelial cells and on enzyme release. See, Arend et al.,
20 Arthritis & Rheumatism, 38:151-160 (1995). Therapeutic regimens have been proposed for blocking both the cytokines with cytokine-specific inhibitors as well as targeting cell adhesion molecules that are expressed in the condition. See, Haskard et al., Cell Adhesion Comm., 2:235-238 (1994).

Thus, inhibition of angiogenesis in arthritic conditions by addressing and directing the
25 therapy to the involvement of the $\alpha_v\beta_5$ adhesion molecule is another preferred embodiment of the invention as prior to this invention.

In an additional related embodiment, a tissue to be treated is a tumor tissue of a patient with a solid tumor, a metastases, a skin cancer, a breast cancer, a hemangioma or angiofibroma and the like cancer, and the angiogenesis to be inhibited is tumor tissue angiogenesis where there
30 is neovascularization of a tumor tissue. Typical solid tumor tissues treatable by the present methods include lung, pancreas, breast, colon, laryngeal, ovarian, and the like tissues.

The role of the complex cytokine network that exists in solid human tumors is the subject of a review by Leek et al., J. Leukocyte Biol., 56:423-435 (1994), the disclosure of which is hereby incorporated by reference. A number of cytokines including VEGF, acidic as well as

basic FGF (bFGF), TGF- α and - β , EGF, TNF- α , platelet derived endothelial cell growth factor, angiogenin, interferons α and γ , interleukins 1, 6 and 8 and the like are thought to influence various cellular mechanisms of angiogenesis in malignant tissues and cell lines. For example, in addition to its localization of various kinds of tumors, VEGF has recently been shown to be
5 linked to angiogenesis in breast carcinoma as described by Brown et al. Human Path., 26:86-91 (1995).

Tumors that secrete various cytokines and therein induce localized angiogenesis in response, specifically in the present invention with the cytokines VEGF, TGF- α and EGF and the resultant $\alpha_v\beta_3$ -mediated angiogenesis, are identifiable by screening tumor tissue samples with
10 anti-cytokine antibodies. Such methods are familiar to one of ordinary skill in the art for either cultured or biopsied tumor tissue samples. Antibodies against the above-described cytokines are commercially available through Oncogene Sciences (Uniondale, NY) or Upstate Biotech Incorporated (Lake Placid, NY). The screening of selected tumor tissues by these means thereby allows one to assess the potential of angiogenesis inhibitory activity by the $\alpha_v\beta_3$ antagonists of
15 this invention.

Exemplary tumor tissue angiogenesis, and inhibition thereof, is described in the Examples.

Inhibition of tumor tissue angiogenesis is still another preferred embodiment of the invention because of the important role neovascularization plays in tumor growth. In the
20 absence of neovascularization of tumor tissue, the tumor tissue does not obtain the required nutrients, slows in growth, ceases additional growth, regresses and ultimately becomes necrotic resulting in killing of the tumor.

Stated in other words, the present invention provides for a method of inhibiting tumor neovascularization by inhibiting tumor angiogenesis according to the present methods.
25 Similarly, the invention provides a method of inhibiting tumor growth by practicing the angiogenesis-inhibiting methods.

The methods are also particularly effective against the formation of metastases because (1) their formation requires vascularization of a primary tumor so that the metastatic cancer cells can exit the primary tumor and (2) their establishment in a secondary site requires
30 neovascularization to support growth of the metastases. In a related embodiment, the invention contemplates the practice of the method in conjunction with other therapies such as conventional chemotherapy directed against solid tumors and for control of establishment of metastases. The administration of angiogenesis inhibitor is typically conducted during or after chemotherapy, although it is preferable to inhibit angiogenesis after a regimen of chemotherapy

at times where the tumor tissue will be responding to the toxic assault by inducing angiogenesis to recover by the provision of a blood supply and nutrients to the tumor tissue. In addition, it is preferred to administer the angiogenesis inhibition methods after surgery where solid tumors have been removed as a prophylaxis against metastases.

5 Insofar as the present methods apply to inhibition of tumor neovascularization, the methods can also apply to inhibition of tumor tissue growth, to inhibition of tumor metastases formation, and to regression of established tumors. For the latter, the diminishment of a tumor mass is evaluated in the rabbit eye assay model as described for use in this invention or with a model system of a chimeric mouse:human model in which skin of a mouse having severe
10 combined immunodeficiency (SCID) is replaced with human neonatal foreskin as described by Yan et al., J. Clin. Invest., 91:986-996 (1993), the disclosure of which is hereby incorporated by reference. The latter model presents an additional in vivo model to investigate angiogenesis and inhibition thereof with the methods of this invention. Exemplary results with the rabbit tumor model and an $\alpha_v\beta_3$ antagonists of this invention are presented in Examples 5C and 6D while
15 results for inhibition of angiogenesis in the SCID mouse model is described in Example 8.

Restenosis is a process of smooth muscle cell (SMC) migration and proliferation at the site of percutaneous transluminal coronary angioplasty which hampers the success of angioplasty. The migration and proliferation of SMC's during restenosis can be considered a process of angiogenesis which is inhibited by the present methods. Therefore, the invention also
20 contemplates inhibition of restenosis by inhibiting angiogenesis according to the present methods in a patient following angioplasty procedures. For inhibition of restenosis, the $\alpha_v\beta_3$ antagonist is typically administered after the angioplasty procedure for from about 2 to about 28 days, and more typically for about the first 14 days following the procedure.

The patient treated in the present invention in its many embodiments is desirably a
25 human patient, although it is to be understood that the principles of the invention indicate that the invention is effective with respect to all mammals, which are intended to be included in the term "patient". In this context, a mammal is understood to include any mammalian species in which treatment of diseases, particularly agricultural and domestic mammalian species, is sought with respect to the methods of this invention.

30 The present method for inhibiting angiogenesis in a tissue, and therefore for also practicing the methods for treatment of angiogenesis-related diseases, comprises contacting a tissue in which angiogenesis is occurring, or is at risk for occurring, with a composition comprising a therapeutically effective amount of an $\alpha_v\beta_3$ antagonist capable of inhibiting $\alpha_v\beta_3$ binding to its natural ligand. Thus, the method comprises administering to a patient a

therapeutically effective amount of a physiologically tolerable composition containing an $\alpha_v\beta_3$ antagonist of the invention.

The dosage ranges for the administration of the $\alpha_v\beta_3$ antagonist depend upon the form of the antagonist, and its potency, as described further herein, and are amounts large enough to produce the desired effect in which angiogenesis and the disease symptoms mediated by angiogenesis are ameliorated. The dosage should not be so large as to cause adverse side effects, such as hyperviscosity syndromes, pulmonary edema, congestive heart failure, and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the patient and can be determined by one of skill in the art. The dosage can also be adjusted by the individual physician in the event of any complication.

An $\alpha_v\beta_3$ antagonist is a molecule that blocks or inhibits the physiologic or pharmacologic activity of $\alpha_v\beta_3$ by inhibiting the binding activity of the receptor to its ligand, namely vitronectin. Preferred $\alpha_v\beta_3$ antagonists can either be a monoclonal antibody, a peptide or an organic-based molecule that is a mimetic of an $\alpha_v\beta_3$ ligand.

A therapeutically effective amount is an amount of $\alpha_v\beta_3$ antagonist sufficient to produce a measurable inhibition of angiogenesis in the tissue being treated. i.e., an angiogenesis-inhibiting amount. Inhibition of angiogenesis can be measured in situ by immunohistochemistry, as described herein, or by other methods known to one skilled in the art.

Insofar as an $\alpha_v\beta_3$ antagonist can take the form of an $\alpha_v\beta_3$ ligand organic mimetic, an RGD-containing peptide, an anti- $\alpha_v\beta_3$ monoclonal antibody, or fragment thereof, or an $\alpha_v\beta_3$ receptor mimetic it is to be appreciated that the potency, and therefore an expression of a "therapeutically effective" amount can vary. However, as shown by the present assay methods, one skilled in the art can readily assess the potency of a candidate $\alpha_v\beta_3$ antagonist of this invention.

Potency of an $\alpha_v\beta_3$ antagonist can be measured by a variety of means including inhibition of angiogenesis in the CAM assay, in the in vivo rabbit eye assay, and by measuring inhibition of binding of natural ligand to $\alpha_v\beta_3$, all as described herein, and the like assays.

A preferred $\alpha_v\beta_3$ antagonist has the ability to substantially inhibit binding of a natural ligand such as vitronectin to $\alpha_v\beta_3$ in solution at antagonist concentrations of less than 0.5 micromolar (μM), preferably less than 0.1 μM , and more preferably less than 0.05 μM . By "substantially" is meant that at least a 50 percent reduction in binding of vitronectin is observed by inhibition in the presence of the $\alpha_v\beta_3$ antagonist, and at 50% inhibition is referred to herein as an IC_{50} value.

A more preferred $\alpha_v\beta_3$ antagonist exhibits selectivity for $\alpha_v\beta_3$ over other integrins. Thus,

a preferred $\alpha_v\beta_5$ antagonist substantially inhibits vitronectin binding to $\alpha_v\beta_5$ but does not substantially inhibit binding of vitronectin to another integrin, such as $\alpha_v\beta_1$, $\alpha_v\beta_3$ or $\alpha_{IIb}\beta_3$. Particularly preferred is an $\alpha_v\beta_5$ antagonist that exhibits a 10-fold to 100-fold lower IC_{50} activity at inhibiting vitronectin binding to $\alpha_v\beta_5$ compared to the IC_{50} activity at inhibiting vitronectin binding to another integrin. Exemplary assays for measuring IC_{50} activity at inhibiting vitronectin binding to an integrin are described in the Examples.

A therapeutically effective amount of an $\alpha_v\beta_5$ antagonist of this invention in the form of a monoclonal antibody is typically an amount such that when administered in a physiologically tolerable composition is sufficient to achieve a plasma concentration of from about 0.01 microgram (μ g) per milliliter (ml) to about 100 μ g/ml, preferably from about 1 μ g/ml to about 5 μ g/ml, and usually about 5 μ g/ml. Stated differently, the dosage can vary from about 0.1 mg/kg to about 300 mg/kg, preferably from about 0.2 mg/kg to about 200 mg/kg, most preferably from about 0.5 mg/kg to about 20 mg/kg, in one or more dose administrations daily, for one or several days.

Where the antagonist is in the form of a fragment of a monoclonal antibody, the amount can readily be adjusted based on the mass of the fragment relative to the mass of the whole antibody. A preferred plasma concentration in molarity is from about 2 micromolar (μ M) to about 5 millimolar (mM) and preferably about 100 μ M to 1 mM antibody antagonist.

A therapeutically effective amount of an $\alpha_v\beta_5$ antagonist of this invention in the form of a polypeptide, or other similarly-sized small molecule $\alpha_v\beta_5$ ligand mimetic, is typically an amount of polypeptide such that when administered in a physiologically tolerable composition is sufficient to achieve a plasma concentration of from about 0.1 microgram (μ g) per milliliter (ml) to about 200 μ g/ml, preferably from about 1 μ g/ml to about 150 μ g/ml. Based on a polypeptide having a mass of about 500 grams per mole, the preferred plasma concentration in molarity is from about 2 micromolar (μ M) to about 5 millimolar (mM) and preferably about 100 μ M to 1 mM polypeptide antagonist. Stated differently, the dosage per body weight can vary from about 0.1 mg/kg to about 300 mg/kg, and preferably from about 0.2 mg/kg to about 200 mg/kg, in one or more dose administrations daily, for one or several days.

The monoclonal antibodies, polypeptides or organic mimetics of this invention can be administered parenterally by injection or by gradual infusion over time. Although the tissue to be treated can typically be accessed in the body by systemic administration and therefore most often treated by intravenous administration of therapeutic compositions, other tissues and delivery means are contemplated where there is a likelihood that the tissue targeted contains the target molecule. Thus, monoclonal antibodies, polypeptides or organic mimetics of this inven-

tion can be administered intraocularly, intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, transdermally, and can also be delivered by peristaltic means.

The therapeutic compositions containing an $\alpha_v\beta_3$ antagonist of this invention are conventionally administered intravenously, as by injection of a unit dose, for example. The term
5 “unit dose” when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for the subject, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent, i.e., carrier, or vehicle.

In one preferred embodiment as shown in the Examples, the $\alpha_v\beta_3$ antagonist is
10 administered in a single dosage intravenously.

The compositions are administered in a manner compatible with the dosage formulation and in a therapeutically effective amount. The quantity to be administered and timing of administration depends on the subject to be treated, capacity of the subject's system to utilize the active ingredient, and degree of therapeutic effect desired. Precise amounts of active ingredient
15 required to be administered depend on the judgement of the practitioner and are peculiar to each individual. However, suitable dosage ranges for systemic application are disclosed herein and depend on the route of administration. Suitable regimens for administration are also variable but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration. Alternatively, continuous intravenous
20 infusion sufficient to maintain concentrations in the blood in the ranges specified for in vivo therapies are contemplated.

D. Therapeutic Compositions

The present invention contemplates therapeutic compositions useful for
25 practicing the therapeutic methods described herein. Therapeutic compositions of the present invention contain a physiologically tolerable carrier together with an $\alpha_v\beta_3$ antagonist as described herein, dissolved or dispersed therein as an active ingredient. In a preferred embodiment, the therapeutic $\alpha_v\beta_3$ antagonist composition is not immunogenic when administered to a mammal or human patient for therapeutic purposes.

As used herein, the terms “pharmaceutically acceptable”, “physiologically tolerable” and
30 grammatical variations thereof, as they refer to compositions, carriers, diluents and reagents, are used interchangeably and represent that the materials are capable of administration to or upon a mammal without the production of undesirable physiological effects such as nausea, dizziness, gastric upset and the like.

The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art and need not be limited based on formulation. Typically such compositions are prepared as injectables either as liquid solutions or suspensions, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared. The preparation can also be emulsified.

The active ingredient can be mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.

The therapeutic composition of the present invention can include pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, tartaric, mandelic and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

Particularly preferred is the HCl salt when used in the preparation of cyclic polypeptide $\alpha_1\beta_5$ antagonists.

Physiologically tolerable carriers are well known in the art. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, polyethylene glycol and other solutes.

Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions.

A therapeutic composition contains an angiogenesis-inhibiting amount of an $\alpha_1\beta_5$ antagonist of the present invention, typically formulated to contain an amount of at least 0.1 weight percent of antagonist per weight of total therapeutic composition. A weight percent is a ratio by weight of inhibitor to total composition. Thus, for example, 0.1 weight percent is 0.1

grams of inhibitor per 100 grams of total composition.

E. Antagonists of Integrin $\alpha_v\beta_3$

$\alpha_v\beta_3$ antagonists are used in the present methods for inhibiting angiogenesis in tissues, and can take a variety of forms that include compounds which interact with $\alpha_v\beta_3$ in a manner such that functional interactions with the natural $\alpha_v\beta_3$ ligands are interfered. Exemplary antagonists include analogs or mimetics of $\alpha_v\beta_3$ derived from the ligand binding site on $\alpha_v\beta_3$, mimetics of a natural ligand of $\alpha_v\beta_3$ that mimic the structural region involved in $\alpha_v\beta_3$ -ligand binding interactions, polypeptides having a sequence corresponding to a functional binding domain of the natural ligand specific for $\alpha_v\beta_3$, particularly corresponding to the RGD-containing domain of a natural ligand of $\alpha_v\beta_3$, and antibodies which immunoreact with either $\alpha_v\beta_3$ or the natural ligand, all of which exhibit antagonist activity as defined herein.

1. Polypeptides

In one embodiment, the invention contemplates $\alpha_v\beta_3$ antagonists in the form of polypeptides. A polypeptide (peptide) $\alpha_v\beta_3$ antagonist can have the sequence characteristics of either the natural ligand of $\alpha_v\beta_3$ or $\alpha_v\beta_3$ itself at the region involved in $\alpha_v\beta_3$ -ligand interaction and exhibits $\alpha_v\beta_3$ antagonist activity as described herein. A preferred $\alpha_v\beta_3$ antagonist peptide contains the RGD tripeptide and corresponds in sequence to the natural ligand in the RGD-containing region.

Preferred RGD-containing polypeptides have a sequence corresponding to the amino acid residue sequence of the RGD-containing region of a natural ligand of $\alpha_v\beta_3$ such as vitronectin, for which the sequence is well known.

A particularly preferred $\alpha_v\beta_3$ antagonist peptide preferentially inhibits $\alpha_v\beta_3$ binding to its natural ligand(s) when compared to other integrins, as described earlier. These $\alpha_v\beta_3$ -specific peptides are particularly preferred at least because the specificity for $\alpha_v\beta_3$ reduces the incidence of undesirable side effects such as inhibition of other integrins. The identification of preferred $\alpha_v\beta_3$ antagonist peptides having selectivity for $\alpha_v\beta_3$ can readily be identified in a typical inhibition of binding assay, such as the ELISA assay described in the Examples.

A polypeptide of the present invention typically comprises no more than about 100 amino acid residues, preferably no more than about 60 residues, more preferably no more than about 30 residues. Peptides can be linear or cyclic, although particularly preferred peptides are cyclic. Preferred peptides are described in the Examples.

Where the polypeptide is greater than about 100 residues, it is typically provided in the

form of a fusion protein or protein fragment, as described herein.

It should be understood that a subject polypeptide need not be identical to the amino acid residue sequence of a $\alpha_v\beta_5$ natural ligand, so long as it includes a sequence necessary for antagonizing the binding of an $\alpha_v\beta_5$ ligand to $\alpha_v\beta_5$ and is able to function as an $\alpha_v\beta_5$ antagonist in an assay such as those described herein.

A subject polypeptide includes any analog, fragment or chemical derivative of a polypeptide whose amino acid residue sequence is shown herein so long as the polypeptide is an $\alpha_v\beta_5$ antagonist. Therefore, a present polypeptide can be subject to various changes, substitutions, insertions, and deletions where such changes provide for certain advantages in its use. In this regard, an $\alpha_v\beta_5$ antagonist polypeptide of this invention corresponds to, rather than is identical to, the sequence of a recited peptide where one or more changes are made and it retains the ability to function as an $\alpha_v\beta_5$ antagonist in one or more of the assays as defined herein.

Thus, a polypeptide can be in any of a variety of forms of peptide derivatives, that includes amides, conjugates with proteins, cyclic peptides, polymerized peptides, analogs, fragments, chemically modified peptides, and the like derivatives.

The term "analog" includes any polypeptide having an amino acid residue sequence substantially identical to a sequence specifically shown herein in which one or more residues have been conservatively substituted with a functionally similar residue and which displays the $\alpha_v\beta_5$ antagonist activity as described herein. Examples of conservative substitutions include the substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another, the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine, the substitution of one basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue, such as aspartic acid or glutamic acid for another.

The phrase "conservative substitution" also includes the use of a chemically derivatized residue in place of a non-derivatized residue provided that such polypeptide displays the requisite inhibition activity.

A "chemical derivative" refers to a subject polypeptide having one or more residues chemically derivatized by reaction of a functional side group. In addition to side group derivatizations, a chemical derivative can have one or more backbone modifications including α -amino substitutions such as N-methyl, N-ethyl, N-propyl and the like, and α -carbonyl substitutions such as thioester, thioamide, guanidino and the like. Such derivatized molecules include for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl

groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine. Also included as chemical derivatives are those peptides which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids. For example: 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine. Polypeptides of the present invention also include any polypeptide having one or more additions and/or deletions or residues relative to the sequence of a polypeptide whose sequence is shown herein, so long as the requisite activity is maintained.

A particularly preferred derivative is a cyclic peptide according to the formula cyclo(Arg-Gly-Asp-D-Phe-NMeVal), abbreviated c(RGDf-NMeV), in which there is an N-methyl substituted α -amino group on the valine residue of the peptide and cyclization has joined the primary amino and carboxy termini of the peptide.

The term "fragment" refers to any subject polypeptide having an amino acid residue sequence shorter than that of a polypeptide whose amino acid residue sequence is shown herein.

When a polypeptide of the present invention has a sequence that is not identical to the sequence of an α,β_5 natural ligand, it is typically because one or more conservative or non-conservative substitutions have been made, usually no more than about 30 number percent, and preferably no more than 10 number percent of the amino acid residues are substituted. Additional residues may also be added at either terminus of a polypeptide for the purpose of providing a "linker" by which the polypeptides of this invention can be conveniently affixed to a label or solid matrix, or carrier.

Labels, solid matrices and carriers that can be used with the polypeptides of this invention are described hereinbelow.

Amino acid residue linkers are usually at least one residue and can be 40 or more residues, more often 1 to 10 residues, but do not form α,β_5 ligand epitopes. Typical amino acid residues used for linking are tyrosine, cysteine, lysine, glutamic and aspartic acid, or the like. In addition, a subject polypeptide can differ, unless otherwise specified, from the natural sequence of an α,β_5 ligand by the sequence being modified by terminal-NH₂ acylation, e.g., acetylation, or thioglycolic acid amidation, by terminal-carboxylamidation, e.g., with ammonia, methylamine, and the like terminal modifications. Terminal modifications are useful, as is well known, to reduce susceptibility by proteinase digestion, and therefore serve to prolong half life of the

polypeptides in solutions, particularly biological fluids where proteases may be present. In this regard, polypeptide cyclization is also a useful terminal modification, and is particularly preferred also because of the stable structures formed by cyclization and in view of the biological activities observed for such cyclic peptides as described herein.

5 Any peptide of the present invention may be used in the form of a pharmaceutically acceptable salt. Suitable acids which are capable of forming salts with the peptides of the present invention include inorganic acids such as trifluoroacetic acid (TFA) hydrochloric acid (HCl), hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, methane sulfonic acid, acetic acid, phosphoric acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, 10 oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid or the like. HCl salt is particularly preferred.

Suitable bases capable of forming salts with the peptides of the present invention include inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like; and organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g. triethylamine, 15 diisopropyl amine, methyl amine, dimethyl amine and the like) and optionally substituted ethanolamines (e.g. ethanolamine, diethanolamine and the like).

In addition, a peptide of this invention can be prepared as described in the Examples without including a free ionic salt in which the charged acid or base groups present in the amino acid residue side groups (e.g., Arg, Asp, and the like) associate and neutralize each other to form 20 an "inner salt" compound.

A peptide of the present invention also referred to herein as a subject polypeptide, can be synthesized by any of the techniques that are known to those skilled in the polypeptide art, including recombinant DNA techniques. Synthetic chemistry techniques, such as a solid-phase Merrifield-type synthesis, are preferred for reasons of purity, antigenic specificity, freedom from 25 undesired side products, ease of production and the like. An excellent summary of the many techniques available can be found in Steward et al., "Solid Phase Peptide Synthesis", W.H. Freeman Co., San Francisco, 1969; Bodanszky, et al., "Peptide Synthesis", John Wiley & Sons, Second Edition, 1976; J. Meienhofer, "Hormonal Proteins and Peptides", Vol. 2, p. 46, Academic Press (New York), 1983; Merrifield, Adv. Enzymol., 32:221-96, 1969; Fields et al., 30 Int. J. Peptide Protein Res., 35:161-214, 1990; and United States Patent No. 4,244,946 for solid phase peptide synthesis, and Schroder et al., "The Peptides", Vol. 1, Academic Press (New York), 1965 for classical solution synthesis, each of which is incorporated herein by reference. Appropriate protective groups usable in such synthesis are described in the above texts and in J.F.W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, New York, 1973,

which is incorporated herein by reference.

In general, the solid-phase synthesis methods contemplated comprise the sequential addition of one or more amino acid residues or suitably protected amino acid residues to a growing peptide chain. Normally, either the amino or carboxyl group of the first amino acid residue is protected by a suitable, selectively removable protecting group. A different, selectively removable protecting group is utilized for amino acids containing a reactive side group such as lysine.

Using a solid phase synthesis as exemplary, the protected or derivatized amino acid is attached to an inert solid support through its unprotected carboxyl or amino group. The protecting group of the amino or carboxyl group is then selectively removed and the next amino acid in the sequence having the complimentary (amino or carboxyl) group suitably protected is admixed and reacted under conditions suitable for forming the amide linkage with the residue already attached to the solid support. The protecting group of the amino or carboxyl group is then removed from this newly added amino acid residue, and the next amino acid (suitably protected) is then added, and so forth. After all the desired amino acids have been linked in the proper sequence, any remaining terminal and side group protecting groups (and solid support) are removed sequentially or concurrently to generate the final linear polypeptide.

The resultant linear polypeptides prepared, for example, as described above may be reacted to form their corresponding cyclic peptides. An exemplary method for preparing a cyclic peptide is described by Zimmer et al., Peptides 1992, pp. 393-394, ESCOM Science Publishers, B.V., 1993. Typically, tertbutoxycarbonyl protected peptide methyl ester is dissolved in methanol and sodium hydroxide solution are added and the admixture is reacted at 20°C (20C) to hydrolytically remove the methyl ester protecting group. After evaporating the solvent, the tertbutoxycarbonyl protected peptide is extracted with ethyl acetate from acidified aqueous solvent. The tertbutoxycarbonyl protecting group is then removed under mildly acidic conditions in dioxane cosolvent. The unprotected linear peptide with free amino and carboxy termini so obtained is converted to its corresponding cyclic peptide by reacting a dilute solution of the linear peptide, in a mixture of dichloromethane and dimethylformamide, with dicyclohexylcarbodiimide in the presence of 1-hydroxybenzotriazole and N-methylmorpholine. The resultant cyclic peptide is then purified by chromatography.

Alternate methods for cyclic peptide synthesis are described by Gurrath et al., Eur. J. Biochem., 210:911-921 (1992), and described in the Examples.

In addition, the $\alpha_v\beta_3$ antagonist can be provided in the form of a fusion protein. Fusion proteins are proteins produced by recombinant DNA methods as described herein in which the

subject polypeptide is expressed as a fusion with a second carrier protein such as a glutathione
sulfhydryl transferase (GST) or other well known carrier. Preferred fusion proteins comprise an
MMP-2 polypeptide described herein. The preparation of a MMP-2 fusion protein is described
in the Examples.

5 Particularly preferred peptides or derivative peptides for use in the present methods in
tissues primarily exhibiting $\alpha_v\beta_3$ -associated angiogenesis are described in the Examples, and
include the polypeptides shown in SEQ ID NOs 4, 6, 7, 8 and 9.

Also preferred are polypeptides derived from MMP-2 described herein, having sequences
shown in SEQ ID Nos 11-22.

10 2. Monoclonal Antibodies

The present invention describes, in one embodiment, $\alpha_v\beta_3$ antagonists in
the form of monoclonal antibodies which immunoreact with $\alpha_v\beta_3$ and inhibit $\alpha_v\beta_3$ binding to its
natural ligand as described herein. The invention also describes cell lines which produce the
15 antibodies, methods for producing the cell lines, and methods for producing the monoclonal
antibodies.

A monoclonal antibody of this invention comprises antibody molecules that 1)
immunoreact with isolated $\alpha_v\beta_3$, and 2) inhibit vitronectin binding to $\alpha_v\beta_3$. Preferred
monoclonal antibodies which preferentially bind to $\alpha_v\beta_3$ include a monoclonal antibody having
20 the immunoreaction characteristics of mAb P1F6 and mAb P5H9, which are described in the
Examples.

The term "antibody or antibody molecule" in the various grammatical forms is used
herein as a collective noun that refers to a population of immunoglobulin molecules and/or
immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an
25 antibody combining site or paratope.

An "antibody combining site" is that structural portion of an antibody molecule
comprised of heavy and light chain variable and hypervariable regions that specifically binds
antigen.

Exemplary antibodies for use in the present invention are intact immunoglobulin
30 molecules, substantially intact immunoglobulin molecules and those portions of an
immunoglobulin molecule that contain the paratope, including those portions known in the art as
Fab, Fab', F(ab')₂ and F(v), and also referred to as antibody fragments.

In another preferred embodiment, the invention contemplates a truncated
immunoglobulin molecule comprising a Fab fragment derived from a monoclonal antibody of

this invention. The Fab fragment, lacking Fc receptor, is soluble, and affords therapeutic advantages in serum half life, and diagnostic advantages in modes of using the soluble Fab fragment. The preparation of a soluble Fab fragment is generally known in the immunological arts and can be accomplished by a variety of methods.

5 For example, Fab and F(ab')₂ portions (fragments) of antibodies are prepared by the proteolytic reaction of papain and pepsin, respectively, on substantially intact antibodies by methods that are well known. See for example, U.S. Patent No. 4,342,566 to Theofilopolous and Dixon. Fab' antibody portions are also well known and are produced from F(ab')₂ portions followed by reduction of the disulfide bonds linking the two heavy chain portions as with
10 mercaptoethanol, and followed by alkylation of the resulting protein mercaptan with a reagent such as iodoacetamide. An antibody containing intact immunoglobulin molecules are preferred and are utilized as illustrative herein.

The phrase "monoclonal antibody" in its various grammatical forms refers to a population of antibody molecules that contain only one species of antibody combining site
15 capable of immunoreacting with a particular epitope. A monoclonal antibody thus typically displays a single binding affinity for any epitope with which it immunoreacts. A monoclonal antibody may therefore contain an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different epitope, e.g., a bispecific monoclonal antibody.

A monoclonal antibody is typically composed of antibodies produced by clones of a
20 single cell called a hybridoma that secretes (produces) only one kind of antibody molecule. The hybridoma cell is formed by fusing an antibody-producing cell and a myeloma or other self-perpetuating cell line. The preparation of such antibodies was first described by Kohler and Milstein, Nature, 256:495-497 (1975), the description of which is incorporated by reference. Additional methods are described by Zola, Monoclonal Antibodies: A Manual of Techniques,
25 CRC Press, Inc. (1987). The hybridoma supernates so prepared can then be screened for the presence of antibody molecules that immunoreact with $\alpha_v\beta_5$, and for inhibition of $\alpha_v\beta_5$ binding to natural ligands.

Briefly, to form the hybridoma from which the monoclonal antibody composition is produced, a myeloma or other self-perpetuating cell line is fused with lymphocytes obtained
30 from the spleen of a mammal hyperimmunized with a source of $\alpha_v\beta_5$.

It is preferred that the myeloma cell line used to prepare a hybridoma be from the same species as the lymphocytes. Typically, a mouse of the strain 129 GLX⁺ is the preferred mammal. Suitable mouse myelomas for use in the present invention include the hypoxanthine-aminopterin-thymidine-sensitive (HAT) cell lines P3X63-Ag8.653, and Sp2/0-Ag14 that are

available from the American Type Culture Collection, Rockville, MD, under the designations CRL 1580 and CRL 1581, respectively.

Splenocytes are typically fused with myeloma cells using polyethylene glycol (PEG) 1500. Fused hybrids are selected by their sensitivity to HAT. Hybridomas producing a
5 monoclonal antibody of this invention are identified using the enzyme linked immunosorbent assay (ELISA), a variation of which is described in the Examples.

A monoclonal antibody of the present invention can also be produced by initiating a monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma that secretes antibody molecules of the appropriate specificity. The culture is maintained under
10 conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium. The antibody-containing medium is then collected. The antibody molecules can then be further isolated by well known techniques.

Media useful for the preparation of these compositions are both well known in the art and commercially available and include synthetic culture media, inbred mice and the like. An
15 exemplary synthetic medium is Dulbecco's minimal essential medium (DMEM; Dulbecco et al., Virol., 8:396, 1959) supplemented with 4.5 gm/l glucose, 20 mM glutamine, and 20% fetal calf serum. An exemplary inbred mouse strain is the Balb/c.

Other methods of producing a monoclonal antibody, a hybridoma cell or a hybridoma cell culture are also well known. See, for example, the method of isolating monoclonal
20 antibodies from an immunological repertoire as described by Sastry, et al., Proc. Natl. Acad. Sci., USA, 86:5728-5732 (1989) and Huse et al., Science, 246:1275-1281 (1989).

Also contemplated by this invention is the hybridoma cell, and cultures containing a hybridoma cell that produce a monoclonal antibody of this invention. Particularly preferred is the hybridoma cell line that secretes monoclonal antibody mAb P1F6 and mAb P5H9, the
25 preparation of which is described in the Examples.

The invention contemplates, in one embodiment, a monoclonal antibody that has the immunoreaction characteristics of mAb P1F6 or mAb P5H9.

It is also possible to determine, without undue experimentation, if a monoclonal antibody has the same (i.e., equivalent) specificity (immunoreaction characteristics) as a monoclonal anti-
30 body of this invention by ascertaining whether the former prevents the latter from binding to a preselected target molecule. If the monoclonal antibody being tested competes with the monoclonal antibody of the invention, as shown by a decrease in binding by the monoclonal antibody of the invention in standard competition assays for binding to the target molecule when present in the solid phase, then it is likely that the two monoclonal antibodies bind to the same,

or a closely related, epitope.

Still another way to determine whether a monoclonal antibody has the specificity of a monoclonal antibody of the invention is to pre-incubate the monoclonal antibody of the invention with the target molecule with which it is normally reactive, and then add the monoclonal antibody being tested to determine if the monoclonal antibody being tested is inhibited in its ability to bind the target molecule. If the monoclonal antibody being tested is inhibited then, in all likelihood, it has the same, or functionally equivalent, epitopic specificity as the monoclonal antibody of the invention.

An additional way to determine whether a monoclonal antibody has the specificity of a monoclonal antibody of the invention is to determine the amino acid residue sequence of the CDR regions of the antibodies in question. Antibody molecules having identical, or functionally equivalent, amino acid residue sequences in their CDR regions have the same binding specificity. Methods for sequencing polypeptides are well known in the art.

The immunospecificity of an antibody, its target molecule binding capacity and the attendant affinity the antibody exhibits for the epitope are defined by the epitope with which the antibody immunoreacts. The epitope specificity is defined at least in part by the amino acid residue sequence of the variable region of the heavy chain of the immunoglobulin the antibody and in part by the light chain variable region amino acid residue sequence.

Use of the term "having the binding specificity of" indicates that equivalent monoclonal antibodies exhibit the same or similar immunoreaction (binding) characteristics and compete for binding to a preselected target molecule.

Humanized monoclonal antibodies offer particular advantages over murine monoclonal antibodies, particularly insofar as they can be used therapeutically in humans. Specifically, human antibodies are not cleared from the circulation as rapidly as "foreign" antigens. In addition, human antibodies do not activate the immune system in the same manner as foreign antigens and foreign antibodies. Methods of preparing "humanized" antibodies are generally well known in the art and can readily be applied to the antibodies of the present invention.

Thus, the invention contemplates, in one embodiment, a monoclonal antibody of this invention that is humanized by grafting to introduce components of the human immune system without substantially interfering with the ability of the antibody to bind antigen.

3. $\alpha_1\beta_1$ -Specific Mimetics

The present invention demonstrates that $\alpha_1\beta_1$ antagonists generally can be used in the present invention, the antagonists of which can include polypeptides, antibodies and

other molecules, designated "mimetics", that have the capacity to interfere with $\alpha_v\beta_3$ function. Particularly preferred are antagonists which specifically interfere with $\alpha_v\beta_3$ function, and do not interfere with function of other integrins.

In this context it is appreciated that a variety of reagents may be suitable for use in the present methods, so long as these reagents possess the requisite biological activity. These reagents are generically referred to as mimetics because they possess the ability to "mimic" an $\alpha_v\beta_3$ ligand involved in the functional interaction of the receptor and ligand by blocking the ligand binding domain in the receptor, and thereby interfere with (i.e., inhibit) normal function. In an alternative embodiment, an $\alpha_v\beta_3$ antagonist may be a mimetic of the receptor rather than its ligand.

A mimetic is any molecule, other than an antibody or ligand-derived peptide, which exhibits the above-described properties. It can be a synthetic peptide, an analog or derivative of a peptide, a compound which is shaped like the binding pocket of the above-described binding domain such as an organic mimetic molecule, or other molecule.

A preferred mimetic of this invention is an organic-based molecule and thus is referred to as organic mimetic. Particularly preferred organic mimetic molecules that function as $\alpha_v\beta_3$ antagonists by being a mimetic to a ligand of $\alpha_v\beta_3$ are Compounds 7, 9, 10, 12, 14, 15, 16, 17 and 18 as described in Example 10.

The design of an $\alpha_v\beta_3$ mimetic can be conducted by any of a variety of structural analysis methods for drug-design known in the art, including molecular modeling, two-dimensional nuclear magnetic resonance (2-D NMR) analysis, x-ray crystallography, random screening of peptide, peptide analog or other chemical polymer or compound libraries, and the like drug design methodologies.

In view of the broad structural evidence presented in the present specification which shows that an $\alpha_v\beta_3$ antagonist can be a fusion polypeptide (e.g., an MMP-2 fusion protein), a small polypeptide, a cyclic peptide, a derivative peptide, an organic mimetic molecule, or a monoclonal antibody, that are diversely different chemical structures which share the functional property of selective inhibition of $\alpha_v\beta_3$, the structure of a subject $\alpha_v\beta_3$ antagonist useful in the present methods need not be so limited, but includes any $\alpha_v\beta_3$ mimetic, as defined herein.

F. Methods For Identifying Antagonists of $\alpha_v\beta_3$

The invention also describes assay methods for identifying candidate $\alpha_v\beta_3$ antagonists for use according to the present methods. In these assay methods candidate molecules are evaluated for their potency in inhibiting $\alpha_v\beta_3$ binding to natural ligands, and

furthermore are evaluated for their potency in inhibiting angiogenesis in a tissue.

The first assay measures angiogenesis in the chick chorioallantoic membrane (CAM) and is referred to as the CAM assay. The CAM assay has been described in detail by others, and further has been used to measure both angiogenesis and neovascularization of tumor tissues. See
5 Ausprunk et al., Am. J. Pathol., 79:597-618 (1975) and Ossonski et al., Cancer Res., 40:2300-2309 (1980).

The CAM assay is a well recognized assay model for in vivo angiogenesis because neovascularization of whole tissue is occurring. Actual chick embryo blood vessels are growing into the CAM or into the tissue grown on the CAM.

10 As demonstrated herein, the CAM assay illustrates inhibition of neovascularization based on both the amount and extent of new vessel growth. Furthermore, it is easy to monitor the growth of any tissue transplanted upon the CAM, such as a tumor tissue. Finally, the assay is particularly useful because there is an internal control for toxicity in the assay system. The chick embryo is exposed to any test reagent. As such, the health of the embryo is an indication of
15 toxicity.

The second assay that measures angiogenesis is the in vivo rabbit eye model and is referred to as the rabbit eye assay. The rabbit eye assay has been described in detail by others and further has been used to measure both angiogenesis and neovascularization in the presence of angiogenic inhibitors such as thalidomide. See D'Amato, et al., Proc. Natl. Acad. Sci., USA,
20 91:4082-4085 (1994).

The rabbit eye assay is a well recognized assay model for in vivo angiogenesis because the neovascularization process, exemplified by rabbit blood vessels growing from the rim of the cornea into the cornea, is easily visualized through the naturally transparent cornea of the eye. Additionally, both the extent and the amount of stimulation or inhibition of neovascularization
25 or regression of neovascularization can easily be monitored over time.

Finally, the rabbit is exposed to any test reagent and as such the health of the rabbit is an indication of toxicity of the test reagent.

The third assay measures inhibition of direct binding of the natural ligand, vitronectin, to $\alpha_v\beta_5$, and a preferred embodiment is described in detail in the Examples. The assay typically
30 measures the degree of inhibition of binding of a natural ligand, such as vitronectin, to isolated $\alpha_v\beta_5$ in the solid phase by ELISA, the inhibition of which is mediated by an $\alpha_v\beta_5$ -specific inhibition.

Thus, the assay can also be used to identify compounds which exhibit specificity for $\alpha_v\beta_5$ and do not inhibit natural ligands from binding other integrins. The specificity assay is

conducted by running parallel ELISA assays where both $\alpha_v\beta_3$ and other integrins are screened concurrently in separate assay chambers for their respective abilities to bind a natural ligand and for the candidate compound to inhibit the respective abilities of the integrins to bind a preselected ligand. Preferred screening assay formats are described in the Examples.

5
G. Article of Manufacture

The invention also contemplates an article of manufacture which is a labelled container for providing an $\alpha_v\beta_3$ antagonist of the invention. An article of manufacture comprises packaging material and a pharmaceutical agent contained within the packaging material.

10 The pharmaceutical agent in an article of manufacture is any of the $\alpha_v\beta_3$ antagonists of the present invention, formulated into a pharmaceutically acceptable form as described herein according to the disclosed indications. The article of manufacture contains an amount of pharmaceutical agent sufficient for use in treating a condition indicated herein, either in unit or multiple dosages.

15 The packaging material comprises a label which indicates the use of the pharmaceutical agent contained therein, e.g., for treating conditions assisted by the inhibition of angiogenesis, and the like conditions disclosed herein. The label can further include instructions for use and related information as may be required for marketing. The packaging material can include container(s) for storage of the pharmaceutical agent.

20 As used herein, the term packaging material refers to a material such as glass, plastic, paper, foil, and the like capable of holding within fixed means a pharmaceutical agent. Thus, for example, the packaging material can be plastic or glass vials, laminated envelopes and the like containers used to contain a pharmaceutical composition including the pharmaceutical agent.

25 In preferred embodiments, the packaging material includes a label that is a tangible expression describing the contents of the article of manufacture and the use of the pharmaceutical agent contained therein.

Examples

30 The following examples relating to this invention are illustrative and should not, of course, be construed as specifically limiting the invention. Moreover, such variations of the invention, now known or later developed, which would be within the purview of one skilled in the art are to be considered to fall within the scope of the present invention hereinafter claimed.

1. Preparation of $\alpha_v\beta_3$ -Specific Monoclonal Antibodies

The monoclonal antibodies, P1F6 and P5H9, were produced using standard hybridoma methods by immunization into RBF/DnJ mice with A549 lung carcinoma cells as described by Wayner et al., J. Cell Biol., 113:919-929 (1991), the disclosure of which is hereby incorporated by reference. Spleens were removed from the immunized mice and fused with Ns-1/FOX-NY myeloma cells. Hybridomas producing antibody directed to carcinoma cell vitronectin receptors were screened by the specific inhibition of UCLA-P3 adhesion to vitronectin-coated surfaces as described by Wayner et al. and cloned by limiting dilution on thymocyte feeder layers.

Both the P1F6 and P5H9 monoclonal antibodies have been shown to specifically immunoreact with the $\alpha_v\beta_3$ complex, and not immunoreact with α_v subunit, with β_3 subunit, or with other integrins. The P1F6 monoclonal antibody is commercially available from Gibco BRL (Life Technologies, Inc., Gaithersburg, MD) and the P5H9 monoclonal is available from Dr. E. Wayner at the Fred Hutchinson Cancer Research Institute, Seattle, WA.

Other $\alpha_v\beta_3$ monoclonal antibodies for use in this invention are similarly derived and characterized as described herein. In addition, $\alpha_v\beta_3$ monoclonal antibodies are produced by fusing spleens isolated from mice that receive immunizations with the $\alpha_v\beta_3$ receptor in either an impure or purified form. Purification of the $\alpha_v\beta_3$ is a procedure well known to one of ordinary skill in the art of integrin biology and has also been described by Smith et al., J. Biol. Chem., 265:11008-11013 (1990), the disclosure of which is hereby incorporated by reference. Once purified, the isolated receptor is prepared as an immunogen for immunizing mice as described in Section E2 and as prepared essentially as described by Kohler and Milstein, Nature, 256:495-497 (1975), the disclosure of which is hereby incorporated by reference. The resultant hybridoma clones are screened for reactivity with the immunogen and are then characterized as described in the following Examples.

2. Characterization of the Specificity of the Anti- $\alpha_v\beta_3$ Monoclonal Antibodies and Use in Mapping the Tissue Distribution of $\alpha_v\beta_3$ Expression

A. Specificity for Vitronectin

The P5H9 monoclonal antibody prepared in Example 1 was shown by Wayner et al., J. Cell. Biol., 113:919-929 (1991) to block attachment of UCLA-P3 carcinoma cells to vitronectin while not affecting cell attachment to collagen or fibronectin. The same cells were also shown to contain only the $\alpha_v\beta_3$ vitronectin receptor and not one with $\alpha_v\beta_3$ specificity, immunoprecipitating a heterodimer consisting of an α chain (160 kD) and a β chain (95 kD) with nonreducing conditions. The $\alpha_v\beta_3$ receptor detected by P5H9 was also shown to mediate

adhesion of M21 melanoma cells and H2981 carcinoma cells to vitronectin. The P1F6 monoclonal antibody has the same immunoreactivity profile.

B. Immunofluorescence with Anti-Integrin Receptor Antibodies

During wound healing, the basement membranes of blood vessels express several adhesive proteins, including von Willebrand factor, fibronectin, and fibrin. In addition, several members of the integrin family of adhesion receptors are expressed on the surface of cultured smooth muscle and endothelial cells. See, Cheresh, Proc. Natl. Acad. Sci., USA, 84:6471 (1987); Janat et al., J. Cell Physiol., 151:588 (1992); and Cheng et al., J. Cell Physiol., 139:275 (1989).

In addition to the structure and function of the integrin β_5 subunit, the tissue distribution of the subunit by mapping with other anti- β_5 monoclonal antibodies has been described by Pasqualini et al., J. Cell Sci., 105:101-111 (1993), the disclosure of which is hereby incorporated by reference.

The β_5 subunit-specific monoclonal antibodies described above, similar to those described in Example 1, were secreted from hybridomas that were prepared using splenocytes from a mouse that received immunizations with the A549 human lung carcinoma cell line. The hybridomas were selected by positive surface staining of A549 cells with the hybridomas culture supernatant and by immunoprecipitation of $\alpha_v\beta_5$ complexes from surface-labeled A549 extracts. The monoclonal antibodies were then used to map the tissue distribution of the β_5 subunit in normal human thymus, skin and kidney. Four micron thick sections were cut from the frozen tissue blocks on a cryostat microtome for subsequent streptavidin-biotin immunoperoxidase staining with antibodies specific for the β_5 integrins performed as described in the Pasqualini et al. reference.

Staining of thymic sections showed the distribution of β_5 on blood vessels, Hassal's corpuscles, cortical and medullary stromal cells, and basement membranes. Skin sections showed β_5 on the basal layer of the epidermis and on some dermal blood vessel walls, and kidney sections showed staining of glomerular regions, juxtaglomerular apparatus, proximal convoluted tubules and collecting tubules. Thus, the distribution of β_5 is heterogeneous to different cell types including and, more importantly, on capillary endothelial cells, the staining of which was consistent with staining of cultured umbilical vein endothelial cells.

C. Immunofluorescence of Human Retinal Tissue from Patients with Ocular Disease with Anti-Integrin Receptor Antibodies

Ocular neovascularization is the most common pathological change observed in the vast majority of eye diseases that result in catastrophic loss of vision. The growth of new blood vessels from the pre-existing choroidal, retinal or paralimbal vessels can lead to edema, hemorrhage or fibrovascular membrane formation resulting in disruption of the normal anatomic relationships of the eye and concomitant loss of normal visual function.

Under physiological conditions, angiogenesis is highly regulated and has been shown to be activated by specific angiogenic cytokines such as basic fibroblast growth factor (bFGF) and tumor necrosis factor- α (TNF- α). As described by Brooks et al., *Science*, 264:569-571 (1994), monoclonal antibodies against $\alpha_v\beta_3$ have been shown to block both bFGF- and TNF- α -induced angiogenesis in model systems including the CAM model described below. As described in Examples 4-6, monoclonal antibodies against $\alpha_v\beta_5$ block a separate pathway of angiogenesis, specifically that induced by vascular endothelial growth factor (VEGF), transforming growth factor- α (TGF- α) and epidermal growth factor (EGF).

Thus, as described herein in the context of the present invention, two pathways of angiogenesis are defined by distinct integrins, $\alpha_v\beta_3$ and $\alpha_v\beta_5$. To investigate the expression and role of these integrins in human ocular disease, epiretinal neovascular membranes and subretinal neovascular membranes were obtained en bloc at vitrectomy from patients with proliferative diabetic retinopathy (PDR). These patients had been followed clinically and were selected for histological evaluation on the basis of having active, proliferative neovascular disease documented by clinical examination and fundus fluorescein angiography. The obtained tissue was frozen immediately in Tissue Tek cryopreservative and sectioned.

When the tissues from these patients were examined by immunofluorescence, the blood vessels were positive for the integrin $\alpha_v\beta_3$ as indicated by immunoreactivity with the mouse monoclonal antibody LM609. The distribution of the integrin appeared to be restricted to blood vessels and coincided with staining for a marker of blood vessels, von Willebrand Factor, as mapped with a rabbit antibody to the factor. The sites of immunoreactivity were visualized with either rhodamine-conjugated anti-mouse immunoglobulin or fluorescein-conjugated anti-rabbit immunoglobulin, the use of both of which allowed co-localization of the integrin location and blood vessel-specific antibodies.

Specimens obtained from normal eyes or patients with atrophic membranes free from actively proliferating blood vessels were negative for the integrin $\alpha_v\beta_3$ by immunofluorescence.

In parallel, the same tissues were analyzed immunohistochemically for the presence and

distribution of $\alpha_v\beta_5$ with the anti- $\alpha_v\beta_5$ monoclonal antibody, P1F6, prepared in Example 1. The staining revealed that $\alpha_v\beta_5$ was present on blood vessels that co-localized with the distribution of von Willebrand factor. However, the non-vascular tissue also displayed limited fluorescence with the P1F6 antibody indicating a wider distribution of $\alpha_v\beta_5$. This was in contrast to the presence of $\alpha_v\beta_3$ that was limited to blood vessels.

When immunofluorescent staining of membranes was compared between $\alpha_v\beta_3$ and $\alpha_v\beta_5$ with the respective antibodies LM609 and P1F6, the pattern of staining on the blood vessel wall was virtually identical indicating that both $\alpha_v\beta_3$ and $\alpha_v\beta_5$ are displayed on the surface of newly proliferating human blood vessels present in neovascular eye diseases such as diabetic retinopathy.

The results described herein thus show that the $\alpha_v\beta_5$ integrin receptor is selectively expressed in specific tissue types in which angiogenesis is occurring, such as that seen with neovascular membranes from patients having active, proliferative neovascular disease. These tissues, along with those tissues exposed to particular growth factors as described below in Examples 4-6, therefore provide ideal targets for therapeutic aspects of this invention.

3. Preparation of Synthetic Peptides

a. Synthesis Procedure

The cyclic polypeptides used in practicing the methods of this invention were synthesized using standard solid-phase synthesis techniques as, for example, described by Merrifield, Adv. Enzymol., 32:221-296 (1969), and Fields, G.B. and Noble, R.L., Int. J. Peptide Protein Res., 35:161-214 (1990).

Two grams (g) of BOC-Arg-Gly-Asp-D-Phe-Val-OMe (SEQ ID NO 1) were first dissolved in 60 milliliters (ml) of methanol to which was added 1.5 ml of 2 N sodium hydroxide solution to form an admixture. The admixture was then stirred for 3 hours at 20 degrees C (20C). After evaporation, the residue was taken up in water and acidified to pH 3 with diluted HCl and extracted with ethyl acetate. The extract was dried over Na_2SO_4 , evaporated again and the resultant BOC-Arg-Gly-Asp-D-Phe-Val-OH (SEQ ID NO 2) was stirred at 20C for 2 hours with 20 ml of 2 N HCl in dioxane. The resultant admixture was evaporated to obtain H-Arg-Gly-Asp-D-Phe-Val-OH (SEQ ID NO 3) that was subsequently dissolved in a mixture of 1800 ml of dichloromethane and 200 ml of dimethylformamide (DMF) followed by cooling to 0C. Thereafter, 0.5 g of dicyclohexylcarbodiimide (DCCI), 0.3 g of 1-hydroxybenzotriazole (HOBt) and 0.23 ml of N-methylmorpholine were added sequentially with stirring.

The resultant admixture was stirred for another 24 hours at 0C and then at 20C for yet

another 48 hours. The solution was concentrated and treated with a mixed bed ion exchanger to remove salts. After the resulting resin was removed by filtration, the clarified solution was evaporated and the residue was purified by chromatography resulting in the recovery of cyclo(Arg-Gly-Asp-D-Phe-Val) (also listed in single letter code as c-RGDfV) (SEQ ID NO 4).

5 The lower case letters in the peptide indicate the D form of the amino acid and not the L form as indicated by capital letters.

The cyclic control peptide, cyclo(Arg-Ala-Asp-D-Phe-Val) (also listed in single letter code as RADfV) (SEQ ID NO 5) was prepared as described above. The cyclic peptide c-RADfV (SEQ ID NO 5) has previously been shown to inhibit binding of fibrinogen to the integrin $\alpha_v\beta_3$, and not inhibit binding of fibrinogen to the integrins $\alpha_{IIb}\beta_3$ or $\alpha_5\beta_1$ (Pfaff, et al., J. Biol. Chem., 269:20233-20238, 1994).

Other peptides that are specifically inhibitory to the binding of natural ligands to $\alpha_v\beta_3$ are similarly prepared as tested for specificity and range of activity as described in the following examples. These include the following peptides that were analogously obtained: cyclo(Gly-D-Arg-Gly-Asp-Phe-Val) (SEQ ID NO 6) and cyclo(Arg-Gly-Asp-Phe-D-Val) (SEQ ID NO 7). The peptides having the amino acid residue sequence Tyr-Thr-Ala-Glu-Cys-Lys-Pro-Gln-Val-Thr-Arg-Gly-Asp-Val-Phe (SEQ ID NO 8) and cyclo (Arg-Gly-Asp-D-Phe-NMeVal) (SEQ ID NO 9) were also synthetically prepared. In SEQ ID NO 9, the prefix "Me" in MeVal signifies that the valine in position 6 is modified by methylation at the alpha amino nitrogen in the amide bond of the valine residue.

b. Alternate Synthesis Procedure

i. Synthesis of cyclo-(Arg-Gly-Asp-DPhe-NmeVal), TFA salt

Fmoc-Arg(Mtr)-Gly-Asp(OBut)-DPhe-NMeVal-ONa is synthesized using solid-phase Merrifield-type procedures by sequentially adding NMeVal, DPhe, Asp(OBut), Gly and Fmoc-Arg(Mtr) in a step-wise manner to a 4-hydroxymethyl-phenoxyethyl-polystyrene resin (Wang type resin) (customary Merrifield-type methods of peptide synthesis are applied as described in Houben-Weyl, 1.c., Volume 15/II, Pages 1 to 806 (1974). The polystyrene resin and amino acid residues precursors are commercially available from Aldrich, Sigma or Fluka chemical companies). After completion of sequential addition of the amino acid residues, the resin is then eliminated from the peptide chain using a 1:1 mixture of TFA/dichloromethane which provides the Fmoc-Arg(Mtr)-Gly-Asp(OBut)-DPhe-NMeVal-OH product. The Fmoc group is then removed with a 1:1 mixture of piperidine/DMF which provides the crude Arg(Mtr)-Gly-Asp(OBut)-DPhe-NMeVal-OH precursor which is then purified by HPLC in the customary manner.

For cyclization, a solution of 0.6 g of Arg(Mtr)-Gly-Asp(OBut)-DPhe-NMeVal-OH (synthesized above) in 15 ml of DMF (dimethylformamide; Aldrich) is diluted with 85 ml of dichloromethane (Aldrich), and 50 mg of NaHCO₃ are added. After cooling in a dry ice/acetone mixture, 40 µl of diphenylphosphoryl azide (Aldrich) are added. After standing at room temperature for 16 hours, the solution is concentrated. The concentrate is gel-filtered (Sephadex G10 column in isopropanol/water 8:2) and then purified by HPLC in the customary manner. Treatment with TFA (trifluoroacetic acid)/H₂O (98:2) gives cyclo-(Arg-Gly-Asp-DPhe-NmeVal) x TFA which is then purified by HPLC in the customary manner; RT = 19.5; FAB-MS (M+H): 589.

ii. Synthesis of "Inner Salt"

TFA salt is removed from the above-produced cyclic peptide by suspending the cyclo-(Arg-Gly-Asp-DPhe-NmeVal) x TFA in water followed by evaporation under vacuum to remove the TFA. The cyclic peptide formed is referred to as an "inner salt" and is designated cyclo-(Arg-Gly-Asp-DPhe-NMeVal). The term "inner salt" is used because the cyclic peptide contains two oppositely charged residues which intra-electronically counterbalance each other to form an overall noncharged molecule. One of the charged residues contains an acid moiety and the other charged residue contains an amino moiety. When the acid moiety and the amino moiety are in close proximity to one another, the acid moiety can be deprotonated by the amino moiety which forms a carboxylate/ammonium salt species with an overall neutral charge.

iii. HCl treatment to give cyclo-(Arg-Gly-Asp-DPhe-NMeVal) x HCl

80 mg of cyclo-(Arg-Gly-Asp-DPhe-NMeVal) are dissolved in 0.01 M HCl five to six times and freeze dried after each dissolving operation. Subsequent purification by HPLC give cyclo-(Arg-Gly-Asp-DPhe-NMeVal) x HCl; FAB-MS (M+H): 589.

iv. Methane sulfonic acid treatment to give cyclo-(Arg-Gly-Asp-DPhe-NMeVal) x MeSO₃H

80 mg of cyclo-(Arg-Gly-Asp-DPhe-NMeVal) are dissolved in 0.01 M MeSO₃H (methane sulfonic acid) five to six times and freeze dried after each dissolving operation. Subsequent purification by HPLC give cyclo-(Arg-Gly-Asp-DPhe-NMeVal) x MeSO₃H; RT = 17.8 ; FAB-MS (M+H): 589.

Alternative methods of cyclization include derivatizing the side group chains of an acyclic peptide precursor with sulfhydryl moieties, and when exposed to slightly higher than normal physiological pH conditions (pH 7.5), intramolecularly forms disulfide bonds with other sulfhydryl groups present in the molecule to form a cyclic peptide. Additionally, the C-terminus carboxylate moiety of an acyclic peptide precursor can be reacted with a free sulfhydryl moiety present within the molecule for producing thioester cyclized peptides.

Table 1

	<u>Peptide</u>	<u>Amino Acid Sequence</u>	<u>SEQ ID NO</u>
	<u>Designation</u>		
10	62184 (66203*)	cyclo(RGDfV)	4
	62185 (69601*)	cyclo(RADfV)	5
	62181	cyclo(GrGDFV)	6
15	62187	cyclo(RGDfV)	7
	62880	YTAECKPQVTRGDVF	8
	121974 (85189*)	cyclo (RDGf-NMeV)	9
	112784	cyclo (RGEf-NMeV)	10
	huMMP-2 (410-631)**		11
20	huMMP-2 (439-631)**		12
	huMMP-2 (439-512)**		13
	huMMP-2 (439-546)**		14
	huMMP-2 (510-631)**		15
	huMMP-2 (543-631)**		16
25	chMMP-2 (410-637)***		17
	chMMP-2 (445-637)***		18
	chMMP-2 (445-518)***		19
	chMMP-2 (445-552)***		20
	chMMP-2 (516-637)***		21
30	chMMP-2 (549-637)***		22

* The peptides designated with an asterisk are prepared in HCl and are identical in sequence to the peptide designated on the same line; the peptides without an asterisk are prepared in TFA. Lower case letters indicate a D-amino acid; capital letters indicate a L-amino acid.

** The human MMP-2 amino acid residue sequences for synthetic peptides are indicated by the corresponding residue positions shown in Figures 15A and 15B and also in Figure 16. (MMP-2 refers to a member of the family of matrix metalloproteinase enzymes). The human MMP-2 sequences are listed with the natural cysteine residues but are not listed with engineered cysteine residues as described for the fusion peptides. The non-natural cysteine residues were substituted for the natural amino acid residue at the indicated residue positions in order to facilitate solubility of the synthetic as well as expressed fusion proteins and to ensure proper folding for presentation of the binding site.

*** The chicken MMP-2 amino acid residue sequences for synthetic peptides are indicated by the corresponding residue positions shown in Figures 15A and 15B. The chicken MMP-2 sequences are listed with the natural cysteine residues but not with the engineered cysteine residues as described for the fusion peptides as described above.

4. Inhibition of Growth Factor-Induced Angiogenesis With $\alpha_v\beta_3$ Antagonists as Measured by In Vivo Rabbit Eye Model Assay

The effect of anti- $\alpha_v\beta_3$ antagonists on growth factor-induced angiogenesis can be observed in naturally transparent structures as exemplified by the cornea of the eye. New blood vessels grow from the rim of the cornea, which has a rich blood supply, toward the center of the cornea, which normally does not have a blood vessels. Stimulators of angiogenesis, such as VEGF and TGF- α , when applied to the cornea induce the growth of new blood vessels from the rim of the cornea. Antagonists of angiogenesis, applied to the cornea, inhibit the growth of new blood vessels from the rim of the cornea. Thus, the cornea undergoes angiogenesis through an invasion of endothelial cells from the rim of the cornea into the tough collagen-packed corneal tissue which is easily visible. The rabbit eye model assay therefore provides an in vivo model for the direct observation of stimulation and inhibition of angiogenesis following the implantation of compounds directly into the cornea of the eye.

A. In Vivo Rabbit Eye Model Assay

1) Angiogenesis Induced by Growth Factors

Angiogenesis was induced in the in vivo rabbit eye model assay with growth factors and is described in the following.

a. Preparation of Hydron Pellets Containing Growth Factor and Monoclonal Antibodies

Hydron polymer pellets containing growth factor and monoclonal antibodies (mAbs) were prepared as described by D'Amato, et al., Proc. Natl. Acad. Sci., 91:4082-4085 (1994). The individual pellets contained 750 ng of the growth factor (also referred to as cytokine), specifically either bFGF or VEGF, bound to sucralfate (carafate) (Carafet, Marion Merrell Dow Corporation, Cincinnati, OH) to stabilize the cytokines and ensure their slow release into the surrounding tissue. In addition, hydron pellets were prepared which contained either 40 µg of the mAb P1F6 (anti- $\alpha_v\beta_3$) or the control antibody, LM609 (anti- $\alpha_v\beta_3$), in PBS.

All of the mAbs tested were purified from ascites fluid using Protein-A Sepharose CL-4B affinity column chromatography according to well-known methods. The eluted immunoglobulin was then dialyzed against PBS and treated with Detoxi-gel (Pierce Chemicals, Rockford, IL) to remove endotoxin. Endotoxin has been shown to be a potent angiogenic and inflammatory stimulant. Monoclonal antibodies were therefore tested for the presence of endotoxin with the Chromogenic Limulus Amebocyte Lysate Assay (BioWhittaker, Walkersville, MD) and only those mAbs without detectable endotoxin were used in the rabbit eye model assay.

The pellets were cast in specially prepared Teflon pegs that had a 2.5 mm core drilled into their surfaces. Approximately 12 µl of casting material was placed into each peg and polymerized overnight in a sterile hood. Pellets were then sterilized by ultraviolet irradiation.

A series of eight animals were used for paired eye experiments where each animal received a Hydron implant containing a preselected cytokine with a preselected antibody or control immunoglobulin. Specifically, for each rabbit, one cornea was surgically implanted with a Hydron pellet containing either bFGF or VEGF in conjunction with mAb P1F6 and the other cornea was treated with either bFGF or VEGF in conjunction with MAb LM609. Individual pellets were implanted into surgically created "pockets" formed in the mid-stroma of the cornea of rabbits. The surgical procedure was done under sterile technique using a Wild model M691 operating microscope equipped with a beamsplitter to which was mounted a camera for photographically recording individual corneas. A 3 mm by 5 mm "pocket" was created in the corneal stroma by making a 3 mm incision to half the corneal thickness with a 69 Beaver blade. The stroma was dissected peripherally using an iris spatula and the pellet was implanted with its peripheral margin 2 mm from the limbus.

During the following 12 days, the cytokines and mAbs diffused from the implanted

pellets into the surrounding tissue thereby effecting angiogenesis from the rim of the cornea.

The left and right corneas are respectively referred to as OS and OD. The corneas were then observed for 12 days. Photographs were taken on postoperative day 10, the time at which neovascularization is maximal.

Representative photographic results of the above-treatments with cytokine/mAb admixtures are shown in Figures 1A-1D. The parallel quantitation of mAb inhibition of cytokine-induced angiogenesis is shown in Figures 2A and 2B. In Figures 1A and 1D, in which corneas were respectively exposed to bFGF/P1F6 and VEGF/LM609 combinations, cytokine-induced angiogenesis with edema is prominent as indicated by the large arrows. Therefore, the $\alpha_v\beta_3$ antibody, P1F6, was not effective at inhibiting bFGF-induced angiogenesis. Similarly, the $\alpha_v\beta_3$ antibody, LM609, was not effective at inhibiting VEGF-induced angiogenesis.

In contrast, when the cytokine/mAb combinations of bFGF/LM609 and VEGF/P1F6 were used in the rabbit model, the cytokine-induced angiogenesis was inhibited by the antibodies as shown in Figures 1B and 1C, respectively. In these figures, normal conjunctival limbal vessels indicated by the small arrows are shown indicating effectiveness of the integrin antibodies in inhibiting one type of cytokine-induced angiogenesis.

The effects of specific mAb integrin immunoreactivity on the above cytokine-induced angiogenesis is also quantified as shown in Figures 2A and 2B. Angiogenesis was stimulated with either bFGF or VEGF as shown respectively in Figures 2A and 2B. The treated eyes were photographed daily through a Wild operating microscope outfitted with a Nikon camera. Photographs were recorded on Kodak Ektachrome 64T slide film and images were converted for computer-assisted quantitation using Biorad's Molecular Analyst 1.1 software after acquisition through a Model GS670 imaging densitometer. Histograms illustrating the mean neovascular area +/- the standard error (n=8 for each of two series) after exposure to the mAbs P1F6 or LM609.

As shown in Figure 2A, LM609 reduced bFGF-induced angiogenesis by 86% (p < 0.005, paired t-test) when compared to treatment of the paired eye on the same animal with P1F6. When VEGF was used to stimulate angiogenesis as shown in Figure 2B, the opposite effect was observed where P1F6 reduced the mean area of neovascularization by 60% (p < 0.03, paired t-test) compared to the LM609-treated eye that had a minimal effect on VEGF-induced angiogenesis.

Significantly, only the newly cytokine-induced blood vessels were effected by exposure to a particular mAb while the pre-existing perilimbal vessels were unaffected by either mAb suggesting that the effects observed are restricted to newly forming blood vessels of the cornea.

Similar assays are performed with synthetic peptides prepared in Example 3 and as described below for use in inhibiting cytokine-induced angiogenesis that is specifically correlated with $\alpha_v\beta_3$ expression.

To confirm these results indicating that angiogenesis induced by a particular cytokine was only effected by one type of anti-integrin antibody, specifically that $\alpha_v\beta_3$ integrin receptor plays a role in VEGF-induced angiogenesis, another neovascular model of the chick chorioallantoic membrane (CAM) was evaluated with the combinations of cytokines and integrin antibodies as shown in the next Example.

b. Treatment with Polypeptides

Each experiment consisted of eight rabbits in which one eye received a pellet comprising 100 nanograms (ng) bFGF and the other eye received a pellet comprising 1 microgram (ug) VEGF. The pellets were inserted into the corneal pocket as described above, and the cytokines subsequently stimulated the growth of new blood vessels into the cornea. Peptides were administered subcutaneously (s.q.) in 1 ml PBS at an initial dosage of 50 ug per kg rabbit the day of pellet insertion, and daily s.q. dosages were given at 20 ug/kg thereafter. After 7 days, the cornea were evaluated as described above.

Rabbits receiving control peptide 69601 showed substantial corneal blood vessel growth at 7 days, in both vFGF and VEGF stimulated eyes. Rabbits receiving peptide 85189 showed less than 50% of the amount of corneal blood vessel growth compared to controls in vFGF-stimulated eyes and nearly 100% inhibition in VEGF-stimulated eyes.

5. Angiogenesis in the Chick Chorioallantoic Membrane (CAM) Preparation

A. Characterization of the Untreated CAM

1) Preparation of the CAM

Angiogenesis can be induced on the chick chorioallantoic membrane (CAM) after normal embryonic angiogenesis has resulted in the formation of mature blood vessels. Angiogenesis has been shown to be induced in response to specific cytokines or tumor fragments as described by Leibovich et al., Nature, 329:630 (1987) and Ausprunk et al., Am. J. Pathol., 79:597 (1975). CAMs were prepared from chick embryos for subsequent induction of angiogenesis and inhibition thereof as described below and in Example 6 with the $\alpha_v\beta_3$ antagonists of this invention.

Ten day old chick embryos were obtained from McIntyre Poultry (Lakeside, CA) and incubated at 37C with 60% humidity. A small hole was made through the shell at the end of the

egg directly over the air sac with the use of a small crafts drill (Dremel, Division of Emerson Electric Co., Racine, WI). A second hole was drilled on the broad side of the egg in a region devoid of embryonic blood vessels determined previously by candling the egg. Negative pressure was applied to the original hole, which resulted in the CAM (chorioallantoic membrane) pulling away from the shell membrane and creating a false air sac over the CAM. A 1.0 centimeter (cm) x 1.0 cm square window was cut through the shell over the dropped CAM with the use of a small model grinding wheel (Dremel). The small window allowed direct access to the underlying CAM.

The resultant CAM preparation was then used at 10 days of embryogenesis where angiogenesis has subsided. The preparation was thus used in this invention for inducing renewed angiogenesis in response to cytokine treatment.

2) Histology of the CAM

To analyze the microscopic structure of the chick embryo CAMs, six micron (μm) thick sections were cut from the frozen blocks on a cryostat microtome for immunofluorescence analysis.

Typical of an untreated 10 day old CAM is an area devoid of blood vessels. As angiogenesis in the CAM system is subsiding by this stage of embryogenesis, the system is useful in this invention for stimulating with various cytokines the production of new vasculature from existing vessels from adjacent areas into areas of the CAM currently lacking any vessels.

As shown in the CAM model and in the following Examples, while the blood vessels are undergoing new growth in normal embryogenesis or induced by cytokines, the blood vessels are expressing $\alpha_v\beta_3$ and $\alpha_v\beta_5$.

B. Angiogenesis Induced by Growth Factors

Angiogenesis has been shown to be induced by cytokines or growth factors as described in Example 4A in the rabbit eye model. In the experiments described herein, angiogenesis in the rabbit corneal preparation described in Example 4 was similarly induced by growth factors that were topically applied onto the CAM blood vessels as described herein.

Angiogenesis was induced by placing a 5 millimeter (mm) X 5 mm Whatman filter disk (Whatman Filter paper No. 1) saturated with Hanks Balanced Salt Solution (HBSS, GIBCO, Grand Island, NY) or HBSS containing preselected cytokines at a preselected concentration, i.e., one to test the effect on angiogenesis, on the CAM of a 10 day chick embryo in a region devoid of blood vessels and the windows were later sealed with tape. Angiogenesis was monitored by

photomicroscopy after 72 hours. CAMs were snap frozen then 6 μ m cryostat sections were fixed with acetone and stained by immunofluorescence as described in Example 2B and 2C with 10 μ g/ml of selected anti-integrin antibodies, including those directed against $\alpha_v\beta_3$ as described in Example 1.

5 Previous studies by Brooks et al., Science, 264:569-571 (1994), have shown that blood vessels are readily apparent in both the bFGF and TNF- α treated preparations but are not present in the untreated CAM. The authors have also shown that $\alpha_v\beta_3$ expression was enhanced following bFGF-induced angiogenesis. While the expression of integrin β_1 did not change from that seen in an untreated CAM, β_1 was also readily detectable on stimulated blood vessels.

10 These published findings indicated that in both human and chick, blood vessels involved in angiogenesis show enhanced expression of $\alpha_v\beta_3$. Consistent with this, expression of $\alpha_v\beta_3$ on cultured endothelial cells were induced by various cytokines in vitro as described by Janat et al., J. Cell Physiol., 151:588 (1992); Enenstein et al., Exp. Cell Res., 203:499 (1992) and Swerlick et al., J. Invest. Derm., 99:715 (1993).

15 In this invention, a separate cytokine-mediated pathway for simulating angiogenesis that is dependent upon expression and activation of a different adhesive integrin receptor, $\alpha_v\beta_5$, has now been determined. The effect of exposure of a CAM as described herein to the cytokines VEGF, TGF- α and EGF in relationship to the expression of $\alpha_v\beta_5$, to angiogenesis and inhibition thereof with $\alpha_v\beta_5$ antagonists is described in Example 6.

20 C. Angiogenesis Induced by Tumors

To investigate the role of $\alpha_v\beta_5$ in tumor-induced angiogenesis, various $\alpha_v\beta_5$ -negative human melanoma and carcinoma fragments are used in the CAM assay that are previously grown and isolated from the CAM of 17 day chick embryo as described by Brooks et al., J. Cell Biol., 122:1351 (1993) and as described herein.

25 Angiogenesis is induced in the CAM assay system by direct apposition of a tumor fragment on the CAM. Preparation of the chick embryo CAM is identical to the procedure described above. Instead of a filter paper disk, a 50 milligram (mg) to 55 mg in weight fragment of one $\alpha_v\beta_5$ -negative tumor resulting from growth of cell line suspensions described below, is placed on the CAM in an area originally devoid of blood vessels.

30 The cell lines, rhabdomyosarcoma, myeloid (HL-60 or KG-1), and lymphoid (T cells - Jurkat, HPB/ALL, PEER; and various B cell lines) as described by Pasqualini et al. J. Cell Sci., 105:101-111 (1993), are used to grow the solid human tumors on the CAMs of chick embryos. A single cell suspension of the various cell lines are first applied to the CAMs in a total volume

of 30 μ l of sterile HBSS. The windows are sealed with tape and the embryos are incubated for 7 days to allow growth of human tumor lesions. At the end of 7 days, now a 17 day embryo, the tumors are resected from the CAMs and trimmed free of surrounding CAM tissue. The tumors are sliced into 50 mg to 55 mg tumor fragments for use in angiogenesis. The tumor fragments are placed on a new set of 10 day chick embryo CAMs as described in Example 5A in an area devoid of blood vessels.

Tumors grown in vivo on the chick embryo CAMs with and without topical or intravenous application of $\alpha_v\beta_3$ -inducing cytokines (VEGF, TGF- α , or EGF) are then stained for $\alpha_v\beta_3$ expression with mAbs, P1F6 or P5H9, as previously described.

These CAM tumor preparations are then subsequently treated as described in Examples 6C and 6D for measuring the effects of antibodies and peptides including MMP-2 C-terminal fragments on tumor-induced angiogenesis.

In one embodiment, hamster melanoma cells, CS-1, obtained from Dr. Caroline Damsky from University of California at San Francisco, were used in the CAM assay as described above for formation of melanoma tumors. Following the transfer of approximately a 50 mg CS-1 tumor fragment on a new 10 day chick embryo CAM, separate preparations received an intravenous injections of either 100 μ g or 300 μ g of P1F6 antibody, LM609 antibody or control CSAT (anti- β_1) antibody. An additional control included a preparation that received no treatment. The results are discussed below in Example 6D.

6. Inhibition of Angiogenesis as Measured in the CAM Assay

A. Inhibition of Growth Factor-Induced Angiogenesis by Intravenous Application of Inhibitors

The effect on growth factor-induced angiogenesis with monoclonal antibodies intravenously injected into the CAM preparation was evaluated for use as an in vivo model system of this invention.

Following active neovascularization, once the vessels have stopped developing, the expression of $\alpha_v\beta_3$ diminishes to levels not detectable by immunofluorescence analysis. This regulation of $\alpha_v\beta_3$ expression in blood vessels undergoing angiogenesis as contrasted to the lack of expression in mature vessels provides for the unique ability of this invention to control and inhibit angiogenesis as shown below as modeled in the CAM angiogenesis assay system.

The preparation of the chick embryo CAMs for intravenous injections was essentially as described above.

Angiogenesis was first induced on 10 day old chick embryos by application of growth

factor-saturated filter disks. Specifically, in the first assays, angiogenesis was induced by exposure to either bFGF or VEGF, each at a concentration of 150 ng/ml.

For application of growth factors, during the candling procedures, prominent blood vessels were selected and marks were made on the egg shell to indicate their positions. The holes were drilled in the shell, the CAMs were dropped and growth factor-saturated filter papers were then separately placed on the CAMs as described above. The windows were sealed with sterile tape and the embryos were replaced in the incubator.

Twenty four hours later, a second small window was carefully cut on the lateral side of the egg shell directly over prominent blood vessels selected previously. The outer egg shell was carefully removed leaving the embryonic membranes intact. The shell membrane was made transparent with a small drop of mineral oil (Perkin-Elmer Corp, Norwalk, CT) which allowed the blood vessels to be visualized easily. Then, phosphate buffered saline (PBS), 75 µg of purified sterile anti-integrin antibodies or 75 µg of synthetic peptides (cyclic peptide RGDfV, SEQ ID NO 4 and control cyclic peptide RADfV, SEQ ID NO 5) in PBS were injected into blood vessels apparent on the growth factor-induced CAMs. The windows were sealed with tape and the embryos were allowed to incubate until 72 hours.

The filter discs and representative surrounding CAM tissues were photographed in a stereomicroscope (Figures 3A-3F and Figures 5A-5F) and the mean angiogenic index +/- the standard error was determined for 12 CAMs per condition (Figures 4A-4B and Figures 6A-6B). Angiogenesis was scored for each embryo in a double blind manner by analyzing the number and extent of branching of blood vessels within the area of each disc. The scores ranged from 1 (low) to 4 (high) and the angiogenesis index was determined by subtracting a background of 1 from all data.

Specificity of integrin antibody-mediated inhibition of growth factor-induced angiogenesis in the CAM model mirrored that seen in the rabbit cornea model described above. As respectively shown in Figures 3A and 3B, both bFGF and VEGF caused angiogenesis in the control PBS-treated CAM. Treatment with the $\alpha_v\beta_3$ -specific antibody, P1F6, however, resulted in inhibition of VEGF-induced angiogenesis as shown in Figure 3D while no inhibition was detected on bFGF-induced angiogenesis as seen in Figure 3C. In contrast, the LM609 $\alpha_v\beta_3$ -specific antibody inhibited bFGF-induced angiogenesis (Figure 3E) but had little effect on angiogenesis in the VEGF-induced CAM (Figure 3F).

These results are also shown in the bar graphs of Figures 4A and 4B, respectively for both bFGF- and VEGF-treated CAMs. in which the angiogenesis index is plotted against exposure to either LM609 or P1F6 along with no antibody exposure as a control. Thus,

inhibition of growth factor-induced angiogenesis by integrin-specific antibodies is dependent upon the type of growth factor.

Exposure to RGD-containing peptides supports the above results. In the presence of PBS, as shown in Figures 5A and 5B, exposure to both bFGF and VEGF resulted in angiogenesis in the control CAM. In contrast, the cyclic peptide antagonist RGDfV (SEQ ID NO 4), directed to both $\alpha_v\beta_3$ and $\alpha_v\beta_5$, abolished angiogenesis induced by either bFGF or VEGF. The cyclic peptide RADfV (SEQ ID NO 5) did not effect angiogenesis in either the bFGF- or VEGF-treated CAM preparations. The results are also shown in Figures 6A and 6B where the angiogenesis index of bFGF- and VEGF-stimulated CAMS are graphed showing exposure to test and control peptides. Thus, these findings together with those in the rabbit corneas indicate that bFGF- and VEGF-induced angiogenesis depend on distinct but homologous α_v -specific integrins that however are both inhibitable with the cyclic peptide RGDfV.

In a further assay performed in the CAM model having VEGF-induced angiogenesis, 2 μ g of peptides 85189 (SEQ ID NO 9) and the inert salt counterpart 121974 were separately intravenously injected as previously described. The effect of the peptides was assessed in comparison to that of control peptide 69601 (SEQ ID NO 5) and to untreated (labeled as NT) preparations.

The effect of the peptides on VEGF-induced angiogenesis is measured through a determination of the number of blood vessel branch points. Thus, angiogenesis or the lack thereof was quantified by counting the number of blood vessels branch points that occur within the confines of the filter discs. The branched blood vessels are considered to correspond primarily to new angiogenic sprouting blood vessels. Quantification was performed in a double blind manner by at least two independent observers. The results are expressed as the Angiogenic Index where the angiogenic index is the number of branch points (VEGF stimulated) minus the number of branch points (control unstimulated) per filter disc. Experiments routinely had 6-10 embryos per condition. As shown in Figure 17, both peptides 85189 and 121974 completely inhibited angiogenesis as indicated by a reduction of the measurable branch points in comparison to untreated or control peptide-treated preparations.

Additional similar assays are performed with synthetic peptides prepared as described in Example 3 to define peptides that exhibit specificity to $\alpha_v\beta_5$ and not $\alpha_v\beta_3$ correlated angiogenesis. Assays are also performed with the MMP-2 C-terminal fragments prepared as described in Example 3 and 7 and with the organic molecules prepared as described in Example 10.

The specificity of integrin antibody-inhibition of growth factor-induced angiogenesis was

further confirmed and strengthened by extending the growth factor angiogenesis induction analyses to include tumor necrosis factor- α (TNF- α), transforming growth factor- α (TGF- α) or the phorbol ester, 4- β -phorbol-12-myristate-13-acetate (PMA).

The above growth factors (cytokines), including bFGF and VEGF, were separately applied at a concentration of 1.0 μ g/ml to the 10 day old CAM model as previously described. PMA was used at a concentration of 20 ng/ml.

After 24 hours after growth factor treatment, the antibodies, LM609 and P1F6, or the protein kinase C (PKC) inhibitor, calphostin C, were separately provided to the CAM model, either by a single intravascular dose as described above or by topical administration as described below in the next example. For intravascular injections over the next 3 day consecutive period, the antibodies were used at a concentration of 75 μ g per embryo and the calphostin C was at a dosage of 100 nM.

On day 13, filter discs and associated CAM tissue were dissected and analyzed for angiogenesis with a stereo microscope. Angiogenesis was scored in a double blind manner by analyzing the number and extent of branching of the blood vessels within the area of the discs. The scores ranged from low (1) to high (4). The angiogenesis index was determined by subtracting a background score of 1 from all data. Experiments were repeated 2-4 times with 5-6 embryos per condition.

As shown respectively in Figures 7A and 7B, the anti- $\alpha_v\beta_3$ antibody, LM609, blocked angiogenesis in response to bFGF and TNF- α whereas the anti- $\alpha_v\beta_5$ antibody, P1F6, had little inhibitory effect. In contrast, as shown respectively in Figures 7C-7E, P1F6 was effective at inhibiting angiogenesis induced by VEGF, TGF- α , or PMA whereas LM609 failed to do so.

PMA, a potent inducer of angiogenesis, is capable of activating protein kinase C (PKC), an intracellular family of serine threonine kinases. Therefore, we also examined the effects of calphostin C, a PKC inhibitor, on angiogenesis on the chick CAM. Calphostin C blocked angiogenesis induced by PMA (Figure 7E) as well as VEGF and TGF- α (respectively shown in Figures 7C and 7D) while having minimal effects on bFGF- or TNF- α mediated angiogenesis (respectively shown in Figures 7A and 7B).

Together, these results indicate the existence of two separate distinct angiogenesis pathways where one is dependent upon an $\alpha_v\beta_3$ -mediated signal that is largely independent of PKC, as previously described by Brooks et al., *Science*, 264:569-571 (1994), and a second pathway is potentiated by an $\alpha_v\beta_5$ -mediated transduction signal that critically depends of PKC activation.

In addition to the above experiments, to determine the localization of the P1F6 and

LM609 mAbs in CAM tissues that were inoculated intravenously with LM609, the fixed sections are blocked with 2.5% BSA in HBSS for 1 hour at room temperature followed by staining with a 1:250 dilution of goat anti-mouse rhodamine labeled secondary antibody (Tago). The sections are then analyzed with a Zeiss immunofluorescence compound microscope.

5
B. Inhibition of Growth Factor-Induced Angiogenesis by Topical Application of Inhibitors

To determine whether $\alpha_v\beta_3$ plays an active role in angiogenesis, filter disks saturated with growth factors described above are placed on CAMs to induce angiogenesis followed by application of either P1F6 or LM609.

10
Disks are then treated with 50 μ l HBSS containing 25 mg of mAb in a total volume of 25 μ l of sterile HBSS at 0, 24, and 48 hours. At 72 hours, CAMs are harvested and placed in a 35 mm petri dish and washed once with 1 ml of PBS. The bottom side of the filter paper and CAM tissue is then analyzed under an Olympus stereo microscope, with two observers in a double-blind fashion. Angiogenesis inhibition is considered significant when CAMs exhibits >50% reduction in blood vessel infiltration of the CAM directly under the disk. Experiments are repeated four times per antibody, with 6 to 7 embryos per condition.

15
To examine the effects of the integrin antibodies on preexisting mature blood vessels present from normal vessel development adjacent to the areas devoid of vessels, filter disks saturated with mAbs are placed on vascularized regions of CAMs from 10 day embryos that do not receive topical application of cytokine.

20
CAM assays are also performed with the synthetic peptides of this invention to determine the effect of cyclic and linearized peptides on growth factor induced angiogenesis. Eight μ g of peptides, prepared as previously described, are separately presented in a total volume of 25 μ l of sterile HBSS. The peptide solution is applied to the CAM preparation immediately and then again at 24 and 48 hrs. At 72 hours the filter paper and surrounding CAM tissue are dissected and viewed as described above.

25
Similar assays are performed with the MMP-2 fragments and organic molecules prepared as respectively described in Examples 7 and 10.

30
C. Inhibition of Tumor-Induced Angiogenesis by Topical Application

1) Treatment with Monoclonal Antibodies

In addition to the angiogenesis assays described above where the effects of anti- $\alpha_v\beta_3$ antibody and peptide antagonists were evaluated, the role of $\alpha_v\beta_3$ in tumor-induced

angiogenesis is also investigated. As an inducer, $\alpha_v\beta_3$ -negative human tissues previously grown and isolated from the CAM of a 17-day chick embryo are used. The fragments are prepared as described in Example 5C.

As described above, mAbs are separately topically applied to the tumor fragments at a concentration of 25 μ g in 25 μ l of HBSS and the windows are then sealed with tape. The mAbs are added again in the same fashion at 24 hours and 48 hours. At 72 hours, the tumors and surrounding CAM tissues are analyzed as described above.

As described in Example 5C, tumors are initially derived by transplanting human cell lines, which do not express integrin $\alpha_v\beta_3$, onto the CAMs of 10 day old chick embryos.

In order to quantitate the effect of the mAbs on the tumor-induced angiogenesis, blood vessels entering the tumor within the focal plane of the CAM are counted under a stereo microscope by two observers in a double-blind fashion.

The synthetic peptides prepared in Example 3, the MMP-2 preparations described in Example 7 and the organic molecules prepared in Example 10 are similarly topically applied to the tumor-induced angiogenic CAM assay system as described above. The effect of the peptides including the MMP-2 preparations and organic molecules described in this invention on the viability of the vessels is similarly assessed.

D. Inhibition of Tumor-Induced Angiogenesis by Intravenous Application

1) Treatment with Monoclonal Antibodies

Tumor-induced blood vessels prepared above were also treated with mAbs applied by intravenous injection. CS-1 melanoma tumors were placed on the CAMs as described in Example 5C and the windows were sealed with tape and 24 hours later, 100 to 300 μ g of purified mAbs were inoculated once intravenously in chick embryo blood vessels as described previously. The chick embryos were then allowed to incubate for 7 days. The extent of angiogenesis was then observed as described in above. After this time period, the tumors were resected and analyzed by their weight to determine the effect of antibody exposure on tumor growth or suppression.

The results of treatment of CS-1 tumors with 300 μ g of $\alpha_v\beta_3$ specific antibody P1F6 are shown in Figure 8. The tumor weight was dramatically reduced to less than 50 mg as compared to untreated to CSAT-treated tumors. The $\alpha_v\beta_3$ specific antibody, LM609, also inhibited tumor growth, however, less effective than that with P1F6. Comparable results were obtained with tumors receiving treatment with 100 μ g of P1F6. Thus, P1F6 was effective at inhibiting $\alpha_v\beta_3$ -mediated angiogenesis in a tumor model on a CAM preparation resulting in a diminution of

tumor cell mass.

2) Treatment with Other $\alpha_v\beta_3$ Antagonists

The effects of peptides, MMP-2 preparations or organic molecules on tumor-induced vasculature in the CAM assay system are also assessed. The tumor-CAM preparation is used as described above with the exception that instead of intravenous injection of a mAb, synthetic peptides including MMP-2 preparations prepared as described in Example 7 and organic molecules prepared in Example 10 are separately intravenously injected into visible blood vessels.

In one particular set of assays, additional tumor regression assays were performed with the $\alpha_v\beta_3$ -reactive peptide 85189 (SEQ ID NO 9) against 69601 (SEQ ID NO 5) as a control. The assays were performed as described above with the exception that 100 ug of peptide was intravenously injected into the CAM at 18 hours postimplantation of the various tumors which in this case included UCLAP-3, M21-L and FgM tumor types. After 48 hours more, the tumors were then resected and wet weights were obtained.

Figures 18, 19 and 20 respectively show the reduction in tumor weight for UCLAP-3, M21-L and FgM tumors following intravenous exposure to peptide 85189 in contrast to the lack of effect with either PBS or peptide 69601.

7. Identification of $\alpha_v\beta_3$ -Specific Antagonists Detected by Inhibition of Cell Attachment and by a Ligand-Receptor Binding Assay

A. Inhibition of Cell Attachment

As one means to determine integrin receptor specificity of the antagonists of this invention, inhibition of cell attachment assays are performed as described below.

Briefly, CS-1 hamster melanoma cells lacking expression of $\alpha_v\beta_3$ and $\alpha_v\beta_5$ are first transfected with a plasmid for expressing the β_3 subunit as previously described by Filardo et al., *J. Cell Biol.*, 130:441-450 (1995). Specificity of potential $\alpha_v\beta_3$ antagonists was determined by the ability to block the binding of $\alpha_v\beta_3$ -expressing CS-1 cells to VN or laminin coated plates. As an example of a typical assay, the wells were first coated with 10 ug/ml substrate overnight. After rinsing and blocking with 1% heat-denatured BSA in PBS at room temperature for 30 minutes, peptide 85189 (SEQ ID NO 9) over a concentration range of 0.0001 uM to 100 uM, are separately mixed with CS-1 cells for applying to wells with a cell number of 50,000 cells/well. After a 10-15 minute incubation at 37C, the solution containing the cells and peptides is discarded. The number of attached cells is then determined following staining with 1% crystal

violet. Cell associated crystal violet is eluted by the addition of 100 microliters (μ l) of 10% acetic acid. Cell adhesion was quantified by measuring the optical density of the eluted crystal violet at a wave length of 600 nm.

Similar assays are performed with fusion proteins or the synthetic peptide counterparts containing various regions of the MMP-2 protein. The MMP-2-derived polypeptides include regions of the C-terminus of MMP-2 active in the binding interaction with $\alpha_v\beta_3$ and thereby capable of inhibiting MMP-2 activation and associated activities. These polypeptides are prepared either as synthetic polypeptides having a sequence derived from the C-terminal domain of MMP-2 as described in Example 1 or as fusion proteins including all or a portion of the C-terminal domain of MMP-2, prepared as described below. MMP-2 C-terminal molecules are presented for both chicken and human specific sequences.

The chicken-derived MMP-2 C-terminal domain, also referred to as the hemopexin domain immediately contiguous with the hinge region, comprises the amino acid residues 445-637 of MMP-2. The complete nucleotide and encoded amino acid sequence of chicken MMP-2 is described below and is shown in Figures 15A and 15B, with the nucleotide and amino acid sequences respectively listed as SEQ ID NOs 23 and 24. The human MMP-2 nucleotide and encoded amino acid sequence is also described below, with the latter shown in Figure 16 and SEQ ID NO 25. The C-terminal domain in the human MMP-2 that corresponds to the chicken region of 445-637 begin at amino acid residue 439 and ends with 631 due to six missing residues from the human sequence as shown in Figures 15A and 15B. Both human- and chicken-derived C-terminal MMP-2 synthetic peptides for use in practicing the methods of this invention are listed in Table 1. The amino acid residue sequences of the synthetic peptides are the same as those generated by the recombinant fusion protein counterparts but without the GST fusion component. The C-terminal MMP-2 fusion proteins derived from both chicken and human are prepared as described below.

A MMP-2 fusion protein is a chimeric polypeptide having a sequence of MMP-2 C-terminal domain or a portion thereof fused (operatively linked by covalent peptide bond) to a carrier (fusion) protein, such as glutathione sulfhydryl transferase (GST).

To amplify various regions of chicken and human MMP-2, primer sequences were designed based on the known respective cDNA sequences of chicken and human MMP-2. The complete top strand of the cDNA nucleotide sequence of unprocessed chicken MMP-2, also referred to as progelatinase, is shown in Figures 15A and 15B along with the deduced amino acid sequence shown on the second line (Aimes et al., *Biochem. J.*, 300:729-736, 1994). The third and fourth lines of the figure respectively show the deduced amino acid sequence of human

(Collier et al., J. Biol. Chem., 263:6579-6587 (1988)) and mouse MMP-2 (Reponen et al., J. Biol. Chem., 267:7856-7862 (1992)). Identical residues are indicated by dots while the differing residues are given by their one letter IUPAC lettering. Missing residues are indicated by a dash. The numbering of the amino acid residues starts from the first residue of the proenzyme, with the residues of the signal peptide being given negative numbers. The nucleotide sequence is numbered accordingly in the figure although in the Sequence Listing, the first nucleotide is listed as number 1. The putative initiation of translation (ATG) is marked with three forward arrowheads and the translation termination signal (TGA) is indicated by an asterisk. The amino terminal sequences for the chicken proenzyme and active enzyme are contained with diamonds and single arrowheads. As previously stated, the chicken procollagenase nucleotide and amino acid residue sequences are listed together as SEQ ID NO 23 while the encoded amino acid residue sequence is listed separately as SEQ ID NO 24.

Templates for generating amplified regions of chicken MMP-2 were either a cDNA encoding the full-length mature chicken MMP-2 polypeptide provided by Dr. J. P. Quigley of the State University of New York at Stony Brook, New York or a cDNA generated from a total cellular RNA template derived by standard techniques from an excised sample of chicken chorioallantoic membrane tissue. For the latter, the cDNA was obtained with MuLV reverse transcriptase and a downstream primer specific for the 3'-terminal nucleotides, 5'ATTGAATTCTTCTACAGTTCA3' (SEQ ID NO 26), the 5' and 3' ends of which was respectively complementary to nucleotides 1932-1912 of the published chick MMP-2 sequence. As described in the Figure 15 figure legend, the nucleotide positions of the primers described herein correspond to those shown in the figure and not as shown in the Sequence Listing as the latter begins with number 1 and not as a negative number as indicated in the figure. Reverse transcriptase polymerase chain reaction (RT-PCR) was performed according to the specifications of the manufacturer for the GeneAmp RNA PCR Kit (Perkin Elmer). The primer was also engineered to contain an internal EcoRI restriction site.

From either of the above-described cDNA templates, a number of C-terminal regions of chicken MMP-2, each having the natural cysteine residue at position 637 at the carboxy terminus, were obtained by PCR with the 3' primer listed above (SEQ ID NO 26) paired with one of a number of 5' primers listed below. The amplified regions encoded the following MMP-2 fusion proteins, having sequences corresponding to the amino acid residue positions as shown in Figures 15A and 15B and also listed in SEQ ID NO 24: 1) 203-637; 2) 274-637; 3) 292-637; 4) 410-637; 5) 445-637. Upstream or 5' primers for amplifying each of the nucleotide regions for encoding the above-listed MMP-2 fusion proteins were designed to encode the

polypeptide start sites 3' to an engineered, i.e., PCR-introduced, internal BamHI restriction site to allow for directional ligation into either pGEX-1 λ T or pGEX-3X expression vectors. The 5' primers included the following sequences, the 5' and 3' ends of which correspond to the indicated 5' and 3' nucleotide positions of the chicken MMP-2 sequence shown in the figure (the amino acid residue position start sites are also indicated for each primer): 1) Nucleotides 599-619, encoding a 203 start site 5'ATGGGATCCACTGCAAATTTTC3' (SEQ ID NO 27); 2) Nucleotides 809-830, encoding a 274 start site 5'GCCGGATCCATGACCAGTGTA3' (SEQ ID NO 28); 3) Nucleotides 863-883, encoding a 292 start site 5'GTGGGATCCCTGAAGACTATG3' (SEQ ID NO 29); 4) Nucleotides 1217-1237, encoding a 410 start 5'AGGGGATCCTTAAGGGGATTC3' (SEQ ID NO 30); and 5) Nucleotides 1325-1345, encoding a 445 start site 5'CTCGGATCCTCTGCAAGCACG3' (SEQ ID NO 31).

The indicated nucleotide regions of the template cDNA were subsequently amplified for 35 cycles (annealing temperature 55C) according to the manufacturer's instructions for the Expand High Fidelity PCR System (Boehringer Mannheim). The resulting PCR products were gel-purified, digested with BamHI and EcoRI restriction enzymes, and repurified before ligation into either pGEX-1 λ T or pGEX-3X vector (Pharmacia Biotech, Uppsala, Sweden) which had been similarly digested as well as dephosphorylated prior to the ligation reaction. The choice of plasmid was based upon the required reading frame of the amplification product. Competent E. coli strain BSJ72 or BL21 cells were transformed with the separate constructs by heat shock. The resulting colonies were screened for incorporation of the respective MMP-2 fusion protein-encoding plasmid by PCR prior to dideoxy sequencing of positive clones to verify the integrity of the introduced coding sequence. In addition, verification of incorporation of plasmid was confirmed by expression of the appropriately-sized GST-MMP-2 fusion protein.

Purification of each of the recombinant GST-MMP-2 fusion proteins was performed using IPTG-induced log-phase cultures essentially as described by the manufacturer for the GST Gene Fusion System (Pharmacia Biotech). Briefly, recovered bacteria were lysed by sonication and incubated with detergent prior to clarification and immobilization of the recombinant protein on sepharose 4B-coupled glutathione (Pharmacia Biotech). After extensive washing, the immobilized fusion proteins were separately eluted from the affinity matrix with 10 mM reduced glutathione in 50 mM Tris-HCl, pH 8.0. and dialyzed extensively against PBS to remove residual glutathione prior to use.

Prior attempts to produce fusion proteins between chicken MMP-2 residues 445 and 637 that only had one encoded cysteine residue resulted in insoluble products. Therefore, in order to generate additional soluble MMP-2 fusion proteins derived from the C-terminal region that did

not include an endogenous terminal cysteine residue as present in the previously-described fusion protein, nucleotide sequences were introduced into amplified MMP-2 regions to encode a cysteine residue if necessary depending on the particular fusion protein. A cysteine residue is naturally present in the chicken MMP-2 sequence at position 446 and at position 637. In the human sequence, these positions correspond respectively to 440 and 631. Therefore, fusion proteins were designed to contain engineered terminal cysteine residues at the amino- or carboxy-terminus of the chicken MMP-2 sequences of interest so as to provide for disulfide-bonding with the naturally occurring cysteine at the other terminus, as required by the construct. Synthetic MMP-2 fragments for both chicken and human are similarly prepared as previously described in Example 3.

Oligonucleotide primers were accordingly designed to allow for amplification of chicken MMP-2 C-terminal regions for expression of soluble MMP-2/GST fusion proteins. Amplified chicken MMP-2 C-terminal regions included those for encoding amino acid residue positions 445-518, 445-552, 516-637 and 549-637. For fusion proteins containing residue 517, the naturally encoded tyrosine residue was substituted for a cysteine to allow for disulfide bonding with either cysteine at residue position 446 or 637. For fusion proteins containing residue 551, the naturally encoded tryptophan residue was substituted for a cysteine to allow for disulfide bonding with either naturally encoded cysteine at residue position 446 or 637.

Briefly, the pGEX-3X plasmid construct encoding the recombinant GST/MMP-2(410-637) fusion protein prepared above was used as a template for amplification according to the manufacturer's protocol for the Expand High Fidelity PCR Kit (Boehringer Mannheim) utilizing a set of oligonucleotide primers whose design was based on the published chicken MMP-2 sequence (also shown in Figures 15A and 15B and in SEQ ID NO 23). One upstream primer, designed to encode a chicken MMP-2 protein start site at position 445 after an engineered internal BamHI endonuclease restriction site for insertion into the pGEX-3X GST vector, had the nucleotide sequence (5'CTCGGATCCTCTGCAAGCACG3' (SEQ ID NO 32)). The 5' and 3' ends of the primer respectively corresponded to positions 1325-1345 of the chicken MMP-2 sequence in Figure 15A and 15B. Another upstream primer, designed to encode a chicken MMP-2 protein start site at position 516 after an engineered internal BamHI restriction site for insertion into the pGEX-1λT GST vector and to encode a cysteine residue at position 517, had the nucleotide sequence (5'GCAGGATCCGAGTGCTGGGTTTATAC3' (SEQ ID NO 33)). The 5' and 3' ends of the primer respectively corresponded to positions 1537-1562 of the chicken MMP-2 sequence in the figure. A third upstream primer, designed to encode a chicken MMP-2 protein start site at position 549 following an engineered internal EcoRI endonuclease restriction

site for insertion into the pGEX-1λT GST vector and to encode a cysteine residue at position 551, had the nucleotide sequence (5'GCAGAATTCAACTGTGGCAGAAACAAG3' (SEQ ID NO 34)). The 5' and 3' ends of the primer respectively corresponded to positions 1639-1665 of the chicken MMP-2 sequence in the figure.

5 These upstream primers were separately used with one of the following downstream primers listed below to produce the above-described regions from the C-terminal domain of chicken MMP-2. A first downstream primer (antisense), designed to encode a chicken MMP-2 protein termination site at position 518, to encode a cysteine residue at position 517, and to contain an internal EcoRI endonuclease restriction site for insertion into a GST vector, had the
10 nucleotide sequence (5'GTAGAATTCCAGCACTCATTTCTGC3' (SEQ ID NO 35)). The 5' and 3' ends of the primer, written in the 5'-3' direction, were respectively complementary in part to positions 1562-1537 of the chicken MMP-2 sequence in the figure. A second downstream primer, designed to encode a chicken MMP-2 protein termination site at position 552, to encode a cysteine residue at position 551, and to contain an internal EcoRI endonuclease restriction site
15 for insertion into a GST vector, had the nucleotide sequence (5'TCTGAATTCTGCCACAGTTGAAGG3' (SEQ ID NO 36)). The 5' and 3' ends of the primer, written in the 5'-3' direction, were respectively complementary in part to positions 1666-1643 of the chicken MMP-2 sequence in the figure. A third downstream primer, designed to encode a chicken MMP-2 protein termination site at position 637 and to contain an internal
20 EcoRI endonuclease restriction site for insertion into a GST vector, had the nucleotide sequence (5'ATTGAATTCTTCTACAGTTCA3' (SEQ ID NO 37)). The 5' and 3' ends of the primer, written in the 5'-3' direction, were respectively complementary in part to positions 1932-1912 of the chicken MMP-2 sequence in the figure.

25 The regions of the chicken MMP-2 carboxy terminus bounded by the above upstream and downstream primers, used in particular combinations to produce the fusion proteins containing at least one engineered cysteine residue as described above, were separately amplified for 30 cycles with an annealing temperature of 55C according to the manufacturer's instructions for the Expand High Fidelity PCR System (Boehringer Mannheim). The resulting amplification products were separately purified, digested with BamHI and or EcoRI restriction enzymes as
30 necessary, and repurified before ligation into the appropriate GST fusion protein vector, either pGEX-3X or pGEX-1λT, as indicated above by the reading frame of the upstream oligonucleotide primer. For ligating the amplified MMP-2 products, the vectors were similarly digested as well as dephosphorylated prior to the ligation reaction. Competent *E. coli* strain BL21 cells were then separately transformed with the resultant MMP-2-containing vector

constructs by heat shock. Resulting colonies were then screened for incorporation of the appropriate fusion protein-encoding plasmid by PCR and production of the appropriate sized GST-fusion protein prior to dideoxy sequencing of positive clones to verify the integrity of the introduced coding sequence. Purification of recombinant GST fusion proteins were then performed using IPTG-induced log-phase cultures essentially as described above for producing the other GST-MMP-2 fusion proteins.

In addition to the chicken MMP-2 GST-fusion proteins described above, two human MMP-2 GST fusion proteins were produced for expressing amino acid regions 203-631 and 439-631 of the mature human MMP-2 proenzyme polypeptide. The indicated regions correspond respectively to chicken MMP-2 regions 203-637 and 445-637. Human MMP-2-GST fusion proteins were produced by PCR as described above for the chicken MMP-2-GST fusion proteins utilizing a cDNA template that encoded the entire human MMP-2 open reading frame provided by Dr. W. G. Stetler-Stevenson at the National Cancer Institute, Bethesda, MD. Upstream 5' primer sequences were designed based upon the previously published sequence of human MMP-2 (Collier et al., *J. Biol. Chem.*, 263:6579-6587 (1988) and to encode an introduced internal EcoRI restriction site to allow for insertion of the amplified products into the appropriate expression vector.

One upstream primer, designed to encode a human MMP-2 protein start site at position 203 after an engineered internal EcoRI endonuclease restriction site for insertion into the pGEX-1 λ T GST vector, had the nucleotide sequence (5'GATGAATTCTACTGCAAGTT3' (SEQ ID NO 38)). The 5' and 3' ends of the primer respectively corresponded to positions 685-704 of the human MMP-2 open reading frame sequence. Another upstream primer, designed to encode a human MMP-2 protein start site at position 439 after an engineered internal EcoRI restriction site for insertion into the pGEX-1 λ T GST vector, had the nucleotide sequence (5'CACTGAATTCATCTGCAAACA3' (SEQ ID NO 39)). The 5' and 3' ends of the primer respectively corresponded to positions 1392 and 1412 of the human MMP-2 open reading frame sequence.

Each of the above primers were used separately with a downstream primer, having 5' and 3' ends respectively complementary to bases 1998 and 1978 of the human MMP-2 sequence that ends distal to the MMP-2 open reading frame and directs protein termination after amino acid residue 631. The amplified products produced expressed fusion proteins containing human MMP-2 amino acid residues 203-631 (SEQ ID NO 40) and 439-631 (SEQ ID NO 12).

The resulting PCR products were purified, digested with EcoRI and repurified for ligation into a pGEX-1 λ T plasmid that was similarly digested and dephosphorylated prior to the

ligation reaction. Cells were transformed as described above.

Other human MMP-2 fusion proteins containing amino acid residues 410-631 (SEQ ID NO 11), 439-512 (SEQ ID NO 13), 439-546 (SEQ ID NO 14), 510-631 (SEQ ID NO 15) and 543-631 (SEQ ID NO 16) are also prepared as described above for use in the methods of this invention.

B. Ligand-Receptor Binding Assay

The $\alpha_v\beta_3$ -immunoreactive antibodies and synthetic peptides prepared respectively in Examples 1 and 3 are screened by measuring their ability to antagonize $\alpha_v\beta_5$, $\alpha_v\beta_3$, and $\alpha_{IIb}\beta_3$ receptor binding activity in purified ligand-receptor binding assays. The method for these binding studies has been described by Barbas et al., Proc. Natl. Acad. Sci., USA, 90:10003-10007 (1993), Smith et al., J. Biol. Chem., 265:11008-11013 (1990) and Pfaff et al., J. Biol. Chem., 269:20233-20238 (1994), the disclosures of which are hereby incorporated by reference.

A method of identifying antagonists in a ligand-receptor binding assay is described in which the receptor is immobilized to a solid support and the ligand and antagonist are soluble. A ligand-receptor binding assay is also described in which the ligand is immobilized to a solid support and the receptor and antagonists are soluble.

Briefly, selected purified integrins are separately immobilized in Titertek microtiter wells at a coating concentration of 50 nanograms (ng) per well. The purification of the receptors used in the ligand-receptor binding assays are well known in the art and are readily obtainable with methods familiar to one of ordinary skill in the art. After incubation for 18 hours at 4C, nonspecific binding sites on the plate are blocked with 10 milligrams/milliliter (mg/ml) of bovine serum albumin (BSA) in Tris-buffered saline. For inhibition studies, various concentrations of selected antibodies or peptides are tested for the ability to block the binding of ^{125}I -vitronectin or other labeled ligands to the integrin receptors, $\alpha_v\beta_5$, $\alpha_v\beta_3$, $\alpha_v\beta_1$ and $\alpha_{IIb}\beta_3$.

Although these ligands exhibit optimal binding for a particular integrin, vitronectin for $\alpha_v\beta_5$ and $\alpha_v\beta_3$ and fibrinogen for $\alpha_{IIb}\beta_3$, inhibition of binding studies using either antibodies or peptides to block the binding of vitronectin to either receptor allows for the accurate determination of the amount in micromoles (μM) of peptide necessary to half-maximally inhibit the binding of receptor to ligand. Radiolabeled ligands are used at concentrations of 1 nM and binding is challenged separately with unlabeled synthetic peptides. Following a three hour incubation, free ligand is removed by washing and bound ligand is detected by gamma counting.

Thus, the ligand-receptor assay described herein is used to screen for both circular or linearized synthetic peptides along with monoclonal antibodies and organic molecules that

exhibit selective specificity for a particular integrin receptor, specifically $\alpha_v\beta_5$, as used as vitronectin receptor ($\alpha_v\beta_5$) antagonists in practicing this invention.

8. In Vivo Regression of Tumor Tissue Growth With $\alpha_v\beta_5$ Antagonists As Measured by Chimeric Mouse:Human Assay

An in vivo chimeric mouse:human model was generated by replacing a portion of skin from a SCID mouse with human neonatal foreskin. The in vivo chimeric mouse:human model was prepared essentially as described in Yan, et al., J. Clin. Invest., 91:986-996 (1993). Briefly, a 2 cm² square area of skin was surgically removed from a SCID mouse (6-8 weeks of age) and replaced with a human foreskin. The mouse was anesthetized and the hair removed from a 5 cm² area on each side of the lateral abdominal region by shaving. Two circular graft beds of 2 cm² were prepared by removing the full thickness of skin down to the fascia. Full thickness human skin grafts of the same size derived from human neonatal foreskin were placed onto the wound beds and sutured into place. The graft was covered with a Band-Aid which was sutured to the skin. Micropore cloth tape was also applied to cover the wound.

After the skin graft was established, the human foreskin was inoculated with melanoma cells. The M21L human melanoma cell line was used to form the solid human tumors on the human skin grafts on the SCID mice. A single cell suspension of 2×10^6 M21L was injected intradermally into the human skin graft. The mice were then observed for 2 to 4 weeks to allow growth of measurable human tumors.

After a measurable tumor was established, either 250 μ g of the peptide (in a volume of 100 μ l) having SEQ ID NO 9 (cyclic RGD-containing peptide Arg-Gly-Asp-D-Phe-Asn-NMeVal) or a control peptide, cyclo Arg- β Ala-Asp-D-Phe-Val, were injected intraperitoneally into the mouse 3 times per week over 3 weeks. At the end of this time, the tumor was excised and analyzed by weight and histology.

The results are shown in Figure 9 where the tumor volume in mm³ is plotted on the Y-axis against the peptide treatments on the X-axis. The test peptide having SEQ ID NO 9, labeled in the figure as peptide 189, significantly reduced the tumor volume to approximately 25 mm³ compared to control peptide (labeled as peptide 601) where the tumor volume was greater than 300 mm³.

Thus, the blocking of the $\alpha_v\beta_5$ receptor by the intravenous application of $\alpha_v\beta_5$ antagonist peptide 189 resulted in a regression of a melanoma tumor in this model system in the same manner as the CAM and rabbit eye model systems as described previously.

In other experiments with M21-L melanoma tumor cells in the mouse:human chimeric

assay system, the response with mAB LM609 was compared with the response obtained with the synthetic peptide 85189 (SEQ ID NO 9) as compared to control synthetic peptide 69601 (SEQ ID NO 5). The assays were performed as described above. The results, shown in Figure 21, demonstrate that the synthetic peptide 85189 reduced tumor volume to below 25 mm³ as compared to control peptide where the tumor volume was approximately 360 mm³. The mAB LM609 also significantly reduced tumor volume to approximately 60 mm³.

Thus, blocking of the $\alpha_v\beta_3$ receptor by the intravenous application of $\alpha_v\beta_3$ -specific LM609 antibody and peptides resulted in a regression of a carcinoma in this model system as compared to the other model systems described in this invention.

In additional assays with the SCID mice model having measurable M21-L tumors, in a preliminary analysis, a dose response curve was performed for peptides 69601 (control) and 85189 (test) injected over a concentration range of 10 to 250 $\mu\text{g/ml}$. The mean volume and weight of resected tumors following treatment were determined with the results respectively shown in Figures 22A and 22B. Peptide 85189 was effective at inhibiting M21-L tumor growth over the concentration range tested compared to treatment with control peptide with the most effective dosage being 250 $\mu\text{g/ml}$.

For analyzing peptide 85189 treatment effectiveness over a time course, two treatment regimens were evaluated in the same SCID tumor model. In one assay, treatment with either peptide 85189 or 69601 was initiated on day 6, with day 0 being the day of M21-L tumor injection of 3×10^6 cells subcutaneously into mouse skin, with intraperitoneal injections of 250 $\mu\text{g/ml}$ peptide 85189 or control 69601 every other day until day 29. The other assay was identically performed with the exception that treatment was initiated on day 20. At the end of the assays, the tumors were resected and the mean tumor volume in mm³ was determined. The data was plotted as this value \pm the standard error of the mean.

The results of these assays, respectively shown in Figures 23A and 23B, indicate that peptide 85189 but not 69601 inhibited tumor growth at various days after treatment was initiated, depending on the particular treatment regimen. Thus, peptide 85189 is an effective $\alpha_v\beta_3$ antagonist of both angiogenesis and thus tumor growth.

The SCID/human chimeric model above is also used for assessing the effectiveness of other $\alpha_v\beta_3$ antagonists of this invention, namely antibodies, MMP-2 preparations, previously prepared, and organic molecules, the latter of which are prepared as described in Example 10.

9. Preparation of a Murine Mouse Model for $\alpha_v\beta_3$ -Mediated Retinal Angiogenesis and Inhibition Thereof with $\alpha_v\beta_3$ Antagonists

Based on the observation in Example 2C of $\alpha_v\beta_3$ and $\alpha_v\beta_5$ expression in retinal neovascular tissue, a novel mouse model was used to study the effects of systemically administered cyclic peptide antagonists of both integrins on retinal angiogenesis. Newborn mice develop retinal vessels during the first two weeks postnatally during which time the superficial retinal vasculature forms a rich, highly branched network of vessels that originate at the optic nerve head and radiate peripherally to cover the retinal surface in a manner similar to that observed in other mammals and humans (Jiang et al., *Glia*, 15:1-10 (1995)).

For the model, newborn mice were injected subcutaneously twice daily for four days starting from day 0 with the cyclic peptide RGDfV (SEQ ID NO 4) (also referred to as peptide 203) or the control peptide RADfV (SEQ ID NO 5). On postnatal day five, globes were removed and fixed in 4.0% paraformaldehyde (PFA) at room temperature.

To quantitate mouse retinal angiogenesis, the distance from the optic nerve head to the most distal point of a single vessel selected in each of six equal sectors around a twelve hour clock was measured. The mean distance was calculated and averaged with similar data obtained from an entire litter. To measure the total volume of retinal blood vessels, the entire specimen was scanned in 2.0 μm optical sections and stored digitally. The "seed" function in Bio-Rad's Lasershar software was then used to threshold and count cubic pixels in each section. A macro was written to sum the volume of all sections and determine the value for all vascular structures.

With the direct measurement of vessel growth in two dimensions from photographs, systemically administered peptide antagonist 203 inhibited retinal vasculogenesis, relative to control peptide, by 44% ($N=9$, $p<.0000001$, paired t-test). No statistical difference was seen between untreated newborn mice and five-day old mice receiving peptide 203, thus the peptide effectively inhibits vasculogenesis. In addition, no statistical difference was seen between untreated five-day old mice and the same aged mice receiving control peptide. Thus, inhibition of retinal vasculogenesis in RGDfV-treated newborn mice when compared to untreated counterparts is effectively 100%.

Using a more quantitative analysis taking the three dimensional nature of vessel growth, a 78% reduction in the retinal vascular volume in the peptide 203-treated animals compared to the controls was seen. The mean volume of vessels on postnatal day five in 203-treated animals was $3.6 \times 10^6 \mu\text{m}^3$ and in control-treated animal was $15.7 \times 10^6 \mu\text{m}^3$. The volume occupied by retinal blood vessels in untreated newborn mice was indistinguishable from the five-day old 203-treated animals.

The results obtained above showed that the antagonists specifically blocked new blood vessel formation with no effect on established vessels. The results indicate that the pathology of retinal neovascular disease is distinct from that seen with subretinal neovascular disease and that antagonists of $\alpha_v\beta_3$ are effective for treating patients with blinding eye disease associated with angiogenesis.


Similar assays are performed with the MMP-2 and organic mimetic $\alpha_v\beta_3$ antagonists prepared as respectively described in Example 7 and Example 10.

10. Preparation of Organic Molecule $\alpha_v\beta_3$ Antagonists

The synthesis of organic $\alpha_v\beta_3$ antagonist Compounds 7, 9, 10, 12, 14, 15, 16, 17 and 18 is described below and is also shown in the noted figures. The resultant organic molecules, referred to as organic mimetics of this invention, are then used in the methods for inhibiting $\alpha_v\beta_3$ -mediated angiogenesis.

For each of the syntheses described below, optical rotations were measured on Perkin-Elmer 241 spectrophotometer UV and visible spectra were recorded on a Beckmann DU-70 spectrometer. ^1H and ^{13}C NMR spectra were recorded at 400 and 500 MHz on Bruker AMX-400 and AMX-500 spectrometer. High-resolution mass spectra (HRMS) were recorded on a VG ZAB-ZSE mass spectrometer under fast atom bombardment (FAB) conditions. Column chromatography was carried out with silica gel of 70-230 mesh. Preparative TLC was carried out on Merck Art. 5744 (0.5 mm). Melting points were taken on a Thomas Hoover apparatus.

A. Compound 1: t-Boc-L-tyrosine benzyl ester as illustrated in Figure 10




COMPOUND 1

To a solution of N-(tert-butoxycarbonyl)-L-tyrosine(t-Boc-L-tyrosine) (1.0 equivalents; Aldrich) in 0.10 M (M) methylene chloride was added dicyclohexylcarbodiimide (DCC) (1.5 equivalents) at 25°C and allowed to stir for 1 hour. Next, 1.5 equivalents benzyl alcohol was added and the mixture was stirred for an additional 12 hours at 25°C. The reaction mixture was


then diluted with ethyl acetate (0.10 M) and washed twice (2X) with water, once (1X) with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography. Compound 1, t-Boc-L-tyrosine benzyl ester can also be commercially purchased from Sigma.

B. Compound 2: (S)-3-(4-(4-Bromobutyloxy)phenyl)-2-N-tert-butyloxycarbonyl-propionic acid benzyl ester as illustrated in Figure 10 step i



A mixture of t-Boc-L-tyrosine benzyl ester (2 grams, 5.38 mmol; synthesized as described above), 1,4-dibromobutane (1.9 ml, 16.2 mmol; Aldrich), potassium carbonate (5 g) and 18-crown-6 (0.1 g; Aldrich), was heated at 80°C for 12 hours. After cooling, the precipitate was filtered off and the reaction mixture was evaporated to dryness in vacuo. The crude product was then purified by crystallization using 100% hexane to yield 2.5 g (92%) of Compound 2.


C. Compound 3: (S)-3-(4-(4-Azidobutyloxy)phenyl)-2-N-tert-butyloxycarbonyl-propionic acid benzyl ester as illustrated in Figure 10 step ii



Compound 2 (2.5 g, 4.9 mmol) was stirred with sodium azide (1.6 g, 25 mmol) in dimethylformamide (DMF) (20 ml) at 25°C for 12 hours. The solvent was then evaporated and the residue was treated with water (approx 10 ml) and extracted twice with ethyl acetate. The


organic layers were combined, dried via magnesium sulfate and evaporated to yield 2.0 grams (90%) of Compound 3 as a colorless syrup (FAB-MS: 469 ($M+H^+$)).

- D. Compound 4: (S)-3-(4-(4-Azidobutyloxy)phenyl)-2-amino-propionic acid benzyl ester as illustrated in Figure 10 step iii




Compound 3 (2.0g (4.4 mmol)) was dissolved in trifluoroacetic acid (TFA; 2 ml) and stirred for 3 hours at room temperature. Evaporation in vacuo yielded 1.6 grams (quantitative) of Compound 4 as a colorless syrup that was used without further purification for the next step. FAB-MS: 369 (M^+H^+).

- E. Compound 5: (S)-3-(4-(4-Azidobutyloxy)phenyl)-2-butylsulfonamido-propionic acid benzyl ester as illustrated in Figure 10 step iv



A mixture of Compound 4 (1.6g; 4.3 mmol), butane sulfonic acid chloride (0.84 ml; 6.6 mmol) and triethyl amine (1.5 equivalents) were stirred in methylene chloride (20 ml) for 12 hours at room temperature. The reaction mixture was then evaporated and the residue was dissolved in ethylacetate, washed with dilute HCl, aqueous sodium bicarbonate and water. After evaporation to dryness the crude product was purified by flash chromatography (silica gel, toluene/ ethylacetate 15:1) to yield 1.4 grams (67%) of Compound 5 as an amorphous solid.


- F. Compound 6: (S)-3-(4-(4-Aminobutyloxy)phenyl)-2-butylsulfonamido-propionic acid as illustrated in Figure 10 step v



COMPOUND 6

5 Compound 5 (1.3 g (2.6 mmol) was dissolved in 20 ml of ethyl acetate/ methanol/ water 5/3/1 and 0.2 ml trifluoroacetic acid (TFA) and hydrogenated under hydrogen (1 atmosphere; Parr Shaker apparatus) at 25°C in the presence of 100 mg palladium (10% on charcoal). After 3 hours, the catalyst was filtered off and the solvent was evaporated to yield Compound 6 as an oily residue. After lyophilization from water 1.0 gram (quantitative) of Compound 6 was
10 obtained as a white powder. FAB-MS: 373 (M⁺H⁺).

- G. Compound 7: (S)-3-(4-(4-Guanidinobutyloxy)phenyl)-2-butylsulfonamido-propionic acid as illustrated in Figure 10 step vi




COMPOUND 7

15

Compound 6 (200 mg; 0.5 mmol), 3,5-dimethylpyrazol-1-carboxamidinium nitrate (DPFN) (170 mg; 0.8 mmol; Aldrich Chemical Company) and triethylamine (0.15 ml, 1.0 mmol) in dimethylformamide (DMF; 5 ml) were heated at 60°C for 12 hours. After cooling, the solvent was evaporated in vacuo, and the residue was purified by HPLC (Lichrocart RP-18, gradient
20 acetonitrile/ water + 0.3% TFA 99:1 to 1:99) to yield 50 mg (25%) of Compound 7 as a white, amorphous powder, after lyophilization. FAB-MS: 415 (M⁺H⁺), m.p.: 70°C.


- H. Compound 8: (S)-3-(4-(4-Aminobutyloxy)phenyl)-2-N-tert.butyloxycarbonyl-propionic acid as illustrated in Figure 11 step iii



COMPOUND 8

Compound 3 (0.5 g (1.07 mmol)) was dissolved in 10 ml of ethyl acetate/ methanol/ water 5/3/1 and 0.1 ml trifluoroacetic acid (TFA) and hydrogenated under hydrogen (1 atmosphere; Parr Shaker apparatus) at 25°C in the presence of 30 mg palladium (10% on charcoal). After 3 hours, the catalyst was filtered off and the solvent was evaporated to yield Compound 8 as an oily residue. After lyophilization from water 370 milligram (quantitative) of Compound 8 was obtained as a white powder. FAB-MS: 353 (M^+H^+).

- I. Compound 9: (S)-3-(4-(4-Guanidinobutyloxy)phenyl)-2-N-tert.butyloxycarbonyl-propionic acid as illustrated in Figure 11 step iv




COMPOUND 9

Compound 8 (200 mg; 0.5 mmol), 3,5-dimethylpyrazol-1-carboxamidine nitrate (DPFN) (170 mg; 0.8 mmol; Aldrich Chemical Company) and triethylamine (0.15 ml, 1.0 mmol) in

dimethylformamide (DMF; 5 ml) were heated at 60°C for 12 hours. After cooling, the solvent was evaporated in vacuo, and the residue was purified by HPLC (Lichrocart RP-18, gradient acetonitrile/ water + 0.3% TFA 99:1 to 1:99) to yield 160 mg (90%) of Compound 9 as a white, amorphous powder, after lyophilization. FAB-MS: 395 (M^+H^+).


J. Compound 10: (R)-3-(4-(4-Guanidinobutyloxy)phenyl)-2-butylsulfonamido-propionic acid as illustrated in Figure 12 steps i-vi



COMPOUND 10

The identical reaction sequence to synthesize Compound 7 was used to prepare the D-tyrosine analog 10 of which 205 mg were obtained as a white amorphous material FAB-MS: 415 (M^+H^+) as follows using intermediate Compounds 100-600 to form Compound 10:

1) Compound 100: t-Boc-D-tyrosine benzyl ester as illustrated in Figure 12




COMPOUND 100

To a solution of N-(tert-butoxycarbonyl)D-tyrosine(t-Boc-L-tyrosine) (1.0 equivalents; Aldrich) in 0.10 M methylene chloride was added dicyclohexylcarbodiimide (DCC) (1.5 equivalents) at 25°C and allowed to stir for 1 hour. Next, 1.5 equivalents benzyl alcohol was added and the mixture was stirred for an additional 12 hours at 25°C. The reaction mixture was then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then


purified by silica gel column chromatography.

- 2) Compound 200: (R)-3-(4-(4-Bromobutyloxy)phenyl)-2-N-tert-butylloxycarbonyl-propionic acid benzyl ester as illustrated in Figure 12 step i




A mixture of t-Boc-D-tyrosine benzyl ester (2 grams, 5.38 mmol; synthesized as described above), 1,4-dibromobutane (1.9 ml, 16.2 mmol; Aldrich), potassium carbonate (5 g) and 18-crown-6 (0.1 g; Aldrich), was heated at 80°C for 12 hours. After cooling, the precipitate was filtered off and the reaction mixture was evaporated to dryness in vacuo. The crude product was then purified by crystallization using 100% hexane to yield 2.5 g (92%) of Compound 200.

- 3) Compound 300: (R)-3-(4-(4-Azidobutyloxy)phenyl)-2-N-tert-butylloxycarbonyl-propionic acid benzyl ester as illustrated in Figure 12 step ii




Compound 200 (2.5 g, 4.9 mmol) was stirred with sodium azide (1.6 g, 25 mmol) in dimethylformamide (DMF) (20 ml) at 25°C for 12 hours. The solvent was then evaporated and the residue was treated with water (approx 10 ml) and extracted twice with ethyl acetate. The organic layers were combined, dried via magnesium sulfate and evaporated to yield 2.0 grams (90%) of Compound 300 as a colorless syrup (FAB-MS: 469 (M+H⁺)).

- 4) Compound 400: (R)-3-(4-(4-Azidobutyloxy)phenyl)-2-amino-propionic acid benzyl ester as illustrated in Figure 12 step iii




5 Compound **300** (2.0g (4.4 mmol)) was dissolved in trifluoroacetic acid (TFA; 2 ml) and stirred for 3 hours at room temperature. Evaporation in vacuo yielded 1.6 grams (quantitative) of Compound **400** as a colorless syrup that was used without further purification for the next step. FAB-MS: 369 (M^+H^+).

- 5) Compound 500: (R)-3-(4-(4-Azidobutyloxy)phenyl)-2-butylsulfonamido-propionic acid benzyl ester as illustrated in Figure 12 step iv



A mixture of Compound **400** (1.6g; 4.3 mmol), butane sulfonic acid chloride (0.84 ml; 6.6 mmol) and triethyl amine (1.5 equivalents) were stirred in methylene chloride (20 ml) for 12 hours at room temperature. The reaction mixture was then evaporated and the residue was dissolved in ethylacetate, washed with dilute HCl, aqueous sodium bicarbonate and water. After evaporation to dryness the crude product was purified by flash chromatography (silica gel, toluene/ ethylacetate 15:1) to yield 1.4 grams (67%) of Compound **500** as an amorphous solid.

- 6) Compound 600: (R)-3-(4-(4-Aminobutyloxy)phenyl)-2-butylsulfonamido-propionic acid as illustrated in Figure 12 step v




COMPOUND 600

5 Compound **500** (1.3 g (2.6 mmol) was dissolved in 20 ml of ethyl acetate/ methanol/ water 5/3/1 and 0.2 ml trifluoroacetic acid (TFA) and hydrogenated under hydrogen (1 atmosphere; Parr Shaker apparatus) at 25°C in the presence of 100 mg palladium (10% on charcoal). After 3 hours, the catalyst was filtered off and the solvent was evaporated to yield Compound **600** as an oily residue. After lyophilization from water 1.0 gram (quantitative) of
10 Compound **600** was obtained as a white powder. FAB-MS: 373 (M⁺H⁺).

- 7) Compound 10: (R)-3-(4-(4-Guanidinobutyloxy)phenyl)-2-butylsulfonamido-propionic acid as illustrated in Figure 12 step vi

15 Compound **600** (200 mg; 0.5 mmol), 3,5-dimethylpyrazol-1-carboxamidine nitrate (DPFN) (170 mg; 0.8 mmol; Aldrich Chemical Company) and triethylamine (0.15 ml, 1.0 mmol) in dimethylformamide (DMF; 5 ml) were heated at 60°C for 12 hours. After cooling, the solvent was evaporated in vacuo, and the residue was purified by HPLC (Lichrocart RP-18, gradient acetonitrile/ water + 0.3% TFA 99:1 to 1:99) to yield 50 mg (25%) of Compound **10** as a white, amorphous powder, after lyophilization. FAB-MS: 415 (M⁺H⁺), m.p.: 70°C.

K. Compound 11: (S)-3-(4-(4-Azidobutyloxy)phenyl)-2-(10-camphorsulfonamido)-propionic acid benzyl ester as illustrated in Figure 4




COMPOUND 11

5

A mixture of compound 4 (1.0g; 2.7 mmol), 10-camphorsulfonic acid chloride (6.6 mmol; Aldrich Chemical Company) and triethyl amine (1.5 equivalents) were stirred in methylene chloride (20 mL) for 12 hours at room temperature. The reaction mixture was then evaporated and the residue was dissolved in ethylacetate, washed with dilute HCl, aqueous sodium bicarbonate and water. After evaporation to dryness the crude product was purified by flash chromatography (silica gel, toluene/ ethylacetate 15:1) to yield 1.4 grams (67%) of compound 11 as an amorphous solid.

15

- L. Compound 12: (S)-3-(4-(4-Guanidinobutyloxy)phenyl)-2-(10-camphorsulfonamido)-propionic acid as illustrated in Figure 4 steps i-ii



COMPOUND 12


5

Compound 12 is obtained after hydrogenation and guanylation of compound 11 according to the following conditions:

Step i: Compound 11 (1.3 g (2.6 mmol) was dissolved in 20 mL of ethyl acetate/
methanol/ water 5/3/1 and 0.2 mL trifluoroacetic acid (TFA) and hydrogenated under hydrogen
10 (1 atmosphere; Parr Shaker apparatus) at 25 °C in the presence of 100 mg palladium (10% on
charcoal). After 3 hours, the catalyst was filtered off and the solvent was evaporated to yield the
intermediate amine as an oily residue. After lyophilisation from water 1.0 gram (quantitative)
of the intermediate amine was obtained as a white powder, which was carried on as follows:

Step ii: The above formed intermediate amine compound (200 mg; 0.5 mmol), 3,5-
15 dimethylpyrazol-1-carboxamidine nitrate (DPFN) (170 mg; 0.8 mmol; Aldrich Chemical
Company) and triethylamine (0.15 mL, 1.0 mmol) in dimethylformamide (DMF; 5mL) were
heated at 60 °C for 12 hours. After cooling, the solvent was evaporated in vacuo, and the
residue was purified by HPLC (Lichrocart RP-18, gradient acetonitrile/ water + 0.3% TFA 99:1
to 1:99) to yield 50 mg (25%) of compound 12 as a white, amorphous powder, after
20 lyophilisation. FAB-MS: 509.6 (M+H+).


- M. Compound 13: (S)-3-(4-(5-Bromopentyloxy)phenyl)-2-N-tert.butyloxycarbonyl-propionic acid benzyl ester as illustrated in Figure 13



COMPOUND 13

- 5 A mixture of t-Boc-L-tyrosine benzyl ester (4.5 grams, 12.1 mmol; Compound 1 synthesized as described above), 1,5-dibromopentane (5 ml, 36.7 mmol; Aldrich), potassium carbonate (10 g) and 18-crown-6 (0.25 g; Aldrich), was heated at 80°C for 12 hours. After cooling, the precipate was filtered off and the reaction mixture was evaporated to dryness in vacuo. The crude product was then purified by crystallization using 100% hexane to yield 5.35 g (85%) of Compound 13.

- N. Compound 14: (S)-3-(4-(5-Guanidinopentyloxy)phenyl)-2-butylsulfonamido-propionic acid as illustrated in Figure 13 steps i-v




COMPOUND 14

- 15 The 5 step reaction sequence of bromine-azide-exchange, Boc-cleavage, sulfonylation with butane sulfonic acid chloride, hydrogenation and guanylation with DPFN was carried out identically to the above procedures using intermediate Compounds 1-6 to form Compound 7 or the procedures using Compounds 100-600 to form Compound 10, as disclosed above.
- 20 Compound 14 was obtained as a white powder FAB-MS: 429 (M⁺H⁺).

O. Compound 15: 3-(4-amidinophenyl)-5-(4-(2-carboxy-2-amino-ethyl)phenoxy)methyl-2-oxazolidinone, dihydrochloride as shown in Figure 14

1) Synthesis of starting material 2-N-BOC-amino-3-(4-hydroxy-phenyl)propionate for Compound 15



COMPOUND 15

The starting material 2-N-BOC-amino-3-(4-hydroxy-phenyl)propionate was obtained via esterification of (D or L), N-(tert-butoxycarbonyl)-L(D)-tyrosine (t-Boc-L(D)-tyrosine) (1.0 equivalents; Sigma) in 0.10 M methanol and dilute 1% HCl. The reaction mixture was stirred at 25°C for 12 hours and then neutralized via potassium carbonate and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain 2-N-BOC-amino-3-(4-hydroxy-phenyl)propionate.

2) Synthesis of starting material 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone for Compound 15: 3-step procedure as follows:

p-amino-benzonitrile (1.0 equivalents; Aldrich) in methylene chloride (0.10 M) was stirred with 2,3-epoxypropanol (1.0 equivalents; Aldrich) for 12 hours at 25°C. The solvent was next removed in vacuo and the crude 4-(2,3-dihydroxypropylamino)benzonitrile was carried onto the next step as follows:

4-(2,3-dihydroxypropylamino)benzonitrile (1.0 equivalents; as described above), in dimethylformamide (0.10 M), at 25°C, was stirred with diethyl carbonate (1.1 equivalents; Aldrich) and potassium tert-butyrate (1.1 equivalents; Aldrich) at 110°C for 6 hours. Next, the reaction mixture was diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain 3-(4-cyanophenyl)-5-hydroxymethyl-2-oxazolidine and carried onto the next step as follows:

3-(4-cyanophenyl)-5-hydroxymethyl-2-oxazolidine (1.0 equivalents; as described above), in methylene chloride (0.10 M) at 25°C was stirred with 1.1 equivalents hydrogen sulfide, 1.1 equivalents methyl iodide, and 1.1 equivalents ammonium acetate. The reaction mixture was stirred for 6 hours and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain the amidine which was carried onto the next step as follows:

1.0 equivalents of the amidine, synthesized as described above, was protected with 1.1 equivalents of BOC-ON (2-(BOC-oxyimino)-2-phenylacetonitrile; Aldrich) in methylene chloride (0.10 M) at 25°C and stirred for 6 hours. Next, the reaction mixture was diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then esterified in 0.10 M methylene chloride and 1.1 equivalents methanesulfonyl chloride. The reaction mixture was stirred at 0°C for 6 hours and then quenched with water (5 equivalents) and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone.


3) Coupling of intermediates 2-N-BOC-amino-3-(4-hydroxy-phenyl)propionate with 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone to form protected form of Compound 15, 3-(4-BOC-amidinophenyl)-5-(4-(2-methoxy-carbonyl-2N-BOC-aminoethyl)phenoxy)methyl-2-oxazolidinone

A mixture of 1.9 grams 2-N-BOC-amino-3-(4-hydroxy-phenyl)propionate (as described above), 20 ml dimethylformamide (DMF) and NaH (1.0 equivalent), was stirred for 30 minutes at room temperature. After stirring, 1.8 grams 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone (as described above) in 10 ml dimethylformamide (DMF) was added and stirred again for 15 minutes at room temperature. The reaction mixture was then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain protected form of Compound 15, 3-(4-BOC-amidinophenyl)-5-(4-(2-methoxy-carbonyl-2N-BOC-aminoethyl)phenoxy)methyl-2-oxazolidinone which was carried onto the next step.

- 4) Deprotection of protected form of Compound 15 to form Compound 15:
3-(4-amidinophenyl)-5-(4-(2-carboxy-2-amino-ethyl)phenoxy)methyl-2-oxazolidinone, dihydrochloride, Figure 14

Treatment of the protected form of Compound 15, 3-(4-BOC-amidinophenyl)-5-(4-(2-methoxy-carbonyl-2N-BOC-aminoethyl)phenoxy)methyl-2-oxazolidinone (1.0 equivalents; synthesized as described above), with 4 ml 2N NaOH for 4 hours at room temperature. The mixture was then followed with 40 ml 2N HCl-solution in dioxane added dropwise at 0°C to 25°C for 3 hours. The reaction mixture was then quenched with sodium bicarbonate (5 equivalents) and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain Compound 15: 3-(4-amidinophenyl)-5-(4-(2-carboxy-2-amino-ethyl)phenoxy)methyl-2-oxazolidinone, dihydrochloride; m.p. 165 °C(d).

- P. Compound 16: 3-(4-amidinophenyl)-5-(4-(2-carboxy-2-N-butylsulfonylaminoethyl)phenoxy)methyl-2-oxazolidinone as shown in Figure 14
- 1) Synthesis of starting material 2-N-butylsulfonylamino-3-(4-hydroxy-phenyl)propionate for Compound 16



COMPOUND 16

The starting material 2-N-butylsulfonylamino-3-(4-hydroxy-phenyl)propionate was obtained via esterification of ((D or L) tyrosine) (1.0 equivalents; Sigma) in 0.10 M methanol and dilute 1% HCl. The reaction mixture was stirred at 25°C for 12 hours and then neutralized via potassium carbonate and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then carried on as follows:

A mixture of the above compound (4.3 mmol), butane sulfonic acid chloride (6.6 mmol)

and triethyl amine (1.5 equivalents) were stirred in methylene chloride (20 ml) for 12 hours at room temperature. The reaction mixture was then evaporated and the residue was dissolved in ethylacetate, washed with dilute HCl, aqueous sodium bicarbonate and water. After evaporation to dryness the crude product was purified by flash chromatography (silica gel, toluene/ethylacetate 15:1) to yield the title compound.

2) Synthesis of starting material 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone for Compound 16: 3-step procedure as follows:

p-amino-benzonitrile (1.0 equivalents; Aldrich) in methylene chloride (0.10 M) was stirred with 2,3-epoxypropanol (1.0 equivalents; Aldrich) for 12 hours at 25°C. The solvent was next removed in vacuo and the crude 4-(2,3-dihydroxypropylamino)benzonitrile was carried onto the next step as follows:

4-(2,3-dihydroxypropylamino)benzonitrile (1.0 equivalents; as described above), in dimethylformamide (0.10 M), at 25°C, was stirred with diethyl carbonate (1.1 equivalents; Aldrich) and potassium tert-butyrate (1.1 equivalents; Aldrich) at 110°C for 6 hours. Next, the reaction mixture was diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain 3-(4-cyanophenyl)-5-hydroxymethyl-2-oxazolidine and carried onto the next step as follows:

3-(4-cyanophenyl)-5-hydroxymethyl-2-oxazolidine (1.0 equivalents; as described above), in methylene chloride (0.10 M) at 25°C was stirred with 1.1 equivalents hydrogen sulfide, 1.1 equivalents methyl iodide, and 1.1 equivalents ammonium acetate. The reaction mixture was stirred for 6 hours and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain the amidine which was carried onto the next step as follows:

1.0 equivalents of the amidine, synthesized as described above, was protected with 1.1 equivalents of BOC-ON (2-(BOC-oxyimino)-2-phenylacetonitrile; Aldrich) in methylene chloride (0.10 M) at 25°C and stirred for 6 hours. Next, the reaction mixture was diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then esterified in 0.10 M methylene chloride and 1.1 equivalents methanesulfonyl chloride. The reaction mixture was stirred at 0°C for 6 hours and then quenched with water (5 equivalents) and then diluted

with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone.

3) Coupling of intermediates 2-N-butylsulfonylamino-3-(4-hydroxy-phenyl)propionate with 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone to form protected form of Compound 16, 3-(4-BOC-amidinophenyl)-5-(4-(2-methoxy-carbonyl-2-N-butylsulfonylaminoethyl)phenoxy)methyl-2-oxazolidinone


A mixture of 1.9 grams 2-N-butylsulfonylamino-3-(4-hydroxy-phenyl)propionate (as described above), 20 ml dimethylformamide (DMF) and NaH (1.0 equivalent), was stirred for 30 minutes at room temperature. After stirring, 1.8 grams 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone (as described above) in 10 ml dimethylformamide (DMF) was added and stirred again for 15 minutes at room temperature. The reaction mixture was then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain protected form of Compound 16, 3-(4-BOC-amidinophenyl)-5-(4-(2-methoxy-carbonyl-2-N-butylsulfonylaminoethyl)-phenoxy)methyl-2-oxazolidinone which was carried onto the next step.

4) Deprotection of protected form of Compound 16 to form Compound 16: 3-(4-amidinophenyl)-5-(4-(2-carboxy-2-N-butylsulfonylaminoethyl)phenoxy)methyl-2-oxazolidinone, Figure 14

Treatment of the protected form of Compound 16, 3-(4-BOC-amidinophenyl)-5-(4-(2-methoxy-carbonyl-2-N-butylsulfonylaminoethyl)phenoxy)methyl-2-oxazolidinone (1.0 equivalents; synthesized as described above), with 4 ml 2N NaOH for 4 hours at room temperature. The mixture was then followed with 40 ml 2N HCl-solution in dioxane added dropwise at 0°C to 25°C for 3 hours. The reaction mixture was then quenched with sodium bicarbonate (5 equivalents) and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain Compound 16: 3-(4-amidinophenyl)-5-(4-(2-carboxy-2-N-butylsulfonylaminoethyl)phenoxy)methyl-2-oxazolidinone; m.p. 236-237°C.

Q. Compound 17: 3-(4-amidinophenyl)-5-(4-(2-carboxy-2-N-propyl-sulfonylaminoethyl)phenoxy)methyl-2-oxazolidinone as shown in Figure 14

1) Synthesis of starting material 2-N-propyl-sulfonylamino-3-(4-hydroxy-phenyl)propionate for Compound 17:



COMPOUND 17

The starting material 2-N-propyl-sulfonylamino-3-(4-hydroxy-phenyl)propionate was obtained via esterification of ((D or L) tyrosine) (1.0 equivalents; Sigma) in 0.10 M methanol and dilute 1% HCl. The reaction mixture was stirred at 25°C for 12 hours and then neutralized via potassium carbonate and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then carried on as follows:

A mixture of the above compound (4.3 mmol), propyl sulfonic acid chloride (6.6 mmol; Aldrich) and triethyl amine (1.5 equivalents) were stirred in methylene chloride (20 ml) for 12 hours at room temperature. The reaction mixture was then evaporated and the residue was dissolved in ethylacetate, washed with dilute HCl, aqueous sodium bicarbonate and water. After evaporation to dryness the crude product was purified by flash chromatography (silica gel, toluene/ ethylacetate 15:1) to yield the title compound.

2) Synthesis of starting material 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone for Compound 17: 3-step procedure as follows:

p-amino-benzonitrile (1.0 equivalents; Aldrich) in methylene chloride (0.10 M) was stirred with 2,3-epoxypropanol (1.0 equivalents; Aldrich) for 12 hours at 25°C. The solvent was next removed in vacuo and the crude 4-(2,3-dihydroxypropylamino)benzonitrile was carried onto the next step as follows:

4-(2,3-dihydroxypropylamino)benzonitrile (1.0 equivalents; as described above), in

dimethylformamide (0.10 M), at 25°C, was stirred with diethyl carbonate (1.1 equivalents; Aldrich) and potassium tert-butyrate (1.1 equivalents; Aldrich) at 110°C for 6 hours. Next, the reaction mixture was diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain 3-(4-cyanophenyl)-5-hydroxymethyl-2-oxazolidine and carried onto the next step as follows:

3-(4-cyanophenyl)-5-hydroxymethyl-2-oxazolidine (1.0 equivalents; as described above), in methylene chloride (0.10 M) at 25°C was stirred with 1.1 equivalents hydrogen sulfide, 1.1 equivalents methyl iodide, and 1.1 equivalents ammonium acetate. The reaction mixture was stirred for 6 hours and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain the amidine which was carried onto the next step as follows:

1.0 equivalents of the amidine, synthesized as described above, was protected with 1.1 equivalents of BOC-ON (2-(BOC-oxyimino)-2-phenylacetonitrile; Aldrich) in methylene chloride (0.10 M) at 25°C and stirred for 6 hours. Next, the reaction mixture was diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then esterified in 0.10 M methylene chloride and 1.1 equivalents methanesulfonyl chloride. The reaction mixture was stirred at 0°C for 6 hours and then quenched with water (5 equivalents) and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone.

3) Coupling of intermediates 2-N-propyl-sulfonylamino-3-(4-hydroxy-phenyl)propionate with 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone to form protected form of Compound 17, 3-(4-BOC-amidinophenyl)-5-(4-(2-methoxy-carbonyl-2-N-propyl-sulfonylaminoethyl)-phenoxy)methyl-2-oxazolidinone

A mixture of 1.9 grams 2-N-propyl-sulfonylamino-3-(4-hydroxy-phenyl)propionate (as described above), 20 ml dimethylformamide (DMF) and NaH (1.0 equivalent), was stirred for 30 minutes at room temperature. After stirring, 1.8 grams 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone (as described above) in 10 ml dimethylformamide


(DMF) was added and stirred again for 15 minutes at room temperature. The reaction mixture was then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain protected form of Compound 17, 3-(4-BOC-amidinophenyl)-5-(4-(2-methoxy-carbonyl-2-N-propyl-sulfonylaminoethyl)-phenoxy)methyl-2-oxazolidinone which was carried onto the next step.

4) Deprotection of protected form of Compound 17 to form Compound 17:
3-(4-amidinophenyl)-5-(4-(2-carboxy-2-N-
propylsulfonylaminoethyl)phenoxy)methyl-2-oxazolidinone, Figure 14

Treatment of the protected form of Compound 17, 3-(4-BOC-amidinophenyl)-5-(4-(2-methoxy-carbonyl-2-N-propylsulfonylaminoethyl)phenoxy)methyl-2-oxazolidinone (1.0 equivalents; synthesized as described above), with 4 ml 2N NaOH for 4 hours at room temperature. The mixture was then followed with 40 ml 2N HCl-solution in dioxane added dropwise at 0°C to 25°C for 3 hours. The reaction mixture was then quenched with sodium bicarbonate (5 equivalents) and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain Compound 17: 3-(4-amidinophenyl)-5-(4-(2-carboxy-2-N-propylsulfonylaminoethyl)phenoxy)methyl-2-oxazolidinone; m.p. 200°C (d).

R. Compound 18: 3-(4-amidinophenyl)-5-(4-(2-carboxy-2-N-ethyl-
sulfonylaminoethyl)phenoxy)methyl-2-oxazolidinone as shown in Figure 14

1) Synthesis of starting material 2-N-ethyl-sulfonylamino-3-(4-hydroxy-
phenyl)propionate for Compound 18:



COMPOUND 18

The starting material 2-N-ethyl-sulfonylamino-3-(4-hydroxy-phenyl)propionate was obtained via esterification of ((D or L) tyrosine) (1.0 equivalents; Sigma) in 0.10 M methanol and dilute 1% HCl. The reaction mixture was stirred at 25°C for 12 hours and then neutralized via potassium carbonate and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then carried on as follows:

A mixture of the above compound (4.3 mmol), ethyl sulfonic acid chloride (6.6 mmol; Aldrich) and triethyl amine (1.5 equivalents) were stirred in methylene chloride (20 ml) for 12 hours at room temperature. The reaction mixture was then evaporated and the residue was dissolved in ethylacetate, washed with dilute HCl, aqueous sodium bicarbonate and water. After evaporation to dryness the crude product was purified by flash chromatography (silica gel, toluene/ ethylacetate 15:1) to yield the title compound.

2) Synthesis of starting material 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone for Compound 18: 3-step procedure as follows:

p-amino-benzonitrile (1.0 equivalents; Aldrich) in methylene chloride (0.10 M) was stirred with 2,3-epoxypropanol (1.0 equivalents; Aldrich) for 12 hours at 25°C. The solvent was next removed in vacuo and the crude 4-(2,3-dihydroxypropylamino)benzonitrile was carried onto the next step as follows:

4-(2,3-dihydroxypropylamino)benzonitrile (1.0 equivalents; as described above), in dimethylformamide (0.10 M), at 25°C, was stirred with diethyl carbonate (1.1 equivalents; Aldrich) and potassium *tert*-butylate (1.1 equivalents; Aldrich) at 110°C for 6 hours. Next, the reaction mixture was diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain 3-(4-cyanophenyl)-5-hydroxymethyl-2-oxazolidine and carried onto the next step as follows:

3-(4-cyanophenyl)-5-hydroxymethyl-2-oxazolidine (1.0 equivalents; as described above), in methylene chloride (0.10 M) at 25°C was stirred with 1.1 equivalents hydrogen sulfide, 1.1 equivalents methyl iodide, and 1.1 equivalents ammonium acetate. The reaction mixture was stirred for 6 hours and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain the amidine which was carried onto the next step as follows:

1.0 equivalents of the amidine, synthesized as described above, was protected with 1.1 equivalents of BOC-ON (2-(BOC-oxyimino)-2-phenylacetonitrile; Aldrich) in methylene chloride (0.10 M) at 25°C and stirred for 6 hours. Next, the reaction mixture was diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then esterified in 0.10 M methylene chloride and 1.1 equivalents methanesulfonyl chloride. The reaction mixture was stirred at 0°C for 6 hours and then quenched with water (5 equivalents) and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone.

3) Coupling of intermediates 2-N-ethyl-sulfonylamino-3-(4-hydroxy-phenyl)propionate with 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone to form protected form of Compound 18, 3-(4-BOC-amidinophenyl)-5-(4-(2-methoxy-carbonyl-2-N-ethyl-sulfonylaminoethyl)-phenoxy)methyl-2-oxazolidinone

A mixture of 1.9 grams 2-N-ethyl-sulfonylamino-3-(4-hydroxy-phenyl)propionate (as described above), 20 ml dimethylformamide (DMF) and NaH (1.0 equivalent), was stirred for 30 minutes at room temperature. After stirring, 1.8 grams 3-p-N-BOC-amidino-phenyl-5-methanesulfonyloxy-methyl-2-oxazolidinone (as described above) in 10 ml dimethylformamide (DMF) was added and stirred again for 15 minutes at room temperature. The reaction mixture was then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain protected form of Compound 18, 3-(4-BOC-amidinophenyl)-5-(4-(2-methoxy-carbonyl-2-N-ethyl-sulfonylaminoethyl)-phenoxy)methyl-2-oxazolidinone which was carried onto the next step.

4) Deprotection of protected form of Compound 18 to form Compound 18: 3-(4-amidinophenyl)-5-(4-(2-carboxy-2-N-ethylsulfonylaminoethyl)phenoxy)methyl-2-oxazolidinone. Figure 14

Treatment of the protected form of Compound 18, 3-(4-BOC-amidinophenyl)-5-(4-(2-methoxy-carbonyl-2-N-ethylsulfonylaminoethyl)phenoxy)methyl-2-oxazolidinone (1.0 equivalents; synthesized as described above), with 4 ml 2N NaOH for 4 hours at room

temperature. The mixture was then followed with 40 ml 2N HCl-solution in dioxane added dropwise at 0°C to 25°C for 3 hours. The reaction mixture was then quenched with sodium bicarbonate (5 equivalents) and then diluted with ethyl acetate (0.10 M) and washed 2X with water, 1X with brine and dried over magnesium sulfate. The solvent was then removed in vacuo and the crude product was then purified by silica gel column chromatography to obtain
5 Compound 18: 3-(4-amidinophenyl)-5-(4-(2-carboxy-2-N-ethylsulfonylaminoethyl)phenoxy)methyl-2-oxazolidinone; m.p. 212°C (d).

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. Indeed, various modifications of the invention in addition to
10 those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

What Is Claimed Is:

1. An article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent is effective for inhibiting angiogenesis in a tissue and wherein said packaging material comprises a label which indicates that said pharmaceutical agent can be used for treating conditions by inhibition of angiogenesis and wherein said pharmaceutical agent comprises an angiogenesis-inhibiting amount of an $\alpha_v\beta_3$ antagonist that comprises a polypeptide having an amino acid residue sequence that includes a portion of the carboxy terminal domain of matrix metalloproteinase, said polypeptide capable of binding to integrin $\alpha_v\beta_3$.

2. The article of manufacture of claim 1 wherein said polypeptide includes an amino acid residue sequence shown in SEQ ID NO 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22.

3. The article of manufacture of claim 1 wherein said tissue is inflamed and said condition is arthritis or rheumatoid arthritis.

4. The article of manufacture of claim 1 wherein said tissue is a solid tumor or solid tumor metastasis.

5. The article of manufacture of claim 1 wherein said tissue is retinal tissue and said condition is retinopathy, diabetic retinopathy or macular degeneration.

6. An $\alpha_v\beta_3$ antagonist comprising a polypeptide having an amino acid residue sequence that includes a portion of the carboxy terminal domain of matrix metalloproteinase, said polypeptide capable of binding to integrin $\alpha_v\beta_3$.

7. The antagonist of claim 6 wherein said polypeptide includes an amino acid residue sequence shown in SEQ ID NO 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22.

8. The antagonist of claim 6 wherein said polypeptide is a fusion protein.

9. The antagonist of claim 6 wherein said polypeptide has an amino acid residue sequence shown in SEQ ID NO 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22.

10. A pharmaceutical agent comprising an $\alpha_v\beta_3$ antagonist according to claim 6 in a pharmaceutically acceptable carrier in an amount sufficient to inhibit angiogenesis in a tissue.

11. A method for inhibiting angiogenesis in a tissue comprising administering to said tissue a composition comprising an angiogenesis-inhibiting amount of an $\alpha_v\beta_3$ antagonist.

12. The method of claim 11 wherein said antagonist is a fusion protein, a polypeptide, a derivatized polypeptide, a cyclic polypeptide, a monoclonal antibody or an organic mimetic compound.

13. The method of claim 11 wherein said integrin $\alpha_v\beta_3$ antagonist preferentially inhibits fibrinogen binding to $\alpha_v\beta_3$ compared to fibrinogen binding to $\alpha_{IIb}\beta_3$.

14. The method of claim 11 wherein said $\alpha_v\beta_3$ antagonist comprises a polypeptide having an amino acid residue sequence that includes a portion of the carboxy terminal domain of matrix metalloproteinase, said polypeptide capable of binding to integrin $\alpha_v\beta_3$.

15. The method of claim 11 wherein said polypeptide includes an amino acid residue sequence shown in SEQ ID NO 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22.

16. The method of claim 11 wherein said polypeptide is a fusion protein.

17. The method of claim 11 wherein said polypeptide has an amino acid residue sequence shown in SEQ ID NO 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22.

18. The method of claim 11 wherein said tissue is inflamed and said angiogenesis is inflamed tissue angiogenesis.

19. The method of claim 18 wherein said tissue is arthritic.

20. The method of claim 19 wherein said arthritic tissue is present in a mammal with rheumatoid arthritis.

21. The method of claim 11 wherein said tissue is the retinal tissue of a patient with diabetic retinopathy and said angiogenesis is retinal angiogenesis.

22. The method of claim 11 wherein said tissue is a solid tumor or a solid tumor metastasis and said angiogenesis is tumor angiogenesis.

23. The method of claim 11 wherein said administering comprises intravenous, transdermal, intrasynovial, intramuscular, or oral administration.

24. The method of claim 22 wherein said administering is conducted in conjunction with chemotherapy.

25. The method of claim 11 wherein said administering comprises a single dose intravenously.

26. A method of inducing solid tumor tissue regression in a patient comprising administering to said patient a composition comprising a therapeutically effective amount of an integrin $\alpha_v\beta_3$ antagonist sufficient to inhibit neovascularization of a solid tumor tissue.

27. The method of claim 26 wherein said antagonist is a fusion protein, a polypeptide, a derivatized polypeptide, a cyclic polypeptide, a monoclonal antibody or an organic mimetic compound.

28. The method of claim 26 wherein said $\alpha_v\beta_3$ antagonist is the $\alpha_v\beta_3$ antagonist according to claim 6.

29. A method of inhibiting solid tumor tissue growth undergoing neovascularization in a patient comprising administering to said patient a composition comprising a therapeutically effective amount of an integrin $\alpha_v\beta_3$ antagonist sufficient to inhibit solid tumor tissue growth.

30. The method of claim 29 wherein said antagonist is a fusion protein, a polypeptide, a derivatized polypeptide, a cyclic polypeptide, a monoclonal antibody or an organic mimetic compound.

31. The method of claim 29 wherein said $\alpha_v\beta_3$ antagonist is the $\alpha_v\beta_3$ antagonist according to claim 6.

32. A method for treating a patient with inflamed tissue in which neovascularization is occurring comprising administering to said patient a composition comprising a therapeutically effective amount of an integrin $\alpha_v\beta_3$ antagonist.

33. The method of claim 32 wherein said antagonist is a fusion protein, a polypeptide, a derivatized polypeptide, a cyclic polypeptide, a monoclonal antibody or an organic mimetic compound.

34. The method of claim 32 wherein said $\alpha_v\beta_3$ antagonist is the $\alpha_v\beta_3$ antagonist according to claim 6.

35. A method for treating a patient in which neovascularization is occurring in retinal tissue comprising administering to said patient a composition comprising a neovascularization-inhibiting amount of an integrin $\alpha_v\beta_3$ antagonist.

36. The method of claim 35 wherein said antagonist is a fusion protein, a polypeptide, a derivatized polypeptide, a cyclic polypeptide, a monoclonal antibody or an organic mimetic compound.

37. The method of claim 35 wherein said $\alpha_v\beta_3$ antagonist is the $\alpha_v\beta_3$ antagonist according to claim 6.

38. A method for treating a patient for restenosis in a tissue wherein smooth muscle cell migration occurs following angioplasty comprising administering to said patient a composition comprising a therapeutically effective amount of an integrin $\alpha_v\beta_3$ antagonist.

39. The method of claim 38 wherein said antagonist is a fusion protein, a polypeptide, a derivatized polypeptide, a cyclic polypeptide, a monoclonal antibody or an organic mimetic compound.

40. The method of claim 38 wherein said $\alpha_v\beta_3$ antagonist is the $\alpha_v\beta_3$ antagonist according to claim 6.

41. A method of reducing blood supply to a tissue required to support new growth of said tissue in a patient comprising administering to said patient a composition comprising a therapeutically effective amount of an integrin $\alpha_v\beta_3$ antagonist sufficient to reduce said blood supply to said tissue.

42. The method of claim 41 wherein said antagonist is a fusion protein, a

polypeptide, a derivatized polypeptide, a cyclic polypeptide, a monoclonal antibody or an organic mimetic compound.

43. The method of claim 41 wherein said $\alpha_v\beta_3$ antagonist is the $\alpha_v\beta_3$ antagonist according to claim 6.

5 44. The method of claim 24 wherein said angiogenesis is present in a patient having an eye disease selected from the group of eye diseases consisting of diabetic retinopathy, age-related macular degeneration, presumed ocular histoplasmosis, retinopathy of prematurity and neovascular glaucoma.

10 45. The method of claim 24 wherein said angiogenesis is present in a patient having a corneal neovascular disorder selected from the group of disorders consisting of corneal transplantation, herpetic keratitis, luetic keratitis, pterygium and neovascular pannus associated with contact lens use.

46. The method of claim 24 wherein said angiogenesis is induced by a cytokine.

15 47. The method of claim 46 wherein said cytokine is selected from the group consisting of vascular endothelial growth factor, transforming growth factor- α and epidermal growth factor.

20 48. The method of claim 46 wherein said cytokine is vascular endothelial growth factor and said angiogenesis is selected from the group consisting of retinal angiogenesis, corneal angiogenesis, tumor angiogenesis and inflamed tissue angiogenesis.

FIG. 1A

OD: anti- $\alpha_v\beta_5$
(PIF6)



FGF

FIG. 1B

OS: anti- $\alpha_v\beta_3$
(LM609)



VEGF



FIG. 1C

FIG. 1D




FIG. 2A

FIG. 2B

3/24

bFGF

VEGF


Control
(PBS)

FIG. 3A

FIG. 3B

Anti- $\alpha_v\beta_5$
(PIF6)

FIG. 3C

FIG. 3D

Anti- $\alpha_v\beta_3$
(LM609)

FIG. 3E

FIG. 3F

4/24




FIG. 4A





FIG. 4B

5/24



6/24




FIG. 6A




FIG. 6B

7/24




FIG. 7A




FIG. 7B

8/24




FIG. 7C




FIG. 7D




FIG. 7E

9/24




FIG. 8




FIG. 9

10/24





FIG. 10

11/24



12/24




FIG. 12

13/24






FIG. 13


14/24




COMPOUND 15



COMPOUND 16



COMPOUND 17



COMPOUND 18

FIG. 14

17/24

APSPIIKFPGDVAPKTDKELAVQYLNTFYG	30
CPKESCNLFVLKDTLKKMQKFFGLPQTGDL	60
DQNTIETMRKPRCGNPDVANYNFFPRKPKW	90
DKNQITYRIIGYTPDLDPETVDDAFARAFQ	120
VWSDVTPLRFSRIHDGEADIMINFGRWEHG	150
DGYPFDGKDGLLAHAFAPGTGVGGDSHFDD	180
DELWTLGEGQVVRVKYGNADGEYCKFPFLF	210
NGKEYNSCTDTGRSDGFLWCSTTYNFEKDG	240
KYGFCPHEALFTMGGNAEGQPCKFPFRFQG	270
TSYDSCTTEGRTDGYRWC GTTEDYDRDKKY	300
GFCPETAMSTVGGNSEGAPCVFPFTFLGNK	330
YESCTSAGRSDGKMWCATTANYDDDRKWGF	360
CPDQGYSLFLVAAHEFGHAMGLEHSQDPGA	390
LMAPIYTYTKNFRLSQDDIKGIQELYGASP	420
DIDLGTGPTPTLGPVTPEICKQDIVFDGIA	450
QIRGEIFFFKDRFIWRTVTPRDKPMGPLLV	480
ATFWPELPEKIDAVYEAPQEEKAVFFAGNE	510
YWIYSASTLERGYPKPLTSLGLPPDVQRVD	540
AAFNWSKNKKTYIFAGDKFWRYNEVKKKMD	570
PGFPKLIADAWNAI PDNLDAVVDLQGGGHS	600
YFFKGAYYLKLENQSLKSVKFGSIKSDWLG	630
C	631

FIGURE 16

18/24




FIGURE 17

19/24


EFFECTS OF MERCK PEPTIDES
ON UCLAP3 TUMOR GROWTH

FIGURE 18

20/24




FIGURE 19

21/24




FIGURE 20

22/24

Melanoma Tumor growth in Human Skin




FIGURE 21

23/24


*Nude Mice***M21L Tumorigenicity (Volume)**

FIGURE 22A


M21L Tumorigenicity (Wet Weight)

FIGURE 22B

24/24

M21-L Tumors in Nude Mice




FIGURE 23A




FIGURE 23B

Initiate i.p. treatment on day 6 or 20
every other day

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/09099

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 14/435, 14/705, 14/78, 16/28; A61K 38/16, 38/39, 39/395

US CL : 424/130.1, 143.1, 155.1; 514/12; 530/350, 387.1, 388.22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/130.1, 143.1, 155.1; 514/12; 530/350, 387.1, 388.22

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FRIEDLANDER, M. et al. Definition of Two Angiogenic Pathways by Distinct α_v Integrins. 01 December 1995, Vol. 270, pages 1500-1502, see entire document.	1, 3 - 6, 8, 10 - 14, 16, 18-48
Y	DRAKE, C. J. et al. An Antagonist of Integrin $\alpha v \beta 3$ Prevents Maturation of Blood Vessels During Embryonic Neovascularization. 1995, Vol. 108, pages 2655-2661, see entire document.	1, 3 - 6, 8, 10 - 14, 16, 18-48
02 AUGUST 1997		

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	(703)	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*T*	
E earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*Z*	
P document published prior to the international filing date but later than the priority date claimed	*G*	document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

ISA/US 13 AUG 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

Facsimile No. (703) 308-0196

Telephone No.